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 ABSTRACT  
Background: Since cerebral thrombi are the proximate cause of acute ischemic stroke (AIS) and 
the primary target for current treatments, defining new thrombus characteristics associated with 
successful recanalization could help us improve treatment outcomes. We utilized Fourier-
transform infrared spectroscopy (FTIR) and synchrotron-based X-ray fluorescence imaging 
(XFI) techniques, in combination with conventional histology and immunohistochemistry to 
analyze biochemical, elemental and histopathological composition of thrombi, respectively.  
Methods: AIS patients who underwent endovascular therapy from September 2017 to January 
2019 were recruited. One-half of all freshly retrieved thrombi were formalin-fixed paraffin 
embedded and stained with H&E, Masson’s Trichrome, CD31, vWF and CD68 while the other 
halves were flash frozen in isopentane and analyzed using FTIR and XFI. Compositional 
findings were correlated with various clinical and interventional parameters collected 
prospectively, including National Institute of Health Stroke Scale (NIHSS), Thrombolysis in 
Cerebral Infarction (TICI) and modified Rankin Scale (mRS). Additionally, permeability to 
Isovue300 contrast agent was used as a biomarker to analyze thrombus perviousness. 
Results: Twenty-eight patients were included. Retrospective analysis revealed that histological 
composition was not associated with pre-treatment NIHSS (p = 0.19), choice of thrombectomy 
iii 
device (p = 0.833), 90-day mRS (p = 0.892) or 90-day NIHSS (p = 0.512). Additionally, stroke 
etiology did not alter histological composition of thrombi (p = 0.437). Patients in whom near-to-
complete recanalization (TICI 2b-3) was achieved had thrombi composed of significantly higher 
proportions of erythrocytes than fibrin (p = 0.01). The choice of primary thrombectomy device, 
stentriever or aspiration, used during thrombus retrieval was not associated with recanalization 
outcomes (p = 536) or 90-day functional outcomes (mRS: p = 0.363; NIHSS: p = 0.869). XFI 
distribution maps demonstrated K and Fe to co-localize with erythrocytes; whereas, Ca and 
taurine to localize with fibrin. Lastly, measurement of thrombus permeability revealed that 
erythrocyte-rich thrombi were less pervious than fibrin-rich thrombi, and thrombus perviousness 
was associated with improved recanalization outcomes. 
Conclusion: XFI has served as a novel technique to identify new markers involved in poor 
clinical outcomes. Characterizing thrombus composition, identifying targets, and correlating 
these findings with clinical information are key steps in improving our understanding of stroke 
treatment outcomes. 
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Chapter One: General Introduction and Rationale 
1.1 Stroke: brain infarct versus hemorrhage  
The brain serves as the hub of the nervous system in all vertebrate animals. The physiological 
function of the brain is to exert centralized control over all the organs to maintain homeostasis 
and behaviour via neurotransmitters and hormones [1]. Perception, motor functions of voluntary 
and involuntary muscles, arousal, motivation, coordination of breathing, blood circulation and 
heart rate, learning, and memory are just few of the many functions controlled by the brain. 
Broadly speaking, each of these functions are controlled by specific parts of the brain, including; 
frontal lobe, parietal lobe, temporal lobe, occipital lobe, cerebellum, and brainstem [1]. As the 
brain has a high metabolic rate, it receives approximately 15-20% of the total cardiac output [2], 
making it the body’s most highly perfused and metabolically demanding organ [3]. The brain is 
the only organ that  exclusively relies on the oxidative metabolism of glucose for its energy and 
function [4], and thus requires a high but constant blood flow.  
Blood circulates through two parallel loops: pulmonary circuit and the systemic circuit [1]. In the 
pulmonary circuit, blood is transported between the heart and the lungs whereas in the systemic 
circuit, blood is transported between the heart and other tissues. In the systemic circuit, 
oxygen-rich blood flows from arteries branching off the heart and aorta into arterioles and then 
into capillaries where nutrients and oxygen diffuse into the surrounding tissue. Capillary beds 
generally connect arterioles to venules which then carry deoxygenated blood into the veins to 
drain it into the superior or inferior vena cavae of the heart. However, in the venous portal 
system, one capillary bed pools into another capillary bed before draining the venous circulation 
into the heart. Two such venous portal systems include the hypophyseal portal system and the 
hepatic portal system [1]. The hypophyseal portal system interconnects the hypothalamus and 
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adenohypophysis for the delivery of releasing and inhibiting hormones that stimulate and inhibit 
the anterior pituitary gland, respectively. Whereas, in the hepatic portal system, blood leaving the 
capillary beds of splenic, superior mesenteric and inferior mesenteric veins are drained into the 
hepatic portal system instead of directly travelling into the inferior vena cava. This ensures 
nutrient absorption, maintenance of nutrient balance and detoxification before the blood enters 
general circulation [1].   
All blood vessels except capillaries, are made up of three histological layers. The outermost layer 
of the vessel is called tunica adventitia and is composed of connective tissue to provide integrity, 
support and shape to the vessel. The middle layer is called tunica media and is primarily 
composed of elastic fibres and smooth muscle cells to regulate vessel diameter (i.e. wall 
thickness) and carry out the functions of vasodilation or vasoconstriction. The smooth muscle 
layer varies in inverse proportion to the elastic tissue, depending on the size of the vessel. Thus, 
larger vessels have more elastic tissue and less smooth muscle to accommodate high pressure 
and shear stress as opposed to smaller vessels that diffuse into an organ and tend to have less 
elastic tissue and more smooth muscle cells. And lastly, the innermost layer is called tunica 
intima and is primarily composed of endothelial cell surface which lies on basal lamina [5].  
The arterial supply to the cerebral hemispheres is derived from anterior and posterior circulations 
supplied by internal carotid arteries (arising from common carotid artery) and vertebral arteries 
(arising from subclavian artery), respectively [6]. The right common carotid artery originates 
from the brachiocephalic trunk off the aorta, while the left carotid artery originates directly from 
the aorta. Both common carotid arteries bifurcate into an internal carotid artery (ICA) and 
external carotid artery (ECA) (Fig. 1-1).  
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Figure 1-1: Computed 
Tomography 
Angiogram (CTA) 
CTA of the common 
carotid artery (CCA) 
bifurcating into the 
internal carotid artery 
(ICA) and external 
carotid artery (ECA). 
 
 
 
 
 
Anterior and posterior circulations meet at the circle of Willis, an anastomotic ring from which 
all other major cerebral vessels arise, to supply the brain. The terminal branches of the ICA 
include the middle cerebral arteries (MCA) and anterior cerebral artery (ACA), where ACA are 
cross-connected via the anterior communicating artery. The ICA anastomoses with posterior 
cerebral artery (PCA) via the posterior communicating artery [6]. The posterior cerebral arteries 
form the posterior circulation by branching off the top of the basilar artery, which is itself formed 
by the only arterial confluence in the body, where left and right vertebral arteries meet and join 
anterior to the medulla oblongata [7]. The basilar artery gives rise to many branches including 
the superior cerebellar arteries, pontine arteries, and the anterior inferior cerebellar artery while 
each of the vertebral arteries branch into the posterior inferior cerebellar artery and contribute to 
the formation of a single anterior spinal artery. 
The three main cerebral arteries (MCA, ACA and PCA) give rise to several small branches that 
supply deep structures of the brain [6]. The ACA supplies the anterior part of the brain, 
externally spanning from frontal to anterior parietal lobes. Deep structures supplied by the ACA 
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branches include: anterior segments of caudate nucleus, putamen and globus pallidus, anterior 
limb of the internal capsule, uncinate fasciculus, dorsal surface of the optic nerve, optic chiasm 
and optic tract, corpus callosum (rostral end), basal surface of the frontal lobe, pre-central, 
central and post-central gyrus [8]. The MCA supplies the lateral surface of the frontal and 
temporal lobes, portions of the parietal lobes and the insula. Deep structures supplied by the 
MCA branches include basal ganglia and internal capsule [6]. PCA supplies inferior and medial 
portions of the temporal and occipital lobes. Deep structures supplied by the PCA branches 
include: thalamus and posterior limb of the internal capsule [6].  
The circle of Willis is arranged in a manner to create redundancy and generate abundant 
opportunities for collateral circulation to help perfuse the brain and obviate tissue death after a 
traumatic brain injury or during states of acute or chronic ischemia. Sometimes, even when the 
brain lesion persists, the tissue around the core of the infarct, known as the penumbra, is still 
salvageable and has the ability to recover. However, once the infarcted tissue dies, the tissue can 
no longer recover in function. Occlusions of the MCA or ICA can have severe clinical impacts. 
Some people have poor collaterals or incomplete circle of Willis while others have good 
functional collaterals. Thus, asymptomatic occlusions of the MCA or ICA vessels could be 
attributed to functional collaterals or built-in redundancy. Collateral circulation routes can be 
divided into primary and secondary pathways, wherein primary collaterals include 
communicating arteries while the secondary collaterals include the ophthalmic and 
leptomeningeal arteries.  
As longevity has increased, cardiovascular and cerebrovascular diseases have now become the 
leading causes of death [9]. Stroke is a clinical syndrome, so-named due to the sudden onset of 
symptoms. It can be a consequence of ischemia, reduced blood supply, oxygen and nutrients to 
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the brain, leading to tissue death, termed necrosis. There are only two major classes of brain 
strokes; hemorrhagic and ischemic. In hemorrhagic stroke, arteries burst either due to aneurysms, 
weakened vessel walls or arteriovenous malformations, and bleed into or around the brain to 
cause swelling and increased intracranial pressure. In subarachnoid hemorrhages (SAH) blood 
leaks into the subarachnoid space either caused by a head trauma or rupture of an intracranial 
aneurysm whereas in intracerebral hemorrhages blood leaks directly into the brain, and can be 
due to an array of diseases including hypertensive arteriolosclerosis, amyloid angiopathy 
(primary hemorrhage) or arteriovenous malformations, aneurysms, neoplasia, cavernous 
angioma or coagulopathies (secondary hemorrhage) [10], [11]. On the other hand, ischemic 
strokes are caused by occluded vessels, either from a thrombus or embolus. When blood clots are 
formed in situ, in one of the intracranial arteries of the circle of Willis, the ischemic stroke is 
categorized as a thrombotic stroke and the blood clot is referred to as a thrombus [12]. If a blood 
clot forms elsewhere, and then migrates into the cerebral vasculature to block one of the vessels 
in the brain, the ischemic stroke is categorized as an embolic stroke and the blocking substance is 
referred to as an embolus [12]. 
Because each side of the brain controls the opposite side of the body, occlusions (thrombotic or 
embolic) in arteries supplying the left hemisphere result in right-sided deficits, while occlusions 
in arteries supplying the right hemisphere result in left-sided deficits. Deficits caused by ACA 
occlusions may include leg weakness, primitive grasp reflex and paratonic rigidity, gait apraxia, 
and partial frontal lobe behavioural abnormalities. MCA occlusions may present as face and arm 
weakness, hemiplegia, hemianesthesia, homonymous hemianopia, global aphasia, change in gaze 
preference, visual field and somatosensory deficits, motor hemiparesis, aphasia (speech difficulty 
caused by left MCA occlusions), and profound hemineglect (caused by right MCA occlusions). 
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PCA occlusions may present as homonymous hemianopia, hemisensory loss, memory loss, 
hemiparesis [6], alexia without agraphia, and prosopagnosia which is characterized by the 
inability to recognize faces.  
1.2 Epidemiology and pathophysiology of stroke 
Stroke is the second leading cause of death in the world, affecting approximately 33 million 
people world-wide each year [13]. Ischemic strokes account for approximately 87% of all stroke 
types, while intracranial hemorrhages (ICH) account for 10% and subarachnoid hemorrhages 
account for 3% of all stroke types [14]. However, as the lesion caused by hemorrhage is usually 
20× bigger than the lesion caused by ischemia [15], hemorrhagic strokes result in higher 
mortalities than ischemic strokes [16]. In 2013, the prevalence of stroke in Canada was 1.15% 
wherein 405,000 Canadians were affected [17]. The incidence of first stroke is higher in men 
than women. Nevertheless, more women are afflicted by stroke than men each year [18]. An 
international, multicenter, case-control study that recruited participants from 22 countries 
showed that there are 10 common risk factors for stroke, including hypertension – the most 
prominent risk factor, diabetes, smoking, abdominal obesity, hyperlipidemia, lack of physical 
activity, alcohol consumption, poor diet, and psychological stress [19].  
Ischemic arterial strokes are almost universally caused by embolism as opposed to in situ 
thrombosis. A system for categorizing ischemic stroke subtypes based on etiology has been 
developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST). TOAST classifies 
stroke etiology into five subtypes: 1) cardioembolism, 2) large artery atherosclerosis (LAA), 3) 
small vessel occlusion, 4) etiology of other determined cause (e.g. dissection), and 5) etiology of 
cryptogenic or undetermined cause [20]. However, emboli that travel to the brain almost always 
arise from either the heart (cardioembolism) or from the carotid artery bifurcation (artery-to-
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artery embolism) [21]. Cardiac emboli arise due to: 1) cardiomyopathies such as hypokinetic or 
akinetic ventricles, atrial septal aneurysms, and atrial myxomas; or 2) valve disorders such as 
rheumatic mitral and aortic valve disease, bacterial endocarditis, fibrous/fibrinous endocardial 
lesions, and mitral annulus calcification; or 3) irregular heartbeats caused by atrial fibrillation 
[22]. Large artery atherosclerosis usually caused by plaque deposits composed of cholesterol, fat, 
and calcium, can lead to artery-to-artery emboli. Other less common embolic agents include air 
bubbles, cancerous cells, or infectious debris [23]. Cardiac-emboli have the highest rates of 
recurrence and in-hospital mortality [24], [25].  
A systemic analysis indicated that there were 80 million stroke survivors in 2016 around the 
world [26]. Approximately 45% of these survivors are affected by long-term devastating 
physical disabilities [27] with an additional likelihood of one-third of the patients developing 
depression or other mental illnesses [18]. It is therefore not only important to determine risk 
factors and preventive measures for ischemic stroke but it is also important to investigate ways to 
improve post-stroke clinical outcomes that minimize impairments and disabilities.   
1.3 Early work on thrombosis 
Jean Cruveilhier, an eminent anatomist of the 19th century proposed that thrombosis occurred de 
novo as a consequence of vessel wall inflammation [28]. However, his contemporary, Rudolf 
Virchow conducted experiments to demonstrate that inflammation was indeed a secondary 
phenomenon to thrombosis and that thrombi (specifically in pulmonary embolism) travelled 
from venous circulation as opposed to in situ formation. Virchow was the first to coin the terms 
thrombosis and embolism. In an experiment, Virchow injected foreign objects (i.e. seeds, berries 
and coagulated blood) in the jugular vein of dogs and observed that the object was transported 
from peripheral circulation to the lung vasculature. He then attributed the occurrence of 
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obstruction to: 1) irritation to the vessels and its surroundings; 2) blood coagulation; and 3) 
interruption of blood stream [28], [29]. Virchow’s findings that are now recognized as Virchow’s 
triad describe the three factors (i.e. vessel wall damage, hypercoagulability and stasis) that 
contribute to the development of thrombosis and the conditions required for thrombus 
propagation. Even though Virchow’s work referred to venous thrombosis, the same processes 
can be applied to arterial thrombosis [30].  
1.3.1 Molecular mechanism: activation of the coagulation cascade and tissue factors 
Formation of a thrombus is a natural physiological response when blood vessels are injured 
either by external or internal trauma that expose the endothelial surface [31]. When this happens, 
the site of vascular injury accumulates platelets and fibrin to form a thrombus and prevent further 
blood loss. However, thrombus formation does not always occur as a result of a vascular injury. 
For instance, patients with atrial fibrillation might suffer an ischemic stroke from thrombosis 
caused by either blood stasis or inherent hypercoagulability. Hemostasis is a process where 
thrombi are formed via a “platelet – plug” after a tissue injury to stop the bleeding [32]. During 
hemostasis, the initial platelet plug is formed by an interaction between platelets, the 
endothelium, tissue factors and leukocytes [31]. Hemostasis is defined in two phases: 1) primary 
hemostasis which involves the activation, adhesion, secretion, and aggregation of platelets [33], 
and 2) secondary hemostasis which is defined by the assembly of coagulation tissue factors 
which cleave fibrinogen into its activate form – fibrin [32]. Platelets, also known as 
thrombocytes are colourless, non-nucleated, disc-shaped cells that arise by differentiation from 
megakaryocytes [33] and were first discovered in 1866 by Giulio Bizzozero [34]. In response to 
a vascular injury, platelets interact with the subendothelial layer, the basal lamina or basement 
membrane, present under the tunica intima layer of the vessel wall. Platelets then undergo 
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morphological changes [refer to section 1.1 for information on vessel wall structure]. The 
subendothelial layer contains collagen, von Willebrand factor (vWF), laminin, vitronectin and 
other adhesive proteins [32]. Vitronectin and vWF are also generated from platelet granules. 
Vitronectin mediates platelet adhesion and binds to plasminogen activator inhibitor to stabilize 
the formed thrombus and prevent it from undergoing lysis [35]. Platelet adhesion depends on 
shear stress in the circulation. Platelets adhere to collagen via vWF, a glycoprotein and carrier 
protein for factor VIII which is released by endothelial cells and deposited in the subendothelial 
layer during high shear stress, which further activates other cell adhesion molecules on platelets 
and integrins. Activated integrin receptors enable binding of fibrinogen, sustain platelet-platelet 
aggregation and adhere to vitronectin [36]. Platelet adhesion to collagen enables platelet granules 
to secret proteins that further sustain hemostasis [31]. There are two types of platelet granules: 
alpha granules and delta granules (dense granules). Alpha granules of platelets contain P-
selectin, fibrinogen, labile tissue factors V and VIII, vWF, other angiogenic, anti-angiogenic and 
growth factors while dense granules essentially contain ATP, ADP, ionized Ca++ (factor IV), and 
serotonin [37], [38]. Platelets also contain cyclooxygenase that converts arachidonic acid into 
thromboxane A2 which enables vasoconstriction during a vascular insult and also mediates 
binding of the ADP molecules to the receptors of other circulating platelets to aid in platelet-
platelet aggregation [39]. While platelets are the key players during hemostasis, the recruitment 
of other types of blood cells is also important for amplifying this process. For instance, under 
hypoxic conditions P-selectin secreted from platelets interacts with the P-selectin glycoprotein 
ligand 1 (PSGL-1) receptor present on neutrophils, monocytes and leukocytes, and recruit them 
to the injury site [36]. In addition, platelets also interact with endothelial cells under 
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inflammatory response. Calcium secreted by the dense granules, binds to the endothelial 
phospholipids and mediates the assembly of coagulation tissue factors for secondary hemostasis.  
Secondary hemostasis involves the activation of the coagulation cascade. According to 
traditional classification, the coagulation cascade is divided into two pathways: the intrinsic 
pathway which is activated by an internal trauma and the extrinsic pathway which is activated by 
an external trauma that allows blood to escape from vessels (eg. skin abrasion). A balance 
between clotting and bleeding is maintained by interactions within coagulation (thrombus 
formation) and fibrinolytic (thrombus degradation) systems [31]. The coagulation system 
contains clotting factors which are precursors of proteolytic enzymes, known as zymogens (i.e. 
enzyme generators) that circulate in an inactive form in the blood until the intrinsic or the 
extrinsic pathways are activated [39]. An activated zymogen is denoted with the letter “a” [31]. 
Activation of the intrinsic pathway begins with the activation of tissue factor XII into XIIa, and 
downstream factors XI and IX while activation of the extrinsic pathway begins with the 
activation of tissue factors VII and VIII. Activation of factor XI into XIa is catalyzed by XIIa 
and the activation of IX into IXa is catalyzed by XIa. Both of these pathways converge into the 
common pathway where tissue factor X is activated into Xa by tenase complex involving 
catalyzing proteins IXa, VIIa and VIIIa. Factor Xa and Va form a prothrombinase complex and 
catalyze the conversion of prothrombin (factor II) into thrombin (factor IIa) enabling the 
assembly of other substrates. Thrombin cleaves arginine-lysine bonds in fibrinogen, thereby 
converting it to its active form – fibrin [39]. Fibrin polymerizes into a cross-linked fibrin 
thrombus with the help of factor XIIIa (fibrin stabilizing factor) which determines the stability of 
the thrombus. Table 1-1 summarizes all the tissue factors involved in the coagulation cascade.  
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Activated thrombin has several downstream targets. Thrombin amplifies the activation of factors 
V, VIII and IX via a positive feedback loop. Thrombin induces inflammation by mobilizing 
P-selectin and producing chemokines, cytokines, cyclooxygenase-2 and prostaglandins, and 
enables the expression of endothelial adhesion molecules to allow leukocyte recruitment [39], 
[40]. Thrombin also cleaves protease activated receptor-1 (PAR-1) to further stimulate platelet 
activation, secretion and aggregation [41]. Activation of tissue factors by tissue factor catalyzing 
enzymes require platelet-dependent calcium ions (tissue factor IV). In response to thrombin and 
collagen, platelet activation causes externalization of phosphatidylserines in the phospholipid 
bilayer of platelets resulting in Ca++ ion production and generation of phosphatidylserine 
microvesicles which contain thrombogenic factors important for sustaining the coagulation 
cascade. Ca++ is also involved in stabilizing factor VIII by linking protein chains within the 
tissue factor as well as anchoring the protein chains to vWF. Ca++ also acts as a linker when 
tenase and prothrombinase complexes are formed where serine proteases of the tissue factors are 
linked to the phospholipids on platelets [42].  
Procoagulants initiate the clotting cascade in response to a tissue injury, while circulating 
anticoagulants naturally aid in dissolving the formed thrombi. Several naturally occurring 
anticoagulants target different tissue factors to inhibit the coagulation process. For instance, 
tissue factor plasminogen inhibitor (TFPI) inhibits the activation of factor X and also 
subsequently inhibits the activation of factor VII via feedback inhibition while antithrombin 
majorly inhibits thrombin and factor Xa [31]. Antithrombin activity is enhanced in the presence 
of heparin cofactor II. Alternatively, thrombin interacts with thrombomodulin on endothelial 
surface which switches its activity from cleaving prothrombotic substrates to cleaving protein C 
[41]. Anticoagulants such as protein C and protein S are vitamin K-dependent serine proteases 
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wherein protein S acts as a cofactor to protein C to inactivate labile factors V and VIII [32]. In 
addition, endothelial cells release prostacyclin (vasodilator) and nitric oxide to decrease 
P-selectin secretion and reduce platelet aggregation [40]. Under normal conditions, a perfect 
balance is maintained between procoagulants and anticoagulants where blood thrombi are 
formed in response to a tissue injury to prevent us from bleeding out, but are also naturally 
dissolved to prevent vessel obstruction [31]. Thus, some of the tissue factors involved in 
activating the coagulation cascade are simultaneously involved in activating the fibrinolytic 
pathway. For instance, factor XIIa converts prekallikrein into kallikrein enabling kallikrein to 
convert kininogen into kinin (eg. Bradykinin) and mediate vasodilation. Kallikrein and 
plasminogen activator secreted by leukocytes and endothelial cells, cleave plasminogen into 
plasmin [39] enabling fibrin degradation and exposure of D-dimer antigens [43]. On the 
contrary, antithrombin can also inactivate kallikrein and plasmin to initiate coagulation [44]. 
Plasmin can also be inactivated by a serine protease inhibitor – α2-antiplasmin. 
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Table 1-1: Summary of tissue factors and enzymes of the coagulation cascade. List of all 
tissue factors (represented in roman numerals), and enzyme catalysts (indicated in red) involved 
in activating the intrinsic, extrinsic, and common pathways in the coagulation cascade.  
Intrinsic Pathway Factors Extrinsic Pathway Factors  
Inactive form Active form Inactive form Active form 
XII (Hageman Factor)                     XIIa VII (Stable factor proconvertin)            VIIa 
XI (Plasma antecedent)                   XIa VIII (anti-hemophilic factor)                 VIIIa 
IX (Christmas factor)                      IXa 
Common Pathway Factors  
Inactive Form Active Form 
X (Stuart-Prower factor)                                                                     Xa 
II (Prothrombin)                                                                                IIa (Thrombin) 
I (Fibrinogen)                                                                                    Ia (Fibrin) 
XIII (Fibrin stabilizing factor)                                                         XIIIa 
- Thrombin also activates thrombomodulin and with protein S catalyst, protein C is activated. 
Furthermore, thrombin can activate factors V and VIII in a positive feedback manner while 
protein C can inhibit VI and VIII  
- Antithrombin (vitamin K independent glycoprotein) can inhibit thrombin, Xa, IXa, XIa, 
kallikrein and plasmin [44] 
Table adapted from [39] 
1.4 Current acute medical and surgical interventions for ischemic stroke 
1.4.1 Tissue plasminogen activator  
Under normal physiological conditions, hemostatic disruptions caused by vascular injuries can 
be naturally fixed by physiological anticoagulants (mentioned in the previous section). However, 
Serine protease 
XIIa 
IXa, Ca2+ 
Tissue factor/trauma 
Thrombin 
IXa, VIIa and/or VIIIa (tenase complex), Ca2+ 
Xa and/or Va (prothrombinase complex), Ca2+ 
    Thrombin (IIa), Ca2+ 
Thrombin (IIa), Ca2+ 
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under pathological conditions such as thrombosis, hemostatic disruptions require additional acute 
management and appropriate treatment. There are several drug treatments available that target 
different aspects of the coagulation cascade. Drugs including Aspirin, Plavix (Clopidogrel), 
Dipyridamole, Tirofiban, Abciximab (Reopro), and Eptifibatide use different modes of 
mechanisms to inhibit platelet aggregation [45], [46]. For instance, aspirin works by irreversibly 
inhibiting cyclooxygenase-dependent conversion of arachidonic acid into thromboxane and it 
also inhibits prostaglandins, consequently reducing the effects of edema during thrombosis. 
Clopidogrel works by blocking the ADP receptors on platelets while Dipryidamole works by 
inhibiting the uptake of adenosine which causes adenosine accumulation, and results in 
inhibition of platelet aggregation. Tirofiban, Abciximab and Eptifibatide competitively bind to 
glycoprotein IIb/IIIa receptors to prevent the binding of fibrinogen and vWF [45]. On the other 
hand, drugs such as Rivaroxaban (Xarelto), Apixaban, Dabigatran (Pradaxa), and heparin target 
thrombin inactivation [45], [46]. Rivaroxaban (Xarelto) and Apixaban are selective direct 
inhibitors of factor X of the coagulation cascade while Dabigatran (Pradaxa) is an hirudin analog 
that directly binds to thrombin and prevents the conversion of fibrinogen into fibrin [46]. 
Heparin on the other hand is an indirect thrombin inhibitor as it binds to antithrombin enzyme, 
activates it to then inhibit thrombin. Warfarin is another anticoagulant but acts as a vitamin K 
antagonist to inhibit γ-carboxylation of vitamin K-dependent synthesis of several tissue factors 
including factor II, VII, IX, and X [31].  
Until recently, one of the most prominent drug treatments for AIS was, the administration of 
intravenous thrombolytic drug, recombinant tissue-plasminogen activator (rtPA). Tissue-
plasminogen activator works by cleaving arginine-valine bonds in plasminogen and converting it 
into plasmin [45]. The Food and Drug Administration (FDA) approval of tPA in 1996 [47] as a 
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first line approach to treating AIS patients, revolutionized stroke care [48]. Similarly, another 
mainstay treatment for AIS included streptokinase, alteplase, reteplase or urokinase 
administration. However, due to several drawbacks associated with rtPA such as its short 
treatment window of 4.5 hrs (tPA efficacy between 3-4.5hrs was proved in the European 
Cooperative Acute Stroke Study – ECASS III clinical trial) [49], [50] and contra-indications list 
including ICH, hyper/hypoglycemia, hypertension, thrombocytopenia and history of 
anticoagulant use [51], only 3-8.9% patients receive this drug in North America [47], [52]. In 
fact, in Canada the administration of thrombolytics between 1999 and 2000 was reportedly only 
1.4% [53]. In addition, the recanalization success for large vessel occlusions is very low [54]. 
Another type of tissue plasminogen activator, Tenecteplase (TNK) which is a FDA approved 
drug for myocardial infarction, is now being expanded into treating AIS. TNK is more resistant 
to plasminogen activator inhibitor and has shown better outcomes for 3-month functionality and 
reduced intracranial bleeding than tPA [55]. Despite the development of various thrombolytic 
drugs, the recanalization rates obtained by IV thrombolysis are slim and also pose higher risks 
for ICH compared to mechanical strategies [56].  
1.4.2 Endovascular Therapy  
Endovascular therapy was primarily developed to expand the treatment window, improve 
recanalization rates and prevent intracranial hemorrhage [57]. Endovascular therapy (EVT), in 
the form of mechanical thrombectomy is a highly effective technique, whereby the thrombus is 
mechanically retrieved often via the femoral artery [58]. However, for those patients that present 
with aorta-iliac femoral disease, a radial or brachial approach might be more appropriate than 
going through the femoral artery. In addition, due to safety concerns, direct carotid puncture is a 
less popular approach while performing EVT [59]. In recent years, with technological advances, 
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EVT has demonstrated an improvement in the health outcomes of AIS patients and has also 
shown superiority over other treatment options for stroke patients with large vessel occlusions 
[60], [61], [62].  
In 1980s, microcatheters were used for intra-arterial delivery of thrombolytics at the occlusion 
site. In the subsequent years, Prolyse in Acute Cerebral Thromboembolism (PROACT) trials 
tested the efficacy of a new thrombolytic drug, prourokinase < 6 hrs after symptom onset in 
patients with M1 and M2 occlusions. PROACT II was not approved by the FDA as the 
significance for good clinical outcomes measured by Modified Rankin Scale mRS < 2 for the 
treatment and placebo groups was (p = 0.04) with a higher occurrence of ICH observed in the 
treatment group [63]. Following that, trials testing intravenous administration of Eptifibatide and 
Abciximab showed no significant differences between the treatment and placebo groups [64]. 
While the PROACT II trial was negative, it did stimulate the development of alternative 
techniques that focused on disrupting the thrombus rather than dissolving it. The first EVT 
clinical trial conducted in 2003 called Thrombectomy in Middle Cerebral Artery Embolism 
(TIME) yielded negative results [57]. Other clinical trials including Interventional Management 
of Stroke (IMS I, II and III) combined the use of IV-tPA and IA-tPA with EKOS ultrasound 
disruption of thrombi but did not achieve promising results either [65]. In 2004, Concentric 
Medical Inc. developed a first generation thrombectomy device called Mechanical Embolus 
Removal in Cerebral Ischemia (MERCI) retriever [57] which was approved by the FDA based 
on the 510K pathway. The MERCI retriever was tested in the MERCI and Multi-MERCI non-
randomized, multi-centre clinical trial where patients with NIHSS ≥ 8 were recruited and treated 
8 hrs after onset. However, because the recanalization rates were close to the mortality rates, the 
efficacy of the MERCI retriever was questionable. Recanalization rates of 46% were obtained 
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with MERCI alone while recanalization rates of 60.8% were achieved when MERCI was 
combined with IA-tPA [66]. In 2008, Penumbra developed the Penumbra Aspiration System to 
aspirate the thrombus via a vacuum pump. The Penumbra system showed better 90-day clinical 
outcomes than MERCI but the mortality rates were still high [64].  
The off-label use and success of detachable stent-retrievers, such as Solitaire (Medtronic Inc., 
Irvine, California, USA) and Trevo (Stryker Inc., Michigan, USA) marked the development of 
2nd generation thrombectomy devices. These devices tested in clinical trials such as Solitaire with 
the Intention for Thrombectomy (SWIFT) and Thrombectomy Revascularization of large vessel 
occlusion in acute ischemic stroke (TREVO) trials showed statistically significant improvements 
in recanalization, mRS scores ≤ 2, mortality rates, and ICH rates compared to the MERCI 
retriever [67]. However, clinical trials testing the efficacy of EVT over IV-tPA, Mechanical 
Retrieval and Recanalization of Stroke Thrombus using Embolectomy (MR RESCUE), IMS III, 
and Local versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS), failed to 
show EVT superiority over IV-tPA [68], [69]. MR RESCUE reported good functional outcomes 
of 12.5% versus 18.5%, p = 0.368 whereas IMS III reported 42.65% versus 40.18%, p = 0.553 
and SYNTHESIS reported 41.99% versus 46.4%, p = 0.397 [70]. Limitations of each of the 
studies were identified including, lack of patient screening, recruitment of patients despite the 
absence of large vessel occlusion, use of 1st generation devices, and delayed door-to-needle time. 
Despite the drawbacks, these trials led to the use of CTA as a standardized means for screening 
EVT-eligible patients [59]. In 2014, introduction of large bore and flexible aspiration catheter 
enabled the development of a direct aspiration first pass technique (ADAPT) which gained 
popularity for its simplicity, cost-effectiveness, shorter procedural times and rapid recanalization 
times [71], [72]. In 2015, 5 clinical trials showed promising results in the development of EVT. 
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Multicentre Randomized Control Trial for Endovascular Treatment for Acute Ischemic Stroke in 
Netherlands (MR CLEAN) was the first randomized control trial (RCT) to publish positive 
results. In this study, 89% of the patients received IV-tPA prior to EVT, patients were treated 6 
hrs after onset, patients eligible had an NIHSS > 2 and the clinical outcomes were measured 
using an odds ratio [73]. Endovascular treatment for Small Core and Anterior circulation 
Proximal occlusion with Emphasis on minimizing CT to recanalization times (ESCAPE) was the 
second RCT and in this study 76% of the patients received IV-tPA prior to EVT, patients were 
treated 12 hrs after onset, and had an NIHSS > 6 and ASPECTS > 5. ESCAPE was the only 
study to show statistically significant reduction in mortality rates (10.4% versus 19.0%, p = 
0.04), and earliest median reperfusion time [62, 74]. Extending the time for Thrombolysis in 
Emergency Neurological Deficits with Intra-Arterial therapy (EXTEND-IA) was the third RCT 
where patients were treated 6 hrs after onset. The inclusion and exclusion criteria were highly 
stringent; however, this study showed excellent reperfusion success and functional independence 
in 71% of the patients [75]. SWIFT-PRIME was the fourth clinical trial and in this study 88% of 
the patients received IV-tPA prior to EVT, patients were treated 6 hrs after onset and even 
though this study showed functional independence in only 60% of the patients, it reported the 
highest success rate for reperfusion [76]. Lastly, in the clinical trial Endovascular 
Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation 
Stroke Within 8 Hours (REVASCAT), patients who were ineligible for receiving IV-tPA with an 
NIHSS and ASPECTS > 6 were recruited and treated 8 hrs after onset [60]. All of these 5 
clinical trials proved the efficacy of EVT to be superior to IV-tPA for establishing higher 
functional independence (mRS 0-2): MR CLEAN (43.7% versus 28.2%, p = 0.001), ESCAPE 
(53.05% versus 29.3%, p = 0.001), EXTENDIA (71% versus 40%, p = 0.009), SWIFT-PRIME 
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(60.2% versus 35.5%, p = 0.001) and REVASCAT (43.7% versus 28.2%, p = 0.021) [70]. In 
addition, these 5 clinical trials also contributed to: mandating clinical imaging for screening 
EVT–eligible patients, showed improved clinical outcomes with an increased treatment window, 
showed increase in functional independence and decrease in ICH despite the combined use of 
thrombolytics, and showed significant reduction in mortality rates [66]. The most recent clinical 
trial, Diffusion Weighted Imaging or Computerized Tomography Perfusion Assessment With 
Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing 
Neurointervention With Trevo (DAWN) tested the efficacy of EVT at 24 hrs [77].  
Even though the long-term clinical outcomes are improved via EVT compared to IV-tPA [78], it 
is still not clear as to which deployment technique and device combination is the most effective 
for quick thrombus retrieval. In an ideal scenario the thrombus can be retrieved quickly and 
efficiently; however, interventionists occasionally have to perform multiple passes to extract the 
thrombus using multiple approaches and sometimes are still unable to completely restore 
intracranial flow. There are different classes of mechanical thrombectomy devices that work to 
achieve recanalization (blood restoration) via different biomechanical mechanisms [79]. The 
table below summarizes the different devices used during thrombectomy (table 1-2)   
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Table 1-2: List of devices used in mechanical thrombectomy. Provides a summary and 
information of the most commonly used devices during endovascular therapy at Royal 
University Hospital, Saskatchewan  
Category Device 
Name 
Measurements Purpose Company [Ref] 
Guide 
catheters
  
 
 
 
 
Neuron 
Max 088 
 
Sheath length – 6F 
Lumen – .088inch 
Provides support 
through the 
aortic arch until 
the cervical 
region (ICA) 
and delivers 
primary device 
through the 
lumen.  
Penumbra  
[https://www.penumbrai
nc.com/wp-
content/uploads/2016/12/
4900C_NeuronMAX_Fl
ex_Comparison_Ordersh
eet_USA.pdf] 
Neuron 
Max 070 
 
Sheath length – 6F 
Lumen – .070 inch 
Neuron 
Max 053 
 
Sheath length – 6F 
Lumen – .053 inch 
Micro-
catheters 
Velocity 
 
 
Length – 160cm 
ID – .025inch 
OD – 2.95F proximal  
          2.60F distal 
Used for 
facilitating 
coaxial delivery 
of the penumbra 
reperfusion 
catheters.  
Penumbra  
[https://www.penumbrai
nc.com/neuro-
device/velocity-system/] 
Microwires Synchro 2 
standard 
 
 
Total length – varies (200 or 
300cm) 
Distal segment – 35cm  
OD for guidewire – .036mm 
(proximal/distal) 
 
Microwires are 
intended to 
provide 
maximum 
flexibility, 
atraumatic entry 
into delicate 
vasculature, 
radiopacity, 
shapeability, 
torque 
transmission, 
and lubrication 
through its 
hydrophilic 
coating.  
 
1. Stryker 
Neurovascular  
[https://www.strykerneu
rovascular.com/us/produ
cts/access/synchro-
guidewires] 
2. Boston 
Scientific  
[https://www.bostonscie
ntific.com/content/dam/b
ostonscientific/pi/portfoli
o-group/PI-92202-
AD_Fathom_Brochure.p
df] 
Fathom  Total length – varies (140, 
180, 200, 215 cm 
Nitinol tip length – 25cm 
Distal floppy tip – 10cm or 
20cm 
Proximal/Distal OD – .016 
inches 
Tip shape – Straight or 
angled 
Reperfusion 
catheter 
ACE 068 Length – 132cm 
Inner lumen – .068 inch 
ACE 
reperfusion 
catheters are 
designed to 
provide optimal 
trackability 
through tortuous 
Penumbra 
[https://www.penumbrai
nc.com/wp-
content/uploads/2016/12/
10667A_ACE68_Scienc
e-of-
Aspiration_Brochure_U
SA.pdf] 
ACE 064 Length – 132cm 
Inner lumen – .064 inch 
nitinol distal lumen/.068 
inch proximal 
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ACE 060 Length – 132cm 
Inner lumen – .060 inch 
nitinol distal lumen/.068 
inch proximal 
vessels. Ace 
catheter attach 
to the aspiration 
tubing and 
provides greater 
aspiration 
power. 
5MAX  
 
Length – 132cm  
OD – 6F proximal  
1.67mm distal 
ID – .064inch proximal 
        .054inch distal 
Max reperfusion 
catheters, 
similar to the 
ACE 
reperfusion 
catheters are 
intended to 
attach to 
aspiration tubing 
and an 
automated 
vacuum to 
aspirate the 
thrombus 
efficiently.  
Penumbra  
[https://www.penumbrai
nc.com/wp-
content/uploads/2016/12/
10667A_ACE68_Scienc
e-of-
Aspiration_Brochure_U
SA.pdf] 
 
 
 
 
3MAX Length – 153cm  
OD – 4.7F proximal  
1.27mm distal 
ID – .043inch proximal 
        .035inch distal 
  
Stent-
retrievers 
Solitaire 
Platinum 
device  
 
 
Length (scaffolding  + 
pushwire) – 130cm  
Diameter – 6mm  
Nitinol retrieval – 40mm 
 
 
 
 
 
 
 
 
 
 
Overlapping 
stent-retriever 
are comprised of 
a nitinol 
scaffolding 
retrieval zone 
attached onto a 
metal pushwire 
to provide 
rigidity when 
delivered 
through a 
microcatheter.   
Medtronic 
[https://www.medtronic.
com/us-en/healthcare-
professionals/products/n
eurological/revasculariza
tion-
stroke/solitaire.html] 
Trevo XP 
 
 
Diameter – 4mm  
Retrieval length – 20mm  
 
Provides full 
length of 
radiopacity for 
efficient and 
easy placement 
using 360° large 
cells, and soft 
distal tip. 
Stryker  
[https://www.strykerneu
rovascular.com/products/
ais/trevo-xp-provue-
retriever] 
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3D 
Separator  
 
Total Length – 26mm 
Diameter – 45mm  
 
 
 
 
 
Has four 
intraluminal 
chambers with 
petals designed 
to extract the 
thrombus faster 
with minimal 
vessel wall 
contact. 
Penumbra  
[https://tinyurl.com/y49
4fx9w] 
 
Angiograph 
catheter  
5F VER 
(vertebral) 
Catheter 
Length – 100cm 
Diameter – .038inch 
 
Angiographic 
catheter used for 
diagnostic 
purposes.  
 
 
Cordis  
[https://tinyurl.com/y63
pd6yj] 
Abbreviations: F = French, ICA = internal carotid artery, ID = internal diameter, OD = outer 
diameter
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During thrombectomy, fluoroscopy is used for guiding instruments through the patient’s arteries 
to retrieve the thrombus. Other clinical imaging modalities such as standard computed 
tomography (CT) scan, computed tomography angiogram (CTA), and magnetic resonance 
imaging (MRI) are utilized to triage patients. Shown below is an image of a cerebral angiogram 
showing right MCA occlusion (Fig. 1-2).  
 
 
 
 
 
 
 
 
 
 
Figure 1-2: Cerebral Angiography of Arterial Occlusion. Cerebral angiography performed 
using Isovue300 contrast agent to capture images before (A) and after (B) mechanical 
thrombectomy. Complete restoration of blood flow through the right MCA is indicated by the 
white arrow. 
1.5 Importance of studying thrombus composition  
Infarction maturation after ischemia depends on four factors: 1) time from onset until complete 
infarct maturation, 2) volume of tissue affected, 3) brain structures affected (neurons, 
interneurons, myelinated fibres), and 4) interindividual differences including recanalization rate, 
thrombus size, thrombus length, location of vessel blockage, systemic blood pressure, blood 
volume, collateral flow status, temperature, serum glucose, and thrombus characteristics [80]. 
The phrase “time is brain” is popularly emphasized while treating a patient with cerebral 
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ischemia because the brain cells begin to die even before the thrombus is removed or blood flow 
is restored. The forebrain contains 22 billion neurons and 157 trillion synapses. With normal 
aging, 31 million neurons are lost each year while with stroke, 1.9 million neurons are lost every 
minute [80]. Since the thrombus is the primary target of most acute treatments: chemical and 
mechanical [81], understanding the composition and identifying targets within the thrombi could 
greatly facilitate the development of new and effective treatment strategies to retrieve them in a 
time-efficient manner, and minimize post-stroke damage. Even though the Solitaire system has 
shown efficient, safer and favourable outcomes including; increase in recanalization success and 
90-day functionality, and decrease in procedural time, mortality rates and symptomatic ICH rates 
than MERCI, [82] mechanical thrombectomy performed by Solitaire and/or aspiration 
techniques still fails to achieve complete recanalization in 15-30% of proximal occlusion strokes 
[83]. Moreover, the number of passes made during thrombectomy is directly proportional to 
intra-arterial damage that occurs. Additionally, the longer the devices are lodged in the vessels 
during retrieval, the more the chances of further coagulation (distal embolization) and vascular 
trauma (vessel perforation, rupture) are increased [56].  
Clinical imaging modalities (CT, CTA and MRI) serve to identify various aspects of ischemia 
including; collateral flow status, occlusion location, early vessel signs and thrombus signs, 
infarct size, and brain regions affected however, these techniques do not reveal any information 
on the texture, gross pathological appearance, or cellular components characterizing thrombi. 
Since thrombi are the proximate cause of ischemic stroke and the immediate target for current 
treatments, identifying targets within the thrombus can provide us with greater insights to further 
improve interventional and long-term clinical outcomes.  
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The earliest studies to conduct histological evaluation, analyzed thrombo-emboli from post-
mortem samples [84]. Marder et al. was the first group to perform systemic analysis on thrombo-
emboli freshly retrieved from the cerebral vasculature [85]. Along with Marder et al., several 
other studies acknowledged the presence of fibrin, platelets, erythrocytes, endothelial cells, 
neutrophils and monocytes to be present in all thrombi [85], [86] [87]. Despite the presence of 
common components, the quantitative proportions and distribution patterns of these histological 
components differed from one thrombus to the next. Histological characterization was important 
for three reasons:  
1) to identify the age of the thrombus based on the presence of histological biomarkers and 
distinctive distribution patterns [88]. A study showed that endothelial cells and organized fibrin 
were biomarkers for > 3 day old thrombi whereby, older thrombi had decreased thrombolytic 
responsiveness [89];  
2) to determine if the source of origin could predict thrombus histology based on erythrocyte, 
fibrin and platelet ratios. It has been previously reported that thrombi originating from a cardiac 
source were rich in erythrocytes due to their development under low shear stress and low blood 
flow while thrombi originating from an arterial source were rich in platelets and fibrin due to 
their development under high shear stress and high blood flow [85]; and  
3) to understand whether individual thrombus structures play a role in treatment failures. For 
instance, many studies have reported fibrin as the primary cause for reduced thrombolytic 
susceptibility to streptokinase [89] as well as rtPA [90], [91]. Similarly, in vitro studies have 
reported an association between thrombus composition and choice of an ideal thrombectomy 
device used during retrieval, indicating the role of composition and texture in device-thrombus 
interaction [92], [93]. In fact, studies have shown that organized fibrin-rich thrombi contribute to 
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hard/rigid texture that make mechanical retrieval difficult [92], [94] and therefore, these thrombi 
require increased maneuvers and retrieval attempts [95]. Nevertheless, treatment failures might 
depend on other factors besides composition including length of the thrombus. Riedel et al. 
reported that IV-tPA responsiveness was very low for thrombi > 8 mm in size [58].  
This study aims to use conventional histochemical techniques to identify tissue morphology in 
freshly retrieved thrombi, and provide new insight into thrombus composition by characterizing 
the distribution of elements and organic molecules using synchrotron-based X-ray fluorescence 
imaging (XFI) and Fourier-transform infrared spectroscopy (FTIR) techniques, respectively to 
identify new compositional markers and correlate these findings with clinical and interventional 
parameters that could potentially aid in improving EVT outcomes. 
1.6 Experimental imaging modalities for characterizing thrombi 
Prior to applying any experimental imaging techniques including histology, 
immunohistochemistry, XFI or FTIR that characterize components in the tissues, it is critical to 
prepare samples correctly. Fresh tissue samples are delicate and damage easily. Thus, to maintain 
cell morphology and tissue architecture it is essential to preserve, fix, and section the samples 
properly. Principles of preservation, fixation and imaging modalities used in this study are thus 
critical, and are elaborately explained in the sections below.  
1.6.1 Tissue preservation and fixation 
Tissues can be preserved through cryopreservation using liquid nitrogen or isopentane, or 
through chemical fixation using aldehyde, acetone, or alcohol-based fixatives [96].  
Cryopreservation is the maintenance of biological tissues at cryogenic temperatures. At 
temperatures between 0°C and -25°C, enzymatic activities within the cells are slowed down. At 
temperatures below -40°C, all physiochemical reactions cease and at temperatures below -196°C, 
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tissues preserve for longer periods of time [97]. Freshly retrieved tissues contain water within 
their cells. Pure frozen water exists in three forms; hexagonal crystalline, cubic crystalline, and 
vitreous form [98]. Cryopreservation can be accomplished either by slow freezing or by 
vitrification/rapid freezing. In slow freezing, samples are preserved uniformly from the outside to 
the inside at 1°C/min [99]. However, this technique forms hexagonal and cubic crystals most 
distally from the freezing surface which expand upon solidification. Thus, slow frozen sections 
undergo “Swiss cheese effect”, a freezing artifact that results in multiple holes in the sections. 
On the other hand, in vitrification, intracellular water does not have time to form ice-crystals as 
the tissues are directly transformed from an aqueous phase to solid glass-state keeping the water 
in a vitreous form and preventing expansion upon solidification [99]. Rapid or flash freezing is 
commonly done using liquid nitrogen or isopentane (2-methylbutane). Usually, samples that are 
rapidly frozen, are placed in an optimal cutting temperature (OCT) embedding matrix, composed 
of 10.24% polyvinyl alcohol, 4.26% polyethylene glycol and 85.5% non-reactive ingredients 
which prevent the samples from cracking while being flash frozen [100]. Because liquid nitrogen 
is the coldest liquid (-196°C) and has a low specific heat constant, when it comes in contact with 
OCT it forms a vapour barrier causing the inner core of the tissue sample to freeze slowly and 
unevenly. Similarly, when isopentane is chilled with dry ice it only attains a temperature of         
-78.5°C which also results in slow freezing of the inner core and increases the risk of ice-crystal 
formation. Thus, to get around this issue, the most effective way to cryopreserve a sample, as 
done in this study (for utilizing XFI and FTIR techniques), is by flash freezing the sample in 
isopentane that is chilled using liquid nitrogen instead of dry ice. Even though cryopreservation 
is a relatively quicker process and a highly effective technique for preserving labile biomolecules 
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than chemical fixation, tissues still get damaged in this process as temperatures fall from 37°C or 
room temperature to -196°C [97].  
With chemical fixation, cell morphology is better maintained than in cryopreservation as 
chemical fixation minimizes cellular and structural damage. There are different classes of 
fixatives that can be used during chemical fixation including: 1) cross-linking fixatives such as 
aldehydes, 2) precipitating fixatives such as alcohols and acetone which are also sometimes used 
for fixing cryosections, 3) oxidizing fixatives such as osmium tetroxide, 4) mercurials such as B-
5 and Zenker’s fixative, and 5) picrates such as picric acid and Bouin’s fluid [101]. Aldehydes 
are the most widely used fixatives [102]. They create covalent bonds crosslinking proteins, 
mostly lysine residues within the tissue. Proteins also get anchored to the cytoskeleton which 
adds rigidity to the tissue. Specimens are commonly fixed in formaldehyde for histology, or 
glutaraldehyde for electron microscopy. In this study (for utilizing histological techniques), 
specimens were fixed in formaldehyde (30.031g/mol MW). Formaldehyde (H-CHO) naturally 
exists in gaseous state. However, in aqueous solutions formaldehyde is combined with water to 
form methylene hydrate (HO-CH2-OH). A study by Sompuram et al. showed that, at a molecular 
level formaldehyde reacts with an amine group on an arginine residue within the tissue protein 
which forms an intermediate iminium ion which then reacts with tyrosine residues via a covalent 
bond, thereby implicating a Mannich reaction [103]. Usually for histological studies, the 
formalin used contains 37-40% of formaldehyde combined with 60-63% of water. Furthermore, 
paraformaldehyde, an insoluble powdered polymer of methylene hydrate molecules can be easily 
hydrolyzed into formaldehyde in the presence of heat (60°C) and OH- ions [102].  
After the fixation step is complete, cryopreserved specimens are sectioned in a -20°C cryostat 
while formalin-fixed samples are infiltrated with a liquid agent such as resin or paraffin that 
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solidifies [96], and then sectioned in a microtome. Steps involved in processing tissues for 
histological staining, immunohistochemistry, X-ray fluorescence imaging, and Fourier transform 
infrared spectroscopy are described below.  
1.7 Principles of histological stains and immunohistochemistry 
Staining techniques were developed in the seventeenth century by pioneers such as Van 
Leeuwenhoek who used natural substances such as plants, insects, and saffron to dye plant and 
animal tissues [104]. As later techniques developed, different histological stains were devised to 
study various types of cellular components.  
A thrombus is a clump of coagulated materials that circulate in the blood. The two major blood 
components include plasma and formed elements [1]. The plasma consists of proteins including 
albumin (66.5 kDa MW), globulins (93-1193 kDa MW), fibrinogen (~340 kDa MW), enzymes, 
electrolytes, nutrients, blood gases (O2, N2, and CO2), and hormones. The formed elements are 
composed of erythrocytes (red blood cells), thrombocytes (platelets) and leukocytes (white blood 
cells). A hematopoietic stem cell gives rise to myeloid progenitor and lymphoid progenitor cells. 
The myeloid cell differentiates into thrombocytes, erythrocytes, and myeloblasts. The 
myeloblasts further give rise to neutrophils, eosinophils, basophils or monocytes. The lymphoid 
stem cell gives rise to natural killer cells (large lymphocytes) and small lymphocytes which 
further differentiate into a T-cell lymphocyte or a B-cell lymphocyte. Neutrophils, eosinophils, 
and basophils contain secretory granules in their cytoplasm and therefore are called granulocytes, 
while monocytes and lymphocytes are called agranulocytes. Granulocytes and agranulocytes 
together are classified as white blood cells [1].  
As mentioned earlier, previous histological evaluations have characterized the presence of 
several biological components in thrombi including platelets, monocytes, erythrocytes, 
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leukocytes and fibrin [85], [86]. Based on their biological components, thrombi have been 
classified as either red thrombi (i.e. rich in erythrocytes and possibly from a cardiac source) or 
white thrombi (i.e. rich in fibrin and possibly from an arterial source) [85], [87]. In this study, 
two histological stains: Hematoxylin and Eosin, and Masson’s trichrome were used for 
identifying the distribution of fibrin, erythrocytes, and leukocytes. On the other hand, to stain for 
platelets, monocytes and endothelial cells, immunohistochemistry techniques were used.  
1.7.1 Hematoxylin and Eosin Stain 
Hematoxylin and Eosin (H&E) is a combination of two stains: Hematoxylin and Eosin. This 
combination was introduced by Wissowzky in 1876 [105]. Hematoxylin is extracted from a 
logwood tree, Hematoxylum Campechianum, and was first used by Wilhelm von Waldeyer-Hartz 
in 1863 [106] as a nuclear stain. The active colour in hematoxylin is hematein. When the 
hematoxylin solution is prepared, sodium iodate is added to catalyze the oxidization of 
hematoxylin into hematein. Because hematein is anionic, it acts as a weak dye to bind the 
negatively charged DNA and therefore is combined with aluminum salts to form a cationic stain 
and bind to the phosphate backbone of DNA via electrostatic forces and covalent bonds [107]. 
Other additives in the solution include ethanol and glacial acetic acid which are used for 
dissolving the dye and increasing selectivity for nuclear staining, respectively.  
There are two staining systems for Hematoxylin: progressive and regressive [108]. In the 
progressive method, such as Gill’s or Mayer’s, tissues are stained for a specific amount of time 
while in the regressive method, such as Harris’s which is used in this study, tissues are 
overstained in the solution and then differentiated in acid alcohol to remove excess stain. 
Differentiation in the acidic solution also stains the nucleus red which is why tissues are blued 
using alkaline-based reagents such as aqueous lithium carbonate that stains the nucleus dark-
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purple or blue [108]. Eosin is used as a counterstain to hematoxylin. Eosin is an acidic, anionic 
dye that binds to positively charged molecules such as proteins, connective tissues and red blood 
cells. The solution is made by dissolving the dye in ethanol and adding acetic acid to intensify 
the stain. Hematoxylin stains white blood cells dark-purple, while eosin stains the fibrin as well 
as red blood cells bright pink and eosinophil granules red.  
H&E is the gold standard stain used to begin tissue examination in pathology, but does not 
contrast different types of tissues and cells resulting in insufficient cytoplasmic and extracellular 
structure differentiation [109]. Thus, to distinctively identify cellular structures and take into 
consideration other key factors of the coagulation cascade such as platelets, macrophages and 
endothelial cells, special stains such as Masson’s trichrome [105] or immunohistochemical tools 
are utilized.  
1.7.2 Masson’s Trichrome Stain 
Masson’s trichrome (MT) protocols evolved from the formulations used by Claude L. Pierre 
Masson in 1929 [110]. Prior to staining with the three primary trichrome stains, tissues are fixed 
in mordant Bouin’s solution and stained with Weigert’s iron hematoxylin. Weigert’s iron 
hematoxylin is used as a nuclear stain and contains ferric chloride, hydrochloric acid, 
hematoxylin, and ethanol to resist decolouration from the following acidic dyes. Ferric chloride 
acts as a mordant and oxidizer for hematoxylin [111]. MT is a combination of three stains: 
Beibrich scarlet-acid fuchsin which is an acidophilic dye and stains erythrocytes bright-red, 
phosphomolybdic/phosphotungstic acid which is used for differentiation and displacement of red 
dye from fibrin fibres, and aniline blue which is applied to stain the fibrin fibres blue [112]. 
Furthermore, acetic acid is used for differentiating and intensifying aniline blue.  
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1.7.3 Chromogenic Immunohistochemistry  
Immunohistochemistry is a technique for selectively identifying antigens within cells and tissues 
using specific antibodies. Antibodies also known as immunoglobins, are Y-shaped monomeric 
glycoproteins that have specific affinity for biomolecules called antigens [113]. The antibody 
contains an antigen-binding site called paratope while the antigen contains an antibody binding 
site called epitope. Epitopes could be composed of a specific amino acid sequence (linear 
structure) or could be in the form of a tertiary structure [114]. When antibodies are developed to 
target antigens, the analytical validity depends on two factors; 1) sensitivity (the smallest amount 
of antigen detectable), and 2) specificity (the ability of the antibody to selectively recognize and 
bind to the desired antigen, and not others) [114]. Antibodies can be monoclonal or polyclonal. 
Both monoclonal and polyclonal antibodies are developed by injecting a protein into a host 
organism. This initiates an immune response where the host generates antibodies against the 
injected protein. Monoclonal antibodies are derived from single B-lymphocyte cell lineages to 
react with a single epitope while polyclonal antibodies are produced by repetitive stimulation and 
multiple B-lymphocyte cell lineages (B plasma cells, B memory cells) to react with multiple 
epitopes on the antigen. Antibodies are then purified from blood serum extractions [113], [115]. 
While monoclonal antibodies provide great specificity and reproducibility, they are less 
sensitive. On the other hand, polyclonal antibodies provide higher sensitivity and are more 
resistance to pH changes but are less reproducible and tend to increase background noise.  
Immunohistochemistry assays consists of five key steps: tissue fixation and processing (as 
previously mentioned), antigen epitope retrieval, blocking, immunolabelling and detection, and 
counterstaining.  
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Antigen retrieval – For formalin fixed paraffin embedded tissues, antigen retrieval is a necessary 
step to open up the cross-linked methylene bridges formed by formaldehyde fixation that mask 
epitopes via Mannich reactions [103]. Protein cross-links can be broken by heat or enzymatic 
treatment. Heat induced epitope retrieval (HIER) is implemented using either of these methods: 
1) water-bath method where sections are incubated in a 97°C water bath containing the retrieval 
working solution, 2) microwave method where sections are placed in a microwaveable vessel 
containing the retrieval working solution, and 3) high pressure method where sections are placed 
in a pressure cooker containing the retrieval working solution. There are different types of 
retrieval working solutions, including citrate buffer solution, Phosphate Buffered Saline (PBS) 
solution, Ethylenediaminetetraacetic acid (EDTA) solution, Tris-EDTA, and Tris-HCl solution. 
On the other hand, proteolytic induced epitope retrieval (PIER) is implemented by incubating 
sections in proteolytic enzymes such as trypsin, proteinase K, pepsin etc. [116], [117].  
Blocking – This step blocks endogenous enzymes, prevents non-specific antibody binding and 
reduces background signal. Blocking can be achieved using protein blocking reagents such as 
serum (goat, donkey, chicken) and bovine serum albumin, or avidin-biotin reagents or 
peroxidase blocking reagents [115]. 
Immunolabelling and Detection – There are two detection methods: direct and indirect. The 
direct method is a one-step process where the primary antibody reacting with the antigen is 
labelled with an enzyme substrate such as horseradish peroxidase (HRP) or alkaline phosphatase 
[118]. This is a simple and specific method but attains a lower signal amplification and lower 
sensitivity. On the other hand, the indirect method is a two-step process where the primary 
antibody reacting with the antigen is labelled with a secondary antibody [119]. For instance, if 
the primary antibody is mouse anti-human (i.e. the antibody is raised in a mouse against a human 
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antigen), the secondary antibody could be goat anti-mouse (i.e. the antibody is raised in a goat 
against a mouse antigen so as to identify the mouse primary antibody). The secondary antibody 
is then conjugated with a HRP enzyme substrate. Sometimes secondary antibodies are 
biotinylated, in other words, conjugated with biotin molecules that recruit avidin proteins to 
amplify the signal further [118], [120]. In both methods, the antigen-antibody-HRP complex is 
then tagged with a chromogenic substrate such as 3, 3'-diaminobenzidine (DAB) which is 
oxidized by hydrogen peroxide to yield an insoluble brown pigment that precipitates at the 
antigen site, a technique developed by Nakano and Pierce in 1960s and described by Sternberger 
and colleagues in 1970 [121], [122]. DAB is effective as a single label or as a second color for 
multiple antigen labeling. Sections stained with DAB can be viewed using a light microscope 
and can be stored for a long time. On the contrary, in fluorescence microscopy, antigen-
antibody-HRP complex are tagged using different fluorophores instead of DAB molecules that 
absorb and emit at different wavelengths when viewed under a fluorescence microscope.  
1.8 Principles of XFI 
1.8.1 XFI beamline components 
The electromagnetic spectrum consists of gamma rays, X-rays, ultraviolet, visible, infrared (near, 
mid and far infrared), microwaves and radio waves. Gamma rays and X-rays have shorter 
wavelengths, higher energy and higher frequencies. They are both types of ionizing radiation due 
to their abilities to ionize atoms. On the other hand, microwaves and radio waves have longer 
wavelengths, lowest energy and lowest frequencies [123]. A wavelength is defined as the 
distance between adjacent crests and troughs of a light wave while frequency measures the 
number of waves that pass a given point per second. Table 1-3 represents the electromagnetic 
spectrum with specific wavelength and frequency range.  
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Table 1-3: Electromagnetic wave spectrum with specific wavelength and frequency range.  
Range Wavelength (m) Frequency range (Hz) 
Gamma rays  10-12 >1019 
X-ray  10-9 - 10-11 1017- 1019 
Ultraviolet  1×10-7-10-9 1014-1017 
Visible light  7×10-7- 4×10-7 4.3×1014 – 7.5×1014 
Near Infrared  7.5×10-7 – 2.5×10-6 1×1014 – 4×1014 
Mid-infrared 3×10-6 – 8×10-6 3×1013 – 1×1014 
Far-infrared 1.5×10-5 – 0.001 3×1011 – 2×1013 
Microwave 0.01-1×10-5 109-1012 
Radio wave >0.01 <109 Hz 
Synchrotron radiation is generated at experimental facilities such as the Canadian Lightsource 
(CLS), Stanford Synchrotron Radiation Lightsource (SSRL) and National Synchrotron 
Lightsource (NSLS). Synchrotron radiation is generated as a result of ultra-relativistic particles 
(usually electrons) accelerating through a magnetic field. At the CLS, electrons are generated by 
an electron gun (hot filament) and are drawn by an electromagnetic field into a linear accelerator 
(LINAC) where they are accelerated to 250 MeV using Radio Frequency (RF) Cavities and are 
then transferred to the booster ring in bunches where the electron bunches are then imparted with 
additional energy from microwave fields generated in the RF cavity to reach a total energy of 2.9 
GeV. Electrons are then injected into the storage ring where they orbit [124]. Electrons prefer to 
travel in a straight line; however, their path is bent by bend magnets or insertion devices – 
(undulators or wigglers) in the storage ring which causes the electrons to radiate photons in the 
form of synchrotron radiation. When emitting light, the energy lost by the electrons are replaced 
by the RF cavities. As the electrons turn, they produce a bright collimated light that goes straight 
into the “front end” of the beamline [124]. Typical XFI beamline components may include: 1) 
monochromator, a device that separates different wavelengths of light using either optical 
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dispersion (as prism) or grating (as diffraction) so that a single energy range can be selected and 
the wavelengths that are not required can be filtered out, 2) slits and micro-focus optics that 
define the horizontal and vertical dimensions of the beam, 3) an upstream detector (ion chamber 
– I0) that is filled with a gas mixture to absorb 20-40% of the incident beam (measures initial 
photon flux), 4) a downstream detector (ion chamber – I1) that detects the beam transmitted 
through the sample (attenuated photons) and thereby absorbs 20-40% of the transmitted beam, 5) 
a X-ray fluorescence detector that detects fluorescence signal from the sample, 6) a precision 
stage to mount samples on, 7) windows to allow monochromatic beam to pass, and 8) shutters 
that turn off the beam to downstream enclosures. Photoelectric effects, coherent scattering, 
Compton scattering, pair production, and photodisintegration are few of the factors that 
contribute to X-ray attenuation as X-rays interact with matter [125]. Figure 1-3 illustrates a 
schematic representation of the X-ray fluorescence imaging beamline at SSRL. 
When the incident X-ray energy is above the absorption edge of an element, it can excite and 
eject a core electron as a photoelectron (photoelectric effect) and create a core hole [125]. To 
stabilize the atom, the core-hole is filled by a neighbouring electron that transitions from an outer 
shell into the core space, emitting an X-ray fluorescence photon. The emitted fluorescence 
photon is detected by the X-ray fluorescence detector placed in the beamline [124]. Most atoms 
comprise of various electron shells (K, L, M, N…). X-ray fluorescence emissions are 
characterized using these shells. Additionally, alpha, beta and gamma designations are also used 
for denoting specific electron transitions from higher orbitals. For instance, a transition from 
LK shell is referred to as Kα or MK shell is referred to as Kβ or ML shell where the 
energy is referred to as Lα. Further designations are made as α1, α2, β1 or β2 to account for any 
higher or lower binding electrons present within the inner orbits of the shells. For instance, Kα1 
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and Kα2 emission lines arise from the decay of 2p3/2 and 2p1/2 electrons to the 1s1/2 orbit, 
respectively [126]. Thus, the emitted photons generate an X-ray emission spectrum where each 
element has a distinct spectral peak identifying it. Electrons transitioning from the p orbital to the 
innermost s orbital result in narrower spectral peaks while electrons transitioning from 
furthermost orbitals into the s orbital result in wider spectral peaks. The X-ray fluorescence 
emission spectrum is collected for each data point from a multichannel analyzer using a fast 
analog-to-digital convertor.  
For the purposes of this study, we used an energy of 13,450 eV, an energy just below the K 
absorption edge of bromine (Br) which enabled us to map the distribution of elements from 
aluminum (Al) to Selenium (Se). In addition to the K-edge energy of Br, we also used a Lα-edge 
energy to map the distribution of iodine (I). The Lα-edge was used as iodine has a higher K-edge 
energy than Br. Along with mapping physiologically relevant elements, we were also interested 
in mapping iodine because every ischemic stroke patient is administered Isovue-300, an iodine 
based contrast agent during pre-procedural imaging as well as during the thrombectomy 
procedure. Thus, we used the contrast agent permeability as a biomarker to study thrombus 
perviousness where we associated increased iodine concentration with increased thrombus 
permeability. 
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Figure 1-3: X-ray fluorescence imaging beamline components. (A) Simplified schematic 
diagram of the apparatus for conducting XFI at Stanford Synchrotron Radiation Lightsource. The 
beam is typically generated by a synchrotron radiation source and passes through downstream 
optical components shown in the schematic. The beamline is equipped with an X-ray double 
crystal monochromator, gas ionization chambers, XFI fluorescence detector and a precision stage 
to mount the samples on. (B) Schematic diagram of the underlying physics. The incident X-ray 
beam hits the sample and ejects the excited core electron as a photoelectron creating a core hole. 
The core hole is filled by an electron from an outer shell subsequently releasing a fluorescent 
photon. The fluorescent photons are detected by the XFI fluorescence detector. Figure adapted 
from Pushie et al. 2014 [127]. 
1.8.2 Sources of errors while quantifying samples using XFI  
There are several factors that should be accounted for to achieve reliable quantification. Samples 
must be standardized and prepared under same conditions to achieve the same sample thickness 
when sectioned. Calibration foils must be run during each beamtime to detect any current 
fluctuations and the foils must not be damaged. Beamline settings must be standardized across 
beamtimes where the samples should be mounted at the same distance from the detector. 
Furthermore, parameters including resolution, dwell time and flux must be kept constant during 
each beamtime. Resolution measures the clarity in the number of pixels used to display an 
image. Low resolution images are often referred to as pixelated or blurry. Resolution depends on 
spot size (size of the beam) and step size (size of the pixel) whereby, if the spot size > step size, 
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the tissue is oversampled while if the spot size < step size, the tissue is under sampled [128]. 
Dwell time measures the amount of time spent scanning each pixel while the flux measures the 
amount of photons emitted. Increase in dwell time or flux, can oversaturate the detector.  
1.8.3 Benefits and limitations of Synchrotron-based XFI 
There are several advantages of using synchrotron-based XFI imaging over conventional 
laboratory-based techniques. For instance, XFI enables us to quantify elemental concentration 
and visualize the distribution of multiple elements simultaneously. Furthermore, based on the 
preliminary spectrum, we can combine fluorescence imaging with micro X-ray absorption 
spectroscopy to visualize specific molecular forms/oxidation states of a single element. XFI 
techniques are far more beneficial than histological stains developed to characterize different 
molecular states of elements such as; von Kossa for Ca2+, an indirect calcium stain where silver 
nitrate reacts with calcium phosphate in the presence of illumination resulting in precipitation of 
silver phosphate; Perls’ Prussian blue for ferric iron (Fe3+); and modified Turnbull for ferrous 
iron (Fe2+) [129]. When performing histology, samples undergo rigorous steps during fixation, 
processing and staining which potentially risk washing out elemental components. On the other 
hand, XFI techniques measure intact tissues with minimal to no pre-treatment, thereby 
eliminating the risk of losing any information on labile elements and molecules. Additionally, 
XFI can detect elements in very small samples with high sensitivity and resolution. Compared to 
benchtop sources, synchrotron-generated beam is: 1) extremely bright which reduces dwell time 
and increases the scanning speed, 2) monochromatic which yields in robust quantification, and 3) 
tuneable which probes chemical speciation [130]. That being said, XFI techniques have certain 
limitations as well. While hard X-ray beamlines show distinct spectra for high Z (atomic 
number) elements, emission lines for some of the low Z elements such as Ca and K overlap. 
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Similarly, for low Z elements, the penetration depth of the beam is limited and only enables 
surface mapping.  
1.9 Principles of Spectroscopy  
1.9.1 X-ray absorption spectroscopy 
X-ray absorption spectroscopy (XAS) techniques have proven useful for determining the local 
geometric and electronic structure of molecules to understand chemical speciation of a particular 
element [131]. XAS can deduce the local structure of atoms because the wavelengths are on the 
same order of magnitude as the atom-atom separation in molecules. Because the ionization of 
core electron requires high energy in the X-ray range and spectroscopy requires a continuous 
energy-spectrum, XAS techniques are conducted using synchrotron sources. However, one of the 
primary concerns of XAS techniques include photo-oxidation/photo-reduction induced damage 
of the samples due to high beam intensity [127]. Similar to the principles of XFI, in XAS, the 
synchrotron beam is absorbed by an electron in the core shell (1s or 2p), thereby ejecting the core 
electron as a photoelectron via the photo-electric effect into an unbound state called continuum 
or is excited and promoted to a higher unoccupied level. XAS is element-specific because each 
element has a unique absorption edge. The absorption edge is the energy required to ionize the 
atom at its core level causing a steep increase in the absorption [131]. When the core electron is 
ejected, the core hole is filled by an electron from a higher energy state that falls into the vacant 
spot, thereby either releasing a photon (fluorescence emission) or emitting an Auger electron 
[124].  
XAS measures the transitions from core electronic states to the excited states and the continuum. 
These measured transitions are represented by two main regions in the XAS spectrum, X-ray 
absorption near-edge spectra (XANES), and extended X-ray absorption fine structure (EXAFS). 
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The range of XANES lies between the threshold energy (E0), energy at which the photoelectron 
is ejected to a continuum, and where EXAFS begins. XANES represent the fingerprint region 
that provides chemical information about the oxidation states in addition to the symmetry and 
local geometry around the absorbing atom [132]. On the other hand, EXAFS provide information 
on specific chemical species present in the sample and are sensitive to: 1) the distance between 
the absorber atom and the backscatterer atoms, 2) to the number of electrons around the 
backscatterer atoms, and 3) number of backscatterer atoms of a particular type. However, 
EXAFS do not provide information on the geometry of the molecule or distinguish between 
similar backscatterer atoms. EXAFS oscillations are produced by constructive and destructive 
interference patterns that arise from the interactions between the absorbing atom and the 
photoelectron waves backscattered by neighbouring atoms [131]. The amplitude of the EXAFS 
oscillations are directly proportional to the size and number of backscatterer atoms. To extract 
information from EXAFS on bond distances as well as number and types of backscatterer atoms, 
the EXAFS can be Fourier-transformed [133]. 
The spectroscopy beamline 7-3 at SSRL consists of similar beamline components as XFI 
beamline, with a few additional components [134]. The beamline is equipped with a 30-element 
Germanium solid-state detector (Mirion technologies Inc., Canberra, Australia) placed at a 90° 
angle to the incoming X-ray beam to reduce the detection of scattered radiation and measure the 
primary fluorescence excitation spectrum. Unlike the XFI beamline, the XAS beamline does not 
use a fixed incident energy as each element has a unique absorption edge. Thus, the 
monochromator and 30-element Ge detector needs to be calibrated and optimized for each 
element separately. Furthermore, a set of elemental filters and Soller slits are placed between the 
sample and the Ge detector to filter out elastic scatter and Compton radiation scatter, and prevent 
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oversaturation of the detector by blocking most of the stray fluorescence. It is essential to select 
an X-ray filter with an element that has an atomic number of one less than the sample (Z-1). The 
sample is placed in an Oxford He cryostat. There are 3 gas ionization chambers used at the 7-3 
beamline to monitor the beam at different positions. The first chamber (I0) is placed before the 
sample to measure initial beam flux, the second chamber (I1) is placed between the sample and 
the metal foil to measure transmitted beam flux and the third chamber (I2) is placed after the 
metal foil to absorb as much of the remaining beam as possible. The metal foil is used for 
calibrating the monochromator energy and prevent it from drifting. In addition to the ionization 
chambers, the beamline is also equipped with Passivated Implanted Planar Silicon (PIPS) 
detectors to monitor fluorescence. Figure 1-4 illustrates a schematic representation of the 
spectroscopy beamline 7-3 at SSRL. 
Figure 1-4: X-ray absorption spectroscopy beamline components. Simplified schematic 
diagram of the apparatus for conducting XAS at the 7-3 beamline at Stanford Synchrotron 
Radiation Lightsource. The beam is generated by a synchrotron radiation source and passes 
through the downstream optical components shown in the schematic. The beamline is equipped 
with an X-ray double crystal monochromator, 30-element Ge solid state detector, gas ionization 
chambers, Oxford He cryostat, filters, foils and Soller slits. Figure adapted from [https://www-
ssrl.slac.stanford.edu/mes/XAFS/INDEX.HTML]. 
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1.9.2 Fourier-transform infrared spectroscopy (FTIR) – Mid Infrared spectroscopy beamline 
components  
Infrared imaging for this study was conducted at the Mid-IR spectroscopy beamline at the 
Canadian Lightsource (CLS). The beamline includes Fourier transform infrared (FTIR) 
spectrometer and microscope which supplies diffraction-limited spatial resolution at a wide 
range of energy in the mid infrared range (i.e. 3-50 μm) [135]. This wide energy range is a 
fingerprint region used for molecular identification. Imaging at this beamline can be conducted 
by either using a globar source or a synchrotron source. A globar is a thermal light source with a 
silicon carbide rod that is electrically heated up to 1,000-1,650°C [135] to produce radiation. 
The beam goes through 1) collimator, a device that produces parallel beams of rays, and 2) 
aperture wheel which enables users to select a slit size that adjusts the beam size and spectral 
resolution. Narrower slits may be useful for lowering background but could result in 
undersampled spectra while wider slits may be used for coarse scans but would compromise 
resolution. 
Once the slit size on the aperture wheel is selected, and the beam passes through it, the beam gets 
focused and narrow. It hits a collimating mirror that directs the beam onto a straight path into a 
FTIR interferometer. The FTIR interferometer is an optical instrument that measures wave 
interference of two beams. The interferometer contains beam splitters, which are devices 
designed to split the beam into two. The material generally used for a beam splitter is potassium 
bromide (KBr) [135]. Using KBr mirrors have few advantages including, they have a wide 
wavelength range for infrared radiation transmission, they prevent large absorption within the 
range, and they have a small refractive index. Interferometers contain a fixed mirror and a 
moving mirror [135]. As the beam passes through the beam splitter and splits into two beams, 
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one of the beams hits the moving mirror while the other beam hits the fixed mirror. The beam 
bounces back and forth and as a result, some of the rays are lost along the way. Eventually, the 
two beams bouncing back and forth from the mirrors combine to create either constructive or 
destructive interference patterns. Constructive patterns are formed when the two waves are in 
phase with each other and additive, thereby intensifying the wave. In addition, in constructive 
wave patterns, the distance from the beam splitter to the moving mirror is equal to the distance 
from the beam splitter to the fixed mirror. On the other hand, destructive patterns are formed 
when two waves are out of phase and therefore the resulting additive wave is less intense. To 
measure the mirror distance and the exact energy calibration, the interferometer has a built- in 
helium-neon (He-Ne) laser to send measurements to its own separate detector [135]. Once the 
rays pass through all the optical components, the resulting beam is focused, collimated, and 
combined. The beam hits the sample mounted under the microscope. The microscope is attached 
to a Focal Plane Array (FPA) detector. The FPA detector is cooled using liquid nitrogen to detect 
photons with higher sensitivity at infrared wavelengths. 
Molecules within the sample vibrate at 6 different vibration modes including; 1) symmetrical 
stretching, 2) asymmetrical stretching, 3) wagging, 4) rocking, 5) bending, and 5) twisting [136]. 
Molecules with N number of atoms have 3N-5 vibrational modes if they are linear molecules and 
3N-6 vibrational modes if they are non-linear molecules [136]. When infrared radiation matches 
the frequency of the vibrational modes, the bonds between the molecules absorb the wavelength 
and go into a higher energy vibrational state.  
Because the samples are measured in transmittance mode, the FPA detector detects photons that 
are transmitted through the sample rather than detecting photons that have been absorbed by the 
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bonds. According to Beer-Lambert law, absorbance (A) and transmittance (T) are measured as 
follows [135]: 
𝐴 =  𝜀𝑙𝑐 
    𝑇 =  10 𝜀𝑙𝑐 
where molar absorptivity is denoted by ɛ, tissue thickness is denoted by l and tissue 
concentration is denoted by c. Absorption of photons is directly proportional to all three 
parameters.  
The spectral peaks produced are representative of the functional groups that are present in the 
samples. In other words, different functional groups present in organic molecules absorb specific 
wavelengths which are measured in wavenumber (cm-1) where 1 μm = 1,000 nm = 10,000 cm-1. 
Molecules absorbed in the mid-IR range have spectral peaks that range from 4000-200 cm-1. We 
were specifically interested in analyzing the distribution of lipids – 1715-1755 cm-1 (>C=O 
stretching of lipid esters), glutamate – 1565-1590 cm-1, amide I band – 1610-1710 cm-1 (C=O 
hydrogen bonded symmetrical stretching), amide II – 1520-1560 cm-1 (C-N stretching or N-H 
and CH2 bending vibrations), platelets – 2905-2944 cm-1 (–CH2 symmetrical stretches of lipid 
acyl chains in platelets), fibrinogen – 1390 cm-1, and cholesterol esters – 2960 cm-1 (C-H 
asymmetrical stretching of methyl groups found in fatty acids, phospholipids and cholesterol 
esters) [137]. These molecules were mapped as they are physiologically relevant for blood 
composition and are known to be affected during ischemia. The spectral range for each of these 
peaks were determined either by directly identifying the peaks present in the samples using 
Orange software or by using reference peaks from previous literature in which bands pertaining 
to fibrinogen, hemoglobin, erythrocyte membrane lipids (cholesterol ester) and other plasma 
proteins were identified in whole blood samples and its constituents [137].  
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1.9.2.1 Globar versus Synchrotron source  
The development of FTIR was followed by the development of IR spectrometers over three 
generations. The FTIR spectrometer was a third generation model which was defined by an 
inbuilt interferometer [135]. The FTIR spectrometer and microscope at the Mid-IR beamline at 
the CLS are setup to function with either a synchrotron or a globar radiation source. FTIR 
performed with a synchrotron source generates 100-1000× higher brightness and yields in 
smaller regions to be probed as opposed to a globar source. In addition, other advantages of 
using a synchrotron source includes pulsed time structure, higher degree of polarization, and 
improved signal-to-noise [138], [139]. While the synchrotron does provide more advantages than 
a globar source, it does have some disadvantages as well. For instance, technical issues that 
result in beam shut-down affect experiments and data collection, and since raster scanning is 
time consuming, it is only practical to scan smaller regions. For samples that are scanned at a 
spatial resolution of ≥ 20 μm, the globar source is sufficient for providing good resolution, 
sensitivity and brightness [138]. 
1.10 Study goals, research questions, and hypothesis  
The aim of this study was to characterize thrombus composition using multimodal imaging tools 
which combined conventional histochemical techniques with advanced-synchrotron based XFI 
and FTIR techniques to answer the following research questions:  
1. Does stroke etiology influence thrombus composition? 
2. Does thrombus composition affect stroke severity, recanalization success, choice of 
thrombectomy device, and 90-day functional outcomes? 
3. Does choice of thrombectomy device and recanalization success affect 90-day functional 
outcomes? 
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4. Does elemental or organic biochemical composition of thrombus correlate with stroke 
etiology or 90-day functional outcomes? 
5. Does thrombus perviousness correlate with stroke etiology or clinical parameters? 
We hypothesized that; 1) there is no significant difference in composition between cardioemboli 
and artery-to-artery emboli, 2) thrombus composition would not be one of the factors in affecting 
stroke severity or EVT outcomes, 3) ADAPT would work better in retrieving erythrocyte-rich 
thrombi, and 4) artery-to-artery emboli would have higher distribution of heavier biological 
elements such as Fe, and Cu. To investigate the proposed research questions, we analyzed the 
composition of freshly retrieved thrombi using multiple imaging techniques including; X-ray 
fluorescence imaging, Fourier transform infrared spectroscopy, conventional histology and 
immunohistochemical techniques, and retrospectively correlated compositional findings with 
clinical and interventional outcomes.  
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Chapter Two: Methodology 
2.1 Demographic and clinical characterization of patients 
Between September 2017 and January 2019, we enrolled 28 patients with AIS who received 
EVT at Royal University Hospital (RUH), Saskatoon, Saskatchewan Canada. The study protocol 
was approved by the Biomedical Research Ethics (Bio-RED) Board of University of 
Saskatchewan (internal ID 17-196). For this particular study, the inclusion criteria included 
participants with AIS ≥18 years old, in whom intracranial hemorrhage had been ruled out. 
Patients gave informed consent for the study prior to hospital discharge. If patients were unable 
to give consent, a family member consented on their behalf. However, we attempted to reconsent 
the patient when they became able to sign.  
During clinical evaluation, information on stroke presentation, including date, time, and 
symptoms of stroke onset, were collected. There are two common sources of origin for thrombo-
emboli that cause ischemia, proximal arteries (artery-to-artery embolism) or the heart 
(cardioembolism). For some patients that presented at the emergency with an unknown cause 
(i.e. etiology) of stroke, the CTA was used to identify the possible cause: if carotid stenosis (i.e. 
narrowing of the carotid) was observed on the CTA, the etiology for ischemia was considered to 
be an artery-to-artery embolism; if carotid stenosis was not observed, the etiology for ischemia 
was considered to be cardioembolism (Fig. 2-1). In addition, the patient’s medical records were 
reviewed to determine stroke etiology. Conditions such as atrial fibrillation, valvular heart 
disease, large artery atherosclerosis, or any other condition of immediate concern to stroke were 
all taken into consideration. We also collected every participant’s smoking status, medical 
history, and medication history from 30 days prior to hospitalization until they were discharged. 
All medications were documented. If participants were administered specific pre- or post-
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procedural medications, including anti-coagulants, thrombolytics, or platelet aggregating 
inhibitors, this information was collected. We collected information on the location of large 
vessel occlusion, collateral flow status, thrombus density sign, surgical outcomes including the 
type of interventional technique performed (i.e. angioplasty, direct contact aspiration and use of 
stentrievers) and all surgical devices used during each approach. Specific stroke scores including 
their Thrombolysis In Cerebral Infarction (TICI), Alberta Stroke Program Early Computed 
Tomography Score (ASPECTS), pre- and post-treatment National Institute of Stroke Scale 
(NIHSS), and 90-day modified Rankin Scale (mRS) were collected as well.  
Figure 2-1: Carotid Stenosis. 
Computed Tomography 
Angiography (CTA) performed 
on patient using Isovue300 
contrast agent. Angiogram shows 
carotid stenosis (indicated by 
arrow). Angiograms were used 
for identifying stroke etiologies 
for those patients who we had no 
information on at the time of 
admission. Presence of stenosis 
indicated artery-to-artery 
embolism and absence high 
grade stenosis indicated 
presumed cardioembolism.  
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2.2 Acute intervention and mechanical thrombectomy procedure 
2.2.1 Neurological examination and Stroke Score Assessment  
 Emerging laboratory work and neurological assessment was performed for all stroke patients 
arriving in RUH. During neurological examination, patients were assigned a pre-treatment 
National Institute of Stroke Scale (NIHSS) score. Following that, pre-procedural Non-Contrast 
Computed Tomography (NCCT) was performed to rule out hemorrhagic strokes and assign an 
Alberta Stroke Program Early Computed Tomography Score (ASPECTS). Furthermore, pre-
procedural CTA confirmed the presence and location of large vessel occlusion, and collateral 
flow status. Additionally, Thrombolysis In Cerebral Infarction (TICI) scores were collected post-
recanalization. All the clinical and radiographic scales used in the study patients are defined 
below.  
2.2.1.1 NIHSS SCORE 
The NIHSS scores range from 0 to 42, where a score of 1 is defined as a minor stroke whereas a 
score of 42 is defined as a severe stroke. The NIH scale assesses and scores a number between 0 
and 4, 0 indicating normal functioning and 4 indicating complete impairment, in each of the 
following categories; level of consciousness, horizontal eye movements (gaze), visual fields, 
facial palsy, arm movements, leg movements, limb ataxia, sensory deficits, aphasia (language), 
dysarthria (slurred speech), and neglect (extinction and inattention) [140]. The final NIHSS 
scores are calculated by adding scores from each individual category. For bar graphs showing 
correlations between stroke severity and clinical outcomes, a NIHSS of 10 was used as a cut-off 
score because, previous studies had shown a score ≥ 10 as a cut-off point for differentiating a 
minor-to-moderate stroke from a moderate-to-severe stroke [141], [142]. 
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2.2.1.2 ASPECTS SCORE 
ASPECTS is a 10-point quantitative scoring system used for evaluating the volume of cerebral 
infarction on NCCT. The score was developed to assess early ischemic changes in regions 
distributed over the MCA territory. To compute the ASPECT score, 1 point is subtracted from 
the initial score of 10 for every region involved. The 10 regions assessed are: 1- frontal 
operculum (M1), 2- anterior temporal lobe (M2), 3- posterior temporal lobe (M3), 4- anterior 
MCA territory (M4), 5- lateral MCA territory (M5), 6- posterior MCA territory, 7- caudate, 8- 
lentiform nucleus, 9- internal capsule, and 10- insular cortex [143]. Variations in the ASPECTS 
scoring system arise when assessing lesions in the posterior circulation. For example, 1 point is 
deducted for lesions of the thalami, occipital lobes, and cerebral hemispheres, and 2 points are 
deducted for lesion of the midbrain or pons [144]. Refer to section 1.1 for detailed information 
on the cerebral vasculature. Different institutions employ different modalities for assessing 
ASPECTS. For example, a study by Molina et al. assessed ASPECTS using diffusion-weighted 
imaging [145] while a study by Campbell et al used infarction volume on cerebral blood flow by 
perfusion CT [75]. 
2.2.1.3 TICI SCORE 
TICI is intended to standardize scoring of the angiographic outcomes by evaluating reperfusion 
and recanalization success in response to thrombolytic therapy [146]. The evaluation categories 
span from no perfusion to complete perfusion where, grade 0 indicates no reperfusion; 1 
indicates incomplete or partial reperfusion with no distal flow; 2a indicates incomplete or partial 
reperfusion with incomplete (< 50%) distal flow; 2b indicates incomplete or partial reperfusion 
with incomplete (> 50%) distal flow; 2c indicates near-to-complete reperfusion; and 3 indicates 
full reperfusion with complete distal flow. Even though the TICI scoring system is criticized for 
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its internal inconsistencies and arbitrary scale, it is still widely used and accepted in medical 
literature [146].  
For bar graphs showing correlations between TICI and other clinical outcomes, TICI scores were 
grouped in either of the two categories (TICI 1-2a or TICI 2b-3) to differentiate incomplete or 
partial recanalization from near-to-complete recanalization. Participants in whom no 
recanalization (TICI 0) was obtained, were excluded from this study as there was no thrombus 
sample retrieved from those patients to analyze.  
2.2.2 Endovascular therapy: thrombectomy procedure  
To be eligible for mechanical thrombectomy, AIS patients had to meet specific clinical and 
radiographic inclusion criteria including; 1) NIHSS > 5, 2) ASPECTS > 5, and 3) confirmation 
of large vessel occlusion on CTA. Of all the patients enrolled in this study, who had a large 
vessel occlusion, 14.3% (4 out of 28) of AIS patients received IV-tPA prior to mechanical 
thrombectomy. CTA was performed using Isovue300 (Iopamidol injection 61%; Bracco 
Diagnostics Inc.), an iodine-based contrast agent. Prior to starting the thrombectomy procedure, 
patients were either administered local anaesthesia - lidocaine with conscious sedation, or a 
general anesthesia. 
Thrombectomy procedure: In all cases, a right 5 French femoral artery sheath and a 5 French 
diagnostic catheter was placed over a 0.35” wire into the affected parent artery. After running 
diagnostic angiography, the diagnostic catheter was exchanged for a 6F sheath (Neuron Max; 
Penumbra Inc., California USA), to provide robust intracranial support. A Velocity 
microcatheter (Penumbra Inc., California USA), and Synchro 2 standard or Fathom microwires 
(Neurovascular, Michigan, USA; and Boston Scientific, USA) were advanced into and across the 
occluded vessel. In some cases, small doses of intra-arterial verapamil were infused to prevent 
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catheter-induced vasospasm. Thrombectomy was performed using either stentrievers or direct 
contact aspiration. Commonly used stent-retrievers included: Platinum Solitaire 
Revascularization device 6×40mm or 4×40mm (Medtronic Inc., Irvine, California, USA), Trevo 
XP 6×25mm (Stryker Inc., Michigan, USA), and Penumbra 3D Separator (Penumbra Inc., 
California, USA). For aspiration, a large bore aspiration catheter, Ace 68 (Penumbra Inc., 
California, USA) was placed at the thrombus face. The catheter was attached to the aspiration 
tube and Pump MAX vacuum (Penumbra Inc., California, USA). If aspiration alone was 
unsuccessful, then a combination technique called Solumbra was used. In this technique, the 
stent-retriever was delivered through the reperfusion catheter [147]. All procedures were 
performed using biplane angiography and roadmapping. To secure closure of the femoral artery, 
StarClose SE Vascular Closure System was used. The retrieved thrombus sample was then sent 
to the laboratory for further analysis within 30-60 minutes of retrieval.  
2.2.3 Post-thrombectomy care and evaluation 
Some patients received anticoagulants or anti-platelet drugs such as heparin, Clopidogrel 
(Plavix), Abciximab (Reopro) or verapamil (calcium channel blocker) post-thrombectomy. 
Long-term clinical conditions for patients were assessed using the modified Rankin Scale (mRS) 
and NIHSS, 90 days after discharge by means of a hospital visit by a neurologist, who was not 
aware of the treatment assignments, and who had specific training and certification in stroke 
outcome assessment. Modified Rankin Score (mRS) evaluated their neurologic disability which 
was scored from 0 to 6, where a score of 0 meant no symptoms while 6 indicated death.  
2.3 Thrombus sample collection and processing  
Freshly retrieved thrombi were cut in half where one half of the thrombus was brought to the 
pathology department (RUH and City Hospital, Saskatchewan, Canada) to be formalin fixed, 
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paraffin embedded and stained with H&E, Masson’s Trichrome, factor VIII/von Willebrand 
factor (vWF), CD31, and CD68. The other half of the thrombus was transported to our laboratory 
where we flash froze the thrombus in 2-methylbutane (isopentane) and stored it at -80°C until 
sectioning. The flash frozen samples were serially cryosectioned for XFI and FTIR analysis. 
Since both XFI and FTIR techniques measure labile elements and molecules, it was essential to 
flash freeze and leave the samples untreated, unlike paraffin embedded sections, to prevent any 
alterations or changes in biochemical information. Alternatively, for histological analysis, we 
used the paraffin sections produced by the pathology laboratories in RUH or City Hospital, 
rather than cryosections because cellular morphology was better preserved in paraffin sections.  
2.3.1 Paraffin embedding and sectioning  
Fresh thrombus samples were fixed in 10% formalin for 2 hours, placed in embedding cassettes, 
and embedded in paraffin wax. To remove water from within the cells, the samples were 
dehydrated in 70% ethanol, 1 change, 1 hour, 95% ethanol, 2 changes, 1 hour each and 100% 
ethanol, 3 changes, 1 hour each. Alcohol and wax are insoluble together. Thus, alcohol must be 
replaced with an intermediate solvent which is miscible in both alcohol as well as paraffin wax. 
The intermediate solvent is called a clearing agent because it imparts transparency on the tissue 
due to its high refractive index [148]. The samples were cleared in Xylene, 2 changes, 1 hour 
each. Lastly, to infiltrate wax into the cells, tissues were incubated in liquid wax at 60°C, 3 
changes, 1 hour each. 
Once the tissues were completely infiltrated in wax, embedding blocks were prepared for 
sectioning, by orienting the tissue and pouring molten wax into the mold over the tissue sample. 
Once the wax block hardened, paraffin blocks were sectioned using a microtome. Ribbons of 
55 
5μm thick sections were floated in a 40-45°C water bath and sections were mounted on slides 
and dried overnight in a 35°C oven.  
Prior to performing any histology or immunohistochemistry, paraffin embedded sections were 
deparaffinized in xylene and hydrated by incubating in 100% ethanol, 70% ethanol and then 
distilled water.   
2.3.2 Flash freezing and cryosectioning  
As previously mentioned, for the purposes of this study, freshly retrieved thrombi were 
processed in two ways, where one half of the thrombus was formalin fixed, and paraffin 
embedded to preserve cellular morphology while the other half was flash frozen to prevent the 
loss of labile biochemical information.  
Samples were placed in an OCT embedding matrix prior to flash freezing to prevent 
fragmentation and sectioning artifacts. 2-methylbutane (Fisher; 03551-4) was used as a flash 
freezing agent, as it froze the samples quicker than liquid nitrogen alone and prevented ice-
crystal formation. The samples were flash frozen within 30-60 minutes after being retrieved out 
of the patients and cryosectioned at -20°C using a cryomicrotome (Avantik) at 7μm thickness for 
histology (H&E), and FTIR analysis, and 30 μm for XFI. Sections produced for histology and 
FTIR analysis were stored in a -80°C freezer while sections produced for XFI analysis were 
stored at room temperature until imaging. Even though cryosections were mainly produced for 
FTIR and XFI analysis, we were keen to determine whether thrombus components such as 
erythrocytes or fibrin contributed to specific distribution patterns or co-localization of elements 
and macromolecules. Thus, adjacent sections to FTIR and XFI were stained with H&E and 
Martius Scarlet Blue. 
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Note: The flashing freezing window was established by conducting an experiment which 
tested the effects of different freezing time-points, including; 5 mins, 15 mins, 30 mins, 1 
hr, and 2hrs on the quality of our samples. While literature recommended for blood 
samples to not sit at room temperature for more than 15 mins, as it compromised blood 
integrity, processing the thrombus sample within 15 mins of retrieval was not feasible for 
us. Thus, taking transportation and preparation times into account, we established 30-60 
mins as our flash-freezing window. 
2.3.3 Histology  
Histology and immunohistochemistry techniques on paraffin sections were performed by the 
histology technicians in RUH or City Hospital pathology laboratory. 5μm paraffin sections were 
stained with H&E, and Masson’s Trichrome and immunolabelled with factor VIII/vWf for 
platelets (rabbit polyclonal anti-human; Dako Agilent), CD31 for endothelial cells (mouse 
monoclonal anti-human; Dako Agilent), and CD68 for macrophages (mouse monoclonal anti-
human; Dako Agilent M 0876). Histology on frozen sections were performed in our laboratory. 7 
μm frozen sections were stained H&E and Martius Scarlet Blue. Detailed protocol of all the 
histological stains and immunohistochemistry performed on paraffin and frozen sections are 
given below.  
2.3.3.1 Hematoxylin and Eosin (H&E) – coverstainer process for paraffin sections 
After deparaffinization, sections were placed in Hematoxylin (S330230-5; Agilent) for 45 
seconds to stain the nuclei, then rinsed in distilled water for 1 min and stained blue in a blue 
buffer for 1 min (IBF-100; Agilent) to convert the soluble red stain within the nucleus into an 
insoluble blue stain. Sections were then washed in tap water and differentiated in 70% alcohol 
for 1 min, followed by counterstaining in Eosin for 1.5 mins to stain the cytoplasm and 
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erythrocytes. Finally the sections were dehydrated in 4 changes of 100% ethanol, and cleared 
using Histoclear (NDIHS-200, Diamed), and then coverslipped. 
Note: Histoclear was used as an alternative to xylene as it prevented tissue brittleness, 
rendered fine details in nuclear morphology and improved H&E staining by yielding a 
brighter Eosin background [148].  
2.3.3.2 Masson’s Trichrome – for paraffin sections 
After deparaffinization, sections were fixed in Bouin’s solution for 12 minutes at 56°C, then 
rinsed in tap water to remove any excess yellow residues from the fixative and washed in 
distilled water for 2 minutes at 42°C. The entire staining process was automated using the 
Artisan Link process (AR17311-2; Agilent). Sections were incubated in Weigert’s A/Weigert’s 
B iron hematoxylin solution for 10 minutes to stain nuclear chromatin, then washed in tap water 
followed by a quick rinse in distilled water. Next, the sections were stained in Biebrich scarlet-
acid fuchsin for 2 minutes to stain acidophilic cytoplasm and erythrocytes and differentiated in 
phosphomolybdic-phosphotungstic acid solution for 12.5 minutes at 40°C. Lastly, the sections 
were stained in aniline blue for 10 minutes at 35°C to stain fibrin, then washed in distilled water 
and differentiated in acetic acid for 3 minutes. Finally, the sections were dehydrated through 
95% ethanol, 100% ethanol, then cleared in xylene and mounted using a resinous mounting 
media such as cytoseal.  
 Note: the differentiation step in phosphomolybdic-phosphotungstic acid solution enabled 
a substitution reaction whereby the phosphomolybdic-phosphotungstic acid taken up by 
 the fibrin was replaced by aniline blue to stain fibrin in blue. 
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2.3.3.3 Hematoxylin and Eosin – manual process for frozen sections 
The H&E protocol used for staining frozen sections was different than that used for the paraffin 
sections wherein, the frozen sections were thawed and fixed in 4% paraformaldehyde (PFA) (J.T. 
Baker; S898-09) for 5 mins, then washed in 0.1M phosphate buffered saline (PBS) for 15 mins 
and stained in modified Harris hematoxylin (C.I. 75290) for 4 mins. The sections were then 
rinsed in 0.5% acid alcohol to remove excess hematoxylin and stained in 1.54% saturated 
aqueous lithium carbonate for 5 seconds to enhance blueing, followed by rinsing in running tap 
water for 3 mins. The sections were then counterstained in Eosin Y (C.I. 45380) working 
solution for 30 seconds which was prepared by adding 1 part stock solution (1.25% Eosin Y in 
70% ethanol containing 1% glacial acetic acid) to 4 parts 70% ethanol. The sections were 
dehydrated through 70% ethanol; 95% ethanol (Commercials Alcohol; 001-02-17N), 100% 
ethanol (Commercials Alcohol; 106-02-17N), and then cleared in xylene (Fischer; X5-4). 
Samples were mounted in resinous mounting media, cytoseal (Richard-Allan Scientific; 8310-4).   
2.3.3.4 Martius Scarlet Blue – manual process for frozen sections  
The MSB stain was an alternative stain to the Masson’s trichrome used on frozen sections for 
staining erythrocytes and fibrin. Sections were thawed and fixed in 4% paraformaldehyde for 5 
mins, then washed in 0.1M PBS for 10 mins, followed by a quick rinse in distilled water. The 
sections were stained in modified Harris hematoxylin stain for 5 mins, then rinsed in 95% 
alcohol for 5 seconds to remove excess hematoxylin and then stained with 0.2% Martius yellow 
(Aldrich; 377767-25G) in 95% ethanol containing 2% phosphotungstic acid (Fischer Scientific; 
12501-23-4) for 2 minutes to stain erythrocytes. The sections were then rinsed in distilled water 
and stained with 1% crystal ponceau 6R (Sigma; C0644-5G) in 2% glacial acetic acid (BDH; 
AC500-78) for 10 mins to stain fibrin, followed by a quick rinse in water and differentiation in 
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1% phosphotungstic acid for 5 minutes. The sections were rinsed in water and stained with 0.5% 
methyl blue (C.I. 42780; Fischer Scientific; 28983-56-4) in 1% glacial acetic acid for 2 minutes 
to stain collagen. Finally, the sections were dehydrated through 70% ethanol; 95% ethanol, 100% 
ethanol, and then cleared in xylene (Fischer; X5-4). Samples were mounted in resinous mounting 
media, cytoseal (Richard-Allan Scientific; 8310-4).  
Note: The MSB stain did not work on frozen sections despite our multiple attempts to 
modify and optimize the protocol with different incubation times, as well as using different 
types of fixatives including: 4% PFA, 10% formalin, acetone, methanol, and PFA vapours. 
Similarly, H&E stain did not work on the frozen sections. Most of the erythrocytes were 
being washed off in the solutions, compromising cellular features and misleading our 
interpretation. Furthermore, we also attempted to optimize the staining protocols on whole 
blood smears collected from mice to eliminate confounders, including product quality 
(which ensured that the staining products worked), and hemolysis (which determined if the 
stains only worked on whole blood cells as opposed to hemolyzed cells present in a 
thrombus). Despite optimizing the protocol with various tweaks, all attempts were 
unsuccessful. Thus, histological results of frozen sections were not included in the analysis 
and thesis. Instead, we solely used paraffin sections for correlating histological findings 
with clinical and interventional outcomes, as well as with XFI and FTIR outcomes. 
However, there was a limitation to this approach. The paraffin sections were not adjacent 
to the frozen XFI or FTIR sections. Nevertheless, since the paraffin and frozen sections 
belonged to the same thrombus, all analyses were performed in an extrapolative manner.  
2.3.4 DAB chromogen immunohistochemistry for paraffin sections 
All immunostaining procedures were performed on the Autostainer link instruments using Dako  
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EnVision Flex + detection system. After deparaffinization, and rehydration, sections underwent 
heat-induced epitope retrieval (HIER) using an enzyme pre-treatment procedure (water-bath 
method). Target retrieval solution (30 ml of 50× concentrate; EnVision Dako; K8004) was 
diluted with 1470 ml distilled water to obtain 1:50 dilution (i.e. 1.50L working solution 
containing Tris/EDTA buffer, pH 9). Agilent PT link tank was filled with 1.5 L of target retrieval 
working solution to ensure that all slides were completely immersed. The solution was preheated 
to 85°C. Deparaffinized, hydrated sections were incubated in the retrieval working solution of 
pH 9 at 97°C for 20 minutes. Sections were allowed to cool in the PT link tank to 85°C, and then 
rinsed in EnVision Flex wash buffer (K8007), 1:20 dilution containing Tris-buffered saline 
solution with Tween 20, pH 7.6, for 5 minutes. 
After the HIER procedure, sections were blocked for 5 minutes using the ready-to-use zFLEX 
peroxidase-blocking reagent (SM801) to reduce non-specific background staining, which was 
then followed by a buffer rinse. Factor VIII/vWF and CD68 were immunolabelled using the Flex 
protocol whereas CD31 was immunolabelled using the Flex+ Mouse Linker protocol. Sections 
were applied with the following primary antibodies: 
- Monoclonal mouse anti-human CD68 (M0876) diluted to 1:250 in ready-to-use 
antibody diluent  (K8006) 
- FLEX monoclonal mouse anti-human CD31 (IR61061-2) prediluted 
- FLEX polyclonal rabbit anti-human vWF (IR52761-2) prediluted 
Flex + Mouse linker protocol included an additional step after primary antibody incubation, 
where sections were treated with secondary antibody mouse linker for 15 minutes prior to 
polymer labelling as opposed to the Flex protocol where sections were directly labelled with 
polymer after completing their incubation in the primary antibody. The polymer-labelling step 
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was performed for 20 minutes using the ready-to-use zFLEX/HRP reagents (SM802) which 
consisted of a dextrane backbone to link up peroxidase molecules to the antibody molecules and 
amplify the detection signals. Sections were then rinsed in wash buffer several times for 5 
minutes and treated with zFLEX DAB + Chromogen substrate working solution for 10 minutes 
which was prepared by adding 1 drop of concentrated DAB chromogen (EnVision Dako; 
DM827) in 1 ml substrate buffer containing hydrogen peroxide (EnVision Dako; SM803). 
Finally, the sections were counterstained with hematoxylin using the coverstainer process, and 
mounted using an aqueous mounting medium. 
All the histology and immunohistochemistry slides were viewed and photographed using a 
Nikon light microscope (Royal University Hospital, Department of Pathology and Laboratory 
Medicine, Saskatchewan, Canada). 
2.4 Histological analysis using ImageJ software  
To classify a thrombus as either red (RBC rich) or white (fibrin rich), Masson’s trichrome 
stained sections were quantified using ImageJ software [https://imagej.net/Fiji], where 
predominant regions stained with fibrin and erythrocytes were separated into red, blue and green 
channels using the software’s trainable WEKA segmentation plugin 
[https://imagej.net/Trainable_Weka_Segmentation]. All images were acquired using the Nikon 
microscope under identical conditions where the automatic exposure and white balance were 
turned off. The images captured from the light microscope were stored in the 24-bit RGB and 
1280 (width) × 960 (height) resolution.  
In ImageJ (version 3.2.28), once the Masson’s trichrome stained image was opened, the image 
was processed using the trainable WEKA segmentation (TWS) plugin. In the new trainable 
WEKA segmentation dialog box, the following steps were applied. First, three separate classes 
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were created: RBC regions, background, and fibrinous regions. Using different selection tools, 
regions of interest (ROIs) were traced and added into their respective classes. Traces for RBC 
regions were highlighted in red, background was highlighted in green, and fibrinous regions in 
purple. Then, we employed the “Gaussian blur” and “Differences of Gaussian” features to reduce 
image noise. All the other default training features were kept the same. Next, a probability map 
of each pixel belonging to its respective class was displayed as a 32-bit hyperstack representing 
the three channels (background, RBC traces, fibrin traces) in a black-white-gray colour hue.  
Thresholding ROIs on the 32-bit hyperstack – Each of the 32-bit channels were manually 
adjusted using the “threshold” feature. The same threshold values were applied to every image.   
RBC regions: upper slider – 0.45   Fibrinous regions: upper slider – 0.50 
        lower slider – 1e30                 lower slider – 1e30 
After thresholding each channel, the background pixels were set to not-a-number by selecting 
“set to NaN”, which allowed us to convert the image into a binary black-white image which 
eliminated gray overlapping areas. The binary images could now be used for an area-based 
analysis to independently measure ROIs representing areas covered by red blood cells and fibrin 
(Fig. 2-2). Raw values obtained for each thrombus were entered into an excel spreadsheet and 
converted into a percentage value (table 3-2) using the following formula:  
 % RBC = RBC measured ROIs/total area × 100 
 % Fibrin = Fibrin measured ROIs/total area × 100 
The total area was obtained by adding the RBC and fibrin ROIs. Thrombi were classified as red 
if % RBCs > % Fibrin, or white if % RBCs < % Fibrin. In the case where patients had multiple 
fragments occluding their vessels, each of those fragments were sectioned serially, and labelled 
as section 1 (s1), section 2 (s2), section 3 (s3), and so on. During quantification, each of the 
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sections were separately quantified, and then added together to obviate bias, as shown in table 
3-2. One of the patients (Pt 24) had two strokes in one day where one thrombus was retrieved 
from the left MCA and the other thrombus was retrieved from the right MCA. Even though the 
thrombi were retrieved from the same patient, they were treated as two separate samples. The 
quantification procedure was not blinded.  
Figure 2-2: Flowchart of ImageJ analysis for histological quantification. A step-by-step 
protocol for quantifying regions of erythrocytes and fibrin on Masson’s trichrome stained 
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sections of cerebral thrombi using the trainable WEKA segmentation plugin in ImageJ software. 
Traces for RBC regions were highlighted in red, background was highlighted in green, and 
fibrinous regions in purple. 
 
2.5 X-ray fluorescence imaging 
Samples were sectioned at 30 μm and collected on metal-free plastic Thermanox coverslips 
(Thermo Scientific). XFI took place at the SSRL where three imaging beamlines, 10-2, 2-3 and 
14-3, were utilized. Beamline 10-2 was used to produce hard x-ray maps at an energy of 13,450 
eV for mapping elements from Al-Se. Beamline 2-3 also used an incident energy of 13,450 eV to 
map elements from Al-Se at a higher resolution. Beamline 14-3 was utilized to produce soft x-
ray maps at two different energies: 4,100 eV was used for mapping Al-Ca while 2,510 eV was 
used for mapping different sulfur species. Data for XFI was analyzed using Sam’s Microprobe 
Analysis Kit (SMAK) [https://www.sams-xrays.com/smak] and ImageJ.  
2.5.1 10-2 beamline setup and data analysis tools  
An incident energy of 13,450 eV, just below the K-edge of Br, was used to map the distribution 
of a wide range of elements at their physiological concentrations including P, S, Cl, K, Ca, Fe, 
Cu, Zn, and I. Even though Na and Mg are biologically relevant elements, they were too low to 
observe in these experiments. The beamline set-up was similar to that described previously by 
Pushie et al. 2018 [149]. The beamline was running with SPEAR3 storage ring operating on a 
top-up mode at an energy of 3 GeV and current of 500 mA. All the data for this study was 
collected over two separate beamtimes. During one of the beamtimes, we used a 1-element 
detector, and collected fine scans at 200 ms dwell time and 30 μm stepsize. During our 
subsequent beamtime, we used a silicon vortex 4-element array detector (Hitachi High-
Technology Science America, Inc., Northridge, CA) and collected fine scans at 100 ms dwell 
time and 30 μm stepsize. Beamline 10-2 employs a 33-pole, 1.27-Tesla wiggler, and 1.5 mrad 
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angular acceptance. The beamline used a Si(111) double crystal monochromator at phi=90° with 
a 1.2 m long horizontally and vertically collimating Rh coated bent cylindrical mirror (M0). The 
beam was microfocused using a pinhole of 35 μm, set at an angle of 34°. The motor and ion 
channels were calibrated prior to the start of data collection. Samples were placed in an ambient 
temperature and mounted horizontally on a precision stage which was placed at a 45° angle to 
the silicon-drift vortex detector. For every sample, we collected coarse scans prior to the fine 
scans to assess the quality of the sample, measure X-Y coordinates required for fine scans, and 
estimate the amount of time required to run a fine scan for each sample.  
Data was directly acquired from the SSRL server and analyzed using the SMAK software. Using 
this software, binned spectra of interested elements were fitted using the multichannel analyzer 
spectrum to yield in more accurate elemental quantification and improve signal-to-noise [149] 
especially for K and Ca. The Kα fluorescence emission lines for K and Ca overlap contributing to 
a falsely high measurement for Ca which is caused by X-ray fluorescence photons from areas 
with high K [149]. The fitted data was then quantified using calibration standards deposited on a 
6.3 μm mylar film which enabled us to convert fluorescence intensities into areal concentrations 
(μg/cm2). When elements of interest were fitted using the multichannel analyzer spectrum, we 
also included argon as one of the elements as argon is abundantly present in the atmosphere and 
should be accounted for during fitting. Elements mounted on the calibration standards had the 
following concentrations: Ca (CaF2 foil, 56.8 μg/cm2); K and Cl (KCl foil, 98.8μg/cm2); Fe (Fe 
foil, 56μg/cm2); Cu and S (CuSx foil, 74.9μg/cm2 and 21.0 μg/cm2, respectively); Zn (ZnTe foil, 
45.8μg/cm2); P (GaP foil, 47.0 μg/cm2); and I (RbI foil, 49.0 μg/cm2).  
In order to quantify the concentration of elements present in the sample, it was important to mask 
any background pixels contributing to false counts and only select the pixels representing the 
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sample. In SMAK, under correlation plots, we plotted sulfur and chlorine columns; however, any 
two columns can be plotted against each other. To select pixels representing the sample and 
mask any background pixels, a red polygon was traced over the region of interest. The pixels that 
were left out from the polygon (white arrow) indicated background pixels (Fig. 2-3). When the 
mask was applied to the image display, it only showed areas of the map where the selected 
correlation existed.  
A total concentration count (mean 
values) was acquired and the quantified 
data was exported into an excel 
spreadsheet and correlated with clinical 
outcomes. Along with the quantified 
data, heat maps were produced to 
visually assess regions containing high 
and low concentrations of elements 
present within the samples using 
rainbow pseudo-coloured maps. To 
obtain XFI heat maps, each of the 
previously fitted and quantified maps were smoothed using the blur feature which took Gaussian 
distribution of the area. The “filter size” was set to 5 which defined how many pixels were 
combined into one using 5×5 pixel area and the “std.dev” was set to 0.8. For each of the blurred 
maps exported to ImageJ as text images, the threshold intensities were set to the same values, 
and the final image panels were created using ImageJ and Adobe Photoshop CC 2018 (Adobe 
Systems, San Diego, USA). 
Figure 2-3: X-ray fluorescence imaging 
correlation plot. A correlation plot of sulfur and 
chlorine used for masking background pixels 
(white arrow) and selectively highlighting pixels 
that represent only the sample (red dotted polygon) 
in Sam’s Microprobe Analysis Kit (SMAK).  
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2.5.2 2-3 beamline setup and data analysis tools 
Higher resolution images of specific regions in the thrombus samples were captured using 
beamline 2-3 at an incident energy of 13,450 eV to image the distribution of P, S, Cl, K, Ca, Fe, 
Cu, Zn, and I. The beamline was running with SPEAR3 storage ring operating on a top-up mode 
at an energy of 3 GeV and current of 200 mA. Beamline 2-3 employs a 33-pole, 1.3-Tesla bend 
magnet, and 0.75 mrad angular acceptance. The beamline used a water cooled Si(111) double 
crystal monochromator at phi=90° with Kirkpatrick-Baez (K-B) mirrors directly imaging the 
bending magnet source. The microfocused beam size was approximately 2×2 microns. The 
motor and ion channels were calibrated prior to the start of data collection. Samples were placed 
in an ambient temperature and mounted horizontally on a metal stage which was placed at a 45° 
angle to the vortex silicon drift detector (Hitachi High-Technology Science America, Inc., 
Northridge, CA). For every sample, we collected coarse scans prior to the fine scans. Fine scans 
were collected at 100 ms dwell time and 2 μm stepsize. 
All the data acquisition and analysis steps were similar to those described in the previous section 
where each of the binned elemental spectra were first fitted using the multichannel analyzer 
spectrum and then quantified using the calibration standard foils (mentioned in section 2.5.1), 
deposited on a 6.3 μm mylar film which enabled us to convert fluorescence intensities into areal 
concentrations (μg/cm2). The quantified maps were then imported into ImageJ as text images 
where they were then applied with a jet colour scheme and set at the same threshold intensities. 
The final image panels were generated using Adobe Photoshop CC 2018.  
2.5.3 14-3 beamline setup and data analysis tools 
The beamline source was comprised of a bending magnet and employed a water-cooled Si(111) 
double crystal monochromator at phi=90° with a flat, bent, vertically collimating, Si-Ni coated 
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M0 mirror and a toroidal, bent, 1.2 m Ni-coated M1 mirror. Samples of 30 μm thickness collected 
on Thermanox coverslips were mounted on a circular metal disc and placed at 45° angle to the 
Vortex detector filled with liquid nitrogen. The samples are placed in a helium environment to 
reduce the relative oxygen content to < 0.5% and avoid X-ray attenuation of lower atomic 
elements (P-Ca) due to absorption by Ar, N2 or O2, and create an environment with zero 
humidity to maintain tissue integrity [150]. Prior to setting up samples, all the motors were 
aligned to ensure consistent current flux in the ion channels. In addition, the monochromator was 
calibrated using a sulfur standard at an energy of 2469.2 eV. For every sample, we collected 
coarse scans prior to the fine scans. Coarse scans were collected with a dwell time of 50 ms and 
stepsize of 200 μm while fine scans were collected with a dwell time of 100 ms and stepsize of 
20 μm. An energy at the calcium edge, 4100 eV, was used for mapping the distribution of low Z 
elements: P, S, Cl, K, and Ca. Unlike beamline 10-2, beamline 14-3 uses a low incident energy 
to provide accurate quantification for low Z elements and prevent overlapping of the K and Ca 
spectral K-edge lines. In addition, since we were interested in mapping different sulfur species 
including sulfonic acid, sulfoxide and organic sulfate esters, we collected sulfur maps at various 
energies including; 2465 eV, 2469.85 eV, 2470.8 eV, 2470.55 eV, 2473.5 eV, 2475 eV, 2478.2 
eV, 2479.8 eV, and 2510 eV (total sulfur map) [150].  
Data was directly acquired from the SSRL server. Chemically specific sulfur images were 
produced using SMAK. All of the energies were imported into SMAK and smoothed using the 
blur feature which took Gaussian distribution of the area. The “filter size” was set to 5 which 
defined how many pixels were combined into one using 5×5 pixel area and the “std.dev” was set 
to 0.8. The background fluorescence map collected at 2465 eV was subtracted from each of the 
remaining energies. The newly generated channels were fit using standard model compounds 
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where the normalized fluorescence intensity values for the model compounds, sulfoxides 
(methionine sulfoxide), sulfonic acid (taurine) and O-linked sulfate ester (dextran sulfate), were 
recorded from Hackett et al. (Table S1) [150]. On the other hand, Ca maps were processed in the 
same manner as the 10-2 data, where the binned spectra for low Z elements (P, S, Cl, K and Ca) 
were fitted using the multichannel analyzer spectrum [149]. The fitted data was then quantified 
using the same calibration standards mentioned in the previous sections. To obtain heat maps, 
each of the quantified channels were imported as text images into ImageJ where the same 
threshold intensities were applied to every map represented by the jet colour scheme. The final 
image panels were generated using Adobe Photoshop CC 2018. 
2.6 X-ray absorption spectroscopy 
XAS spectroscopic analysis was conducted at SSRL using beamline 7-3 which utilizes an energy 
range between 5,000-35,000 eV to detect chemical forms for elements from Al-Se. However, we 
were only interested in analyzing the different oxidation states of Fe present in these thrombi 
since Fe is the most abundant element in erythrocytes. Thus, for Fe spectroscopy, we used an 
incident energy of 7,112 eV (Fe K-edge). The beamline was running with SPEAR3 storage ring 
operating on a top-up mode at an energy of 3 GeV and current of 100 or 200 mA. Beamline 7-3 
employs a 20-pole, 2-Tesla wiggler, and 0.8 mrad beam. The experimental and beamline setup 
was adapted from George GN et al. [151]. The beamline was equipped with a 1 m long vertically 
collimating Si, Rh-coated bent mirror (M0) placed upstream of the Si(220) double crystal 
monochromator at phi=90°. Samples were placed in 1 mm×12 mm plastic cuvettes which were 
wrapped with metal-free plastic Teflon tape and stored at -80°C. During data acquisition samples 
were placed in an Oxford Instruments CF1204 He cryostat at a 45° angle. For Fe spectroscopy, 
calibration was performed using a standard cuvette (300 μl of Fe citrate) and a Fe metal foil. The 
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monochromator and the detector were optimized for each element separately. The beam size was 
established based on the sample size, 1 mm×8 mm for the bigger cuvettes and 0.5 mm×6 mm for 
the smaller cuvettes. 30-element Ge detector was windowed using Ge30 plus software. Data 
analysis including calibration, averaging, splining and normalization of XANES was performed 
using the EXAFSPAK tool kit [https://www-ssrl.slac.stanford.edu/exafspak.html]. An X-
environment, Xming [https://sourceforge.net/projects/xming/] was required to display the 
windows for running EXAFSPAK.  
2.7 FTIR spectroscopic imaging 
Samples for infrared imaging were sectioned at 7μm, collected on calcium fluoride (CaF2) discs 
(Crystran, UK) and stored at -80°C until imaging. Mid-infrared beamline at the Canadian Light 
Source (CLS) was used for imaging the distribution of organic molecules. Samples were placed 
on the stage under a purge chamber to remove residual water vapour and increase the amount of 
light. Scans were collected after 15 minutes of purge. Globar-FTIR spectroscopic imaging was 
performed with a Cary 620 FTIR Microscope (Agilent Technologies, Inc.) fitted with an upper 
15× magnification objective with a numerical aperture of 0.4. The microscope was equipped 
with a 128×128 FPA detector with the following parameters specified; speed = 2.5 kHz, 
interferogram sampling interval = 4, and 4 aggregated pixels for 15× magnification and 1 
aggregated pixel for high resolution. This arrangement produced 2×2 binning for 15× 
magnification and 1×1 binning for high resolution. Images were acquired at a spectral resolution 
of 4 cm-1. After correcting for non-uniformity, 64 scans of a background area were collected for 
subsequent background subtraction. After collecting background images, the region of interest 
was scanned.  
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Data for FTIR was analyzed and semi-quantified using Orange software (version 3.15.0) 
[https://orange.biolab.si/download/#windows]. In orange, once the workflow was opened, 
spectrum range for the following peak areas of interest were setup; lipids (1715-1755 cm-1), 
glutamate (1565-1590 cm-1), –CH2 symmetrical stretches of lipid acyl chains in platelets (2905-
2944 cm-1), amide I bands (1610-1710 cm-1), amide II bands (1520-1560 cm-1),  C-H 
asymmetrical stretches of –CH3 groups in cholesterol esters (2960 cm-1), and fibrinogen (1390 
cm-1). Each sample files (.dmt format) were loaded one tile at a time and the preprocessed peak 
areas were automatically applied to each tile. For quantification, we manually selected multiple 
regions of interest (ROIs) from the edges as well as from the middle regions of the sample. The 
second derivative spectra were vector normalized and generated using 13 smoothing points 
Savitzky-Golay function [152] and inverted by multiplying the spectra with a value of -1. All the 
pixels in the selected ROIs were averaged for each peak area in absorbance units (A.U.) and 
represented in a table with their respective standard deviations. All the data tables were exported 
into an excel spreadsheet for further analysis. FTIR distribution maps were generated as .txt files 
using the program Datpush v2.0 [Pushie MJ, © 2018] where each individually extracted energy 
channel was imported into ImageJ, applied with the BGY colour scheme and set to the same 
threshold intensities. The final image panels were generated using Adobe Photoshop CC 2018. 
2.8 Statistical analysis  
Prior to performing statistics, it is important to choose an appropriate type of study design. 
Choosing the right study design determines the way in which a study is conducted, especially for 
ensuring appropriate sampling and data analysis that is intended to achieve reliable results as 
well as answer the research questions proposed in the study [153]. The two primary types of 
study designs include: experimental studies and observational studies. In scientific research, 
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experimental studies can be further categorized into controlled trials (randomized or non-
randomized controlled trials) or uncontrolled trials while observational studies can be 
categorized into cohort studies, case-control studies or cross-sectional studies [154].  
2.8.1 Use of parametric versus non-parametric tests  
Statistics are used for presenting meaningful interpretations of the data, validating the hypothesis 
and providing correct conclusions for the study [155]. When data is interpreted, the p-value, an 
arbitrarily set value, determines the significance of the results and tests the validity of the 
predicted hypothesis. P < 0.05 means that there is less than 5% probability that the results 
obtained are due to chance alone, and the test is considered statistically significant [156]. 
Therefore, all statistical tests are designed to interpret the p value among other parameters such 
as: correlation coefficient (r) which provides evidence for how strongly two variables are 
associated with each other and indicates how changing one variable, changes the direction of the 
other variable without implying any prediction for the outcome variable; Odd’s Ratios (OR) 
which measures an association between treatment and outcome variables to identify the odds that 
the outcome would occur; and 95% confidence intervals (CI) which provide a range of values to 
estimate precision of the mean.  
Parametric and Non-parametric tests are two broad categories in statistics that encompass 
different types of tests that are designed to discover the trends in a population and state a general 
observation for the population (e.g. effects of drugs on a population) using a sample from the 
population. Because we use sample estimates to draw conclusions about a population, we use 
statistical procedures to estimate and validate the mean, standard deviation, and proportions 
[157]. Because we are interested in testing how far the sample mean of the data is from the true 
population mean, we use standard error of the mean (SEM) as opposed to using standard 
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deviation (SD) because SEM measures variability and dispersion of a sample mean around the 
true population mean, assuming that the data is normally distributed. An important distinction 
between parametric and non-parametric statistics is that parametric tests assume that the sample 
is normally distributed while non-parametric tests make no such assumptions and are therefore 
called “distribution-free”. In addition, parametric tests analyze group means while non-
parametric tests analyze group median. Choosing the most appropriate statistical test depends on 
the following factors: 1) sample size, 2) types of variables, 3) type of study design (paired or 
unpaired), and 4) whether or not assumptions pertaining to that particular statistical test are 
satisfied [158], [159].  
1. Sample size (n): for sample size < 25, non-parametric tests are better suited while for n > 
25, parametric tests give stronger and valid results [160]. In general, parametric tests 
yield 5% more statistical power compared to non-parametric tests, but can only be used 
when the data is normally distributed [161]. Thus, in cases where the sample size is 
small, but the data is normally distributed, parametric tests have higher validity, and 
greater power to detect differences.  
2. Variable Types: An independent variable, also known as a predictor variable, is a 
variable that is controlled or manipulated in a study to observe its effects on the 
dependent variable, which is also known as a response or outcome variable. The 
independent or the dependent variable can be measured either on a continuous or 
categorical level. A continuous variable can have infinite number of values between two 
given values as opposed to a categorical variable which only has a finite number of 
categories or distinct groups. A continuous variable can be further categorized as an 
interval or ratio variable. An interval variable is a measurement where the difference 
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between two values is considered meaningful and where the scale is void of true zero 
(examples: temperature in °C). On the other hand, a ratio variable encompasses the same 
properties as an interval variable; however, it is not void of absolute zero (examples: age, 
weight, height). Similarly, a categorical variable can be further categorized as an ordinal 
or a nominal variable. An ordinal variable is organized into ordered categories, where 
assigning ranks to the categories have meaning (e.g.: ranks such as 1st, 2nd, 3rd, or 
educational experience which occurs in an order such as elementary school graduate, high 
school graduate, college graduate and so on). A nominal variable, is one that cannot be 
ordered or measured (e.g. sex, colours, marital status).  
Before choosing a statistical test, one must identify the types of variable being 
investigated to answer the research question.  
3. Type of study design: In scientific experiments, data analysis often involves comparing 
two or more sets of data. If the data is obtained from a single subject at different time 
points (e.g. comparing blood pressure values before and after administering a drug), the 
data is considered to be paired or dependent. If the data is obtained from different 
subjects and the results of two or more groups are compared (e.g. comparing blood 
pressure values of subjects who were given a drug to the blood pressure values of 
subjects in the control group), the data is considered to be unpaired or independent.  
4. Assumptions: Assumptions in statistics play an important role in choosing appropriate 
tests. When assumptions are violated, the power of that test decreases as a result of type I 
and type II errors, consequently leading to either overestimation or underestimation of the 
results. The following are few of the commonly used assumptions in research studies 
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i. Assumption of normality: Data that is normally distributed shows symmetry 
around the centre and follows a bell-shaped curve. The Central Limit Theorem 
states that, as the sample size gets larger, the sample mean tends to approach 
normal distribution. Normality can be tested using skewness and kurtosis, where 
the values should range within ±2 and ±7, respectively, or Shapiro-Wilk test or 
Kolmogorov-Smirnov test where the p value should be greater than 0.05 to satisfy 
this assumption. 
ii. Assumption of homogeneity of variance: This assumption assesses if the two 
groups of variables have equal variances. To satisfy this assumption, Levene’s 
test could be used where a p value greater than 0.05 indicates equality in 
variances. 
iii. Assumption of linearity: This assumption assesses if the two variables have a 
straight-line relationship. Usually when assumptions of normality and 
homogeneity of variances are met, the assumption of linearity is automatically 
taken care of.  
2.8.2 Statistical tests used in this study 
All statistical analyses were performed using IBM SPSS software (version 25.0; Armonk, NY, 
USA: IBM Corp). The baseline characteristics/study demographics are summarized as mean 
(with standard deviation [SD]), or median (with interquartile range). The sample size used for 
this entire study, including analysis of both frozen and paraffin samples, was n = 28.  
In the case where we were investigating the correlation between stroke etiology and thrombus 
composition (Fig. 3-2), we used a parametric test because the data showed nothing against 
normality (Shapiro-Wilk’s test: p > 0.05). Statistical differences between the means were 
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compared using 2-tailed independent samples t-test. This was an appropriate test as the 
independent variable, stroke etiology, was categorical (nominal) while the dependent variable, 
thrombus composition, was measured on a continuous scale. 
In the case where we were investigating correlations between stroke severity and thrombus 
composition (Fig 3-3), we used binary logistic regression to compare means across the two 
groups as the independent variable, thrombus composition, was measured on a continuous scale 
while the dependent variable, NIHSS score, was dichotomous and measured on an ordinal level. 
On the other hand, the 2-tailed independent samples t-test was used to determine statistical 
differences within each of the NIHSS groups independently which were normally distributed. In 
addition, for investigating correlations between stroke severity and occlusion location, where the 
independent variable, occlusion location, and the dependent variable, NIHSS score, were both 
categorical, we used Fisher’s exact test, the non-parametric counterpart of the Chi-Square test.  
In the case, where we were investigating variables that were correlating the effects of thrombus 
composition on EVT device and recanalization success (Fig. 3-4 A–B), we used binary logistic 
regression, as the independent variable, thrombus composition, was measured on a continuous 
scale while the dependent variables, EVT devices and TICI scores, were measured on a nominal 
and ordinal level, respectively. However, to compare means within groups independently, which 
were normally distributed, we used 2-tailed independent samples t-test. In addition, for 
investigating correlations between EVT device and recanalization success (Fig. 3-4C), where the 
independent variable, EVT device, and the dependent variable, TICI score, were both 
categorical, we used Fisher’s exact test.  
In the case where we were investigating the effects of thrombus composition on 90-day mRS and 
NIHSS (Fig. 3-5A–B), we used 2-tailed independent samples t-test to compare means within 
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each individual group, since the data was normally distributed. We used ordinal regression to 
express correlations between EVT device, TICI scores and mRS scores (Fig. 3-5 C, E) and 
determine whether recanalization status obtained or devices chosen during thrombectomy had an 
effect on the functional outcome. Because the dependent variable, mRS scores, had three 
categories, ordinal regression was an appropriate test. On the other hand, we used Chi-Square 
test to express correlations between TICI scores, effects of longer procedural time and attempts 
with mRS scores (table 3-3 and Fig 3-6 A, B).  
In the case of expressing the effects of thrombus composition on elemental composition (Fig 
3-7), we used non-parametric Mann-Whitney U-test, where the independent variable, thrombus 
type, was categorical (nominal) while the dependent variable, elemental composition, was 
measured on a continuous scale.  
In the case where we were investigating the effects of stroke etiology on elemental and organic 
biochemical composition (Fig 3-13 A-C), we used the Mann-Whitney U-test, a non-parametric 
version of independent samples t-test, as the data was not normally distributed and the dependent 
variables, elemental and biochemical composition, were measured on a continuous scale while 
the independent variable, etiology, was measured on a nominal categorical level.  
Binary logistic regression was used in the case where we were expressing the effects of 
elemental composition and organic biochemical composition on recanalization success (Fig. 3-
14 A and Fig. 3-15 A-C). The 2-tailed independent samples t-test was used to compare means 
between elemental composition and mRS scores (Fig. 3-14 B) (data showed normality), and 
ordinal regression was used to compare means between organic biochemical composition and 
mRS scores (Fig. 3-15 D-F).  
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The Mann-Whitney U-test was used for measuring thrombus perviousness and stroke etiology 
(Fig. 3-16 B). Lastly, the correlation between thrombus perviousness and recanalization outcome 
was tested using binary logistic regression (Fig. 3-16C).  
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Chapter Three: Results 
3.1 Patient demographics 
Twenty-eight patients were included in the analysis (13 men and 15 women; mean age ± 
standard deviation, 71.2 ± 15.4 years). The patient and treatment characteristics including their 
ASPECTS, pre-treatment NIHSS, 90-day NIHSS and 90-day mRS are summarized in table 3-1.  
39.2% (11/28) of the patients had left middle cerebral artery (MCA) occlusion, 50% (14/28) of 
the patients had right MCA occlusions, and 10.7% (3/28) of the patients had basilar artery 
occlusions. 25% (7/28) of the patients had a smoking history, either previous or current. 14.3% 
(4/28) of the patients received intravenous tissue plasminogen activator (tPA) before 
thrombectomy, and 35.7% (10/28) of the patients received anti-platelet drugs post-
thrombectomy. 71% (20/28) of the patients were treated with stentrievers, which included either 
stenting alone or the Solumbra technique, while 29% (8/28) of the patients were treated with 
aspiration alone (ADAPT technique). 7.1% (2/28) of the patients had a TICI score of 1-2a, and 
92.9% (26/28) patients had a TICI score of 2b-3. (Table 3-1). 
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Table 3-1: Patient Demographics. Summary of the study population and demographics 
collected from September 2017 until January 2019.  
 Total 
Sample size n = 28 
Mean Age (years ± SD) 71.2 ± 15.4 years 
Sex 
Males 
 
13 
Females 15 
Active Smoking Status  7 
Stroke Etiology 
Cardioembolic 
 
17 
Arterial  11 
Occlusion location  
Left MCA/ICA 11 
Right MCA/ICA 14 
Basilar 3 
Intervention Drugs  
Intravenous tPA (thrombolytic) 4 
Reopro (anti-platelets) 8 
Plavix (anti-platelet) 2 
TICI   
0 – no reperfusion  0 
1-2a – incomplete reperfusion 2 
2b-3 – near-to-complete reperfusion 26 
90 day mRS  
mRS 0-2 No symptoms-minor disabilities 
 
15 
mRS 3-5 moderate-severe disabilities 4 
mRS 6 Dead  9 
Thrombectomy Devices  
Stentriever 
 
20 
ADAPT  8 
Pre-Treatment NIHSS* Median 17, IQR 7.5 (19-11.5) 
90-day NIHSS Median 0.5 , IQR 10 (10-0)  
ASPECTS Median 8, IQR 3 (10-7) 
SD = standard deviation, MCA = Middle Cerebral Artery, ICA = Internal Carotid Artery, tPA = tissue 
plasminogen activator, NIHSS = National Institute of Health Stroke Scale, IQR = interquartile range, 
TICI = Thrombolysis In Cerebral Infarction, ASPECTS = Alberta Stroke Program Early Computer 
Tomography Score, mRS = Modified Rankin Scale.  
*3 of 28 participants (pt 22, pt 26, and pt 28) were not accounted for in the median and IQR counts of 
NIHSS as their pre-treatment NIHSS scores were not collected. NIHSS and ASPECTS, are presented 
using their respective median values and interquartile range (IQR) [162]
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3.2 Histology results  
3.2.1 Quantifying percent composition of erythrocytes and fibrin in thrombi  
As mentioned in the Methods section, each thrombus sample was cut in half where half of the 
sample was formalin-fixed while the other half was flash frozen. Four of the 28 formalin-fixed 
samples were misplaced during sample transportation to the laboratory and therefore were 
eliminated from all histological analysis including ImageJ classification of red and white 
thrombus proportions. However, the other halves of these 4 samples that were flash frozen were 
still processed and analyzed using synchrotron and IR imaging modalities. Thus, for histological 
analysis only 24 of the 28 thrombi were stained with Masson’s trichrome to visualize the 
distribution of erythrocytes and fibrin, and thereby quantitatively classify these thrombi as either 
red or white. Even though previous studies have histologically characterized thrombi and 
confirmed the presence of inflammatory mediators, platelets, macrophages, white blood cells, 
RBCs, and endothelial cells [85], [87], [163], it was still important for us to confirm the presence 
of these components, to visualize the distribution of different cells simultaneously on adjacent 
sections, and to validate the classification of thrombi using a standardized software technique. 
Table 3-2 contains the raw data obtained by quantifying regions of erythrocytes and fibrin on the 
Masson’s trichrome stained images. 62.5% (15/24) thrombi were identified as red thrombi. 
Additionally, retrospective analysis of thrombi revealed that the 4 patients that received IV-tPA 
had thrombi classified as red thrombi (i.e. %RBCs > % fibrin).  
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Table 3-2: Raw data representing quantification of erythrocytes and fibrin. Data shows 
quantitative characterization of thrombi as red or white based on percent composition of 
erythrocytes and fibrin obtained by measuring red and blue areas on the Masson’s trichrome 
sections using trainable WEKA segmentation plugin in ImageJ software. White thrombi define 
fibrin-rich clots while red thrombi define erythrocyte-rich clots. 
Thrombus 
ID 
Region 
highlighted 
Count Particle 
Area 
Particle 
Avg Size 
%Area 
 
% composition Type of 
thrombus 
015 s1 RBC-rich 
area 
525 23615 44.981 1.922 23615/131640 
=17.94% 
white 
  Fibrin-rich 
area 
624 108025 173.117 8.791 108025/131640 
82.06% 
  
  Total Area s1 
 
23615+ 
108025 
=131640 
   
  
015 s2 RBC-rich 
area 
958 35860 37.432 2.918 20.67% white 
  Fibrin-rich 
area 
723 137654 190.393 11.202 79.33%   
  Total Area s2 
 
173514 
   
  
s1 + s2 RBC-rich 
area 
 
59475 
  
19.49% white 
thrombus 
  Fibrin-rich 
area 
 
245679 
  
80.51%   
  Total Area 
 
305154 
   
  
016 s1 RBC-rich 
area 
215 45116 209.842 3.672 70.88% red 
  Fibrin-rich 
area 
1044 18536 17.755 1.508 29.12%   
  Total Area s1 
 
63652 
   
  
016 s2 RBC-rich 
area 
531 51679 97.324 4.206 51.28% red 
  Fibrin-rich 
area 
1022 49093 48.036 3.995 48.72%   
  Total Area s2 
 
100772 
   
  
016 s3 RBC-rich 
area 
656 302107 460.529 24.586 84.39% red 
  Fibrin-rich 
area 
2191 55879 25.504 4.547 15.61%   
  Total Area s3 
 
357986 
   
  
s1 + s2 + 
s3  
RBC-rich 
area 
 
398902 
  
76.36% red 
thrombus 
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  Fibrin-rich 
area 
 
123508 
  
23.64%   
  Total Area 
 
522410 
   
  
017 s1 RBC-rich 
area 
223 29176 130.834 2.374 47.49% white 
  Fibrin-rich 
area 
396 32259 81.462 2.625 52.51%   
  Total Area s1 
 
61435 
   
  
017 s2 RBC-rich 
area 
362 42440 117.238 3.454 59.28% red 
  Fibrin-rich 
area 
1125 29156 25.916 2.373 40.72%   
  Total Area s2 
 
71596 
   
  
s1 + s2  RBC-rich 
area 
 
71616 
  
53.83% red 
thrombus 
  Fibrin-rich 
area 
 
61415 
  
46.17%   
  Total Area 
 
133031 
   
  
019 RBC-rich 
area 
248 79898 322.169 6.502 60.61% red 
thrombus 
  Fibrin-rich 
area 
154 51916 337.117 4.225 39.39%   
  Total Area 
 
131814 
   
  
020 s1 RBC-rich 
area 
1739 234368 134.772 19.073 64.13% red 
  Fibrin-rich 
area 
3504 131078 37.408 10.667 35.87%   
  Total Area s1 
 
365446 
   
  
020 s2 RBC-rich 
area 
856 131355 153.452 10.69 60.23% red 
  Fibrin-rich 
area 
2845 86726 30.484 7.058 39.77%   
  Total Area s2 
 
218081 
   
  
020 s3 RBC-rich 
area 
200 19196 95.98 1.562 47.67% white 
  Fibrin-rich 
area 
559 21072 37.696 1.715 52.33%   
  Total Area s3 
 
40268 
   
  
s1 + s2 + 
s3  
RBC-rich 
area 
 
384919 
  
61.71% red 
thrombus 
  Fibrin-rich 
area 
 
238876 
  
38.29%   
  Total Area 
 
623795 
   
  
021 s1 RB- rich area 401 330474 824.125 26.894 85.74% red 
  Fibrin-rich 
area 
935 54941 58.76 4.471 14.26%   
  Total Area s1 
 
385415 
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021 s2 RBC-rich 
area 
114 155821 1366.851 12.681 69.80% red 
  Fibrin-rich 
area 
636 67431 106.024 5.488 30.20%   
  Total Area s2 
 
223252 
   
  
s1 + s2  RBC-rich 
area 
 
486295 
  
79.90% red 
thrombus 
  Fibrin-rich 
area 
 
122372 
  
20.10%   
  Total Area 
 
608667 
   
  
023 s1 RBC-rich 
area 
922 142666 154.735 11.61 53.57% red 
  Fibrin-rich 
area 
2201 123639 56.174 10.062 46.43%   
  Total Area s1 
 
266305 
   
  
023 s2 RBC-rich 
area 
1282 150516 117.407 12.249 43.26% white 
  Fibrin-rich 
area 
1178 197400 167.572 16.064 56.74%   
  Total Area s2 
 
347916 
   
  
s1 + s2  RBC-rich 
area 
 
293182 
  
47.73% white 
thrombus 
  Fibrin-rich 
area 
 
321039 
  
52.27%   
  Total Area 
 
614221 
   
  
*024_1 RBC-rich 
area 
1024 59805 58.403 4.867 26.69% white 
thrombus 
  Fibrin-rich 
area 
644 164297 255.12 13.371 73.31%   
  Total Area 
 
224102 
   
  
*024_2 RBC rich 
area 
1845 341515 185.103 27.793 71.93% red 
thrombus 
  Fibrinous 
area 
3326 133278 40.072 10.846 28.07%   
  Total Area 
 
474793 
   
  
025 RBC-rich 
area 
863 193798 224.563 15.771 65.31% red 
thrombus 
  Fibrin-rich 
area 
2002 102920 51.409 8.376 34.69%   
  Total area  
 
296718 
   
  
026 RBC-rich 
area 
516 125422 243.066 10.207 73.57% red 
thrombus 
  Fibrin-rich 
area 
1313 45056 34.315 3.667 26.43%   
  Total area  
 
170478 
   
  
027 s1 RBC-rich 
area 
337 32071 95.166 2.61 19.44% white 
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  Fibrin-rich 
area 
475 132881 279.749 10.814 80.56%   
  Total area s1 
 
164952 
   
  
027 s2 RBC-rich 
area 
993 114066 114.87 9.283 39.13% white 
  Fibrin-rich 
area 
2006 177471 88.47 14.443 60.87%   
  Total area s2 
 
291537 
   
  
027 s3 RBC-rich 
area 
827 205680 248.706 16.738 59.47% red  
  Fibrin-rich 
area 
1339 140163 104.677 11.406 40.53%   
  Total area s3 
 
345843 
   
  
 s1 + s2 + 
s3  
RBC-rich 
area 
 
351817 
  
43.85% white 
thrombus 
  Fibrin-rich 
area 
 
450515 
  
56.15%   
  Total area  
 
802332 
   
  
028 s1 RBC-rich 
area 
1255 185042 147.444 15.059 64.79% red 
  Fibrin-rich 
area 
4028 100542 24.961 8.182 35.21%   
  Total area s1 
 
285584 
   
  
028 s2 RBC-rich 
area 
1027 39951 38.901 3.251 33.88% white 
  Fibrin-rich 
area 
1144 77967 68.153 6.345 66.12%   
  Total area s2 
 
117918 
   
  
028 s3 RBC-rich 
area 
2945 82575 28.039 6.72 34.83% white 
  Fibrin-rich 
area 
2799 154499 55.198 12.573 65.17%   
  Total area s3  
 
237074 
   
  
028 s4 RBC-rich 
area 
423 179743 424.924 14.628 87.82% red 
  Fibrin-rich 
area 
2893 24925 8.616 2.028 12.18%   
  Total area s4 
 
204668 
   
  
s1 + s2 + 
s3 + s4  
RBC-rich 
area 
 
487311 
  
57.65% red 
thrombus 
  Fibrin-rich 
area 
 
357933 
  
42.35%   
  Total area  
 
845244 
   
  
029 RBC-rich 
area 
593 145759 245.799 11.862 70.41% red 
thrombus 
  Fibrin-rich 
area 
2778 61246 22.047 4.984 29.59%   
  Total area  
 
207005 
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030 RBC-rich 
area 
1267 212592 167.792 17.301 71.79% red 
thrombus 
  Fibrin-rich 
area 
1605 83549 52.055 6.799 28.21%   
  Total area  
 
296141 
   
  
031 s1 RBC-rich 
area 
843 285344 338.486 23.221 77.84% red 
  Fibrin-rich 
area 
3179 81213 25.547 6.609 22.16%   
  Total area s1  
 
366557 
   
  
031 s2 RBC-rich 
area 
107 65907 615.953 5.364 92.03% red 
  Fibrin-rich 
area 
958 5706 5.956 0.464 7.97%   
  Total area s2 
 
71613 
   
  
031 s3 RBC-rich 
area 
1235 86429 69.983 7.034 63.12% red 
  Fibrin-rich 
area 
1728 50491 29.219 4.109 36.88%   
  Total area s3 
 
136920 
   
  
s1 + s2 + 
s3  
RBC rich 
area 
 
437680 
  
76.11% red 
thrombus 
  Fibrinous 
area 
 
137410 
  
23.89%   
  Total area  
 
575090 
   
  
034 RBC-rich 
area 
588 55687 94.706 4.532 60.42% red 
thrombus 
  Fibrin-rich 
area 
1217 36477 29.973 2.969 39.58%   
  Total area  
 
92164 
   
  
037 s1 RBC-rich 
area 
1041 62242 59.791 5.065 50.35% red 
  Fibrin-rich 
area 
1416 61369 43.34 4.994 49.65%   
  Total area s1 
 
123611 
   
  
037 s2 RBC-rich 
area 
565 91225 161.46 7.424 47.14% white 
  Fibrin-rich 
area 
1697 102289 60.276 8.324 52.86%   
  Total area s2 
 
193514 
   
  
037 s3 RBC-rich 
area 
663 37569 56.665 3.057 39.29% white 
  Fibrin-rich 
area 
1549 58054 37.478 4.724 60.71%   
  Total area s3 
 
95623 
   
  
s1 + s2 + 
s3  
RBC-rich 
area 
 
191036 
  
46.28% white 
thrombus 
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  Fibrin-rich 
area 
 
221712 
  
53.72%   
  Total area  
 
412748 
   
  
038 RBC-rich 
area 
767 376835 491.31 30.667 79.35% red 
thrombus 
  Fibrin-rich 
area 
1366 98081 71.802 7.982 20.65%   
  Total area  
 
474916 
   
  
039 RBC-rich 
area 
1098 102847 93.668 8.37 60.15% red 
thrombus 
  Fibrin-rich 
area 
2931 68126 23.243 5.544 39.85%   
  Total area  
 
170973 
   
  
040 RBC-rich 
area 
768 61043 79.483 4.968 43.23% white 
thrombus 
  Fibrin-rich 
area 
981 80176 81.729 6.525 56.77%   
  Total area  
 
141219 
   
  
044 s1 RBC-rich 
area 
1387 191939 138.384 15.62 42.21% white 
  Fibrin-rich 
area 
1497 262741 175.512 21.382 57.79%   
  Total area s1 
 
454680 
   
  
044 s2 RBC-rich 
area 
985 224353 227.77 18.258 47.66% white 
  Fibrin-rich 
area 
963 246382 255.848 20.051 52.34%   
  Total area s2 
 
470735 
   
  
s1 + s2  RBC-rich 
area 
 
416292 
  
44.98% white 
thrombus 
  Fibrin-rich 
area 
 
509123 
  
55.02%   
  Total area  
 
925415 
   
  
045 s1 RBC-rich 
area 
179 240944 1346.056 19.608 54.82% red 
  Fibrin-rich 
area 
1349 198561 147.191 16.159 45.18%   
  Total area s1 
 
439505 
   
  
045 s2 RBC-rich 
area 
190 74682 393.063 6.078 33.29% white 
  Fibrin-rich 
area 
269 149679 556.428 12.181 66.71%   
  Total area s2 
 
224361 
   
  
s1 + s2  RBC-rich 
area 
 
315626 
  
47.54% white 
thrombus 
  Fibrin-rich 
area 
 
348240 
  
52.46%   
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*Pt 24 had two strokes on the same day. s1 = section 1, s2 = section 2, s3 = section 3 
3.2.2 Distribution of erythrocytes, fibrin, platelets, endothelial cells, and macrophages 
While histological examination is important to identify cellular characteristics and components 
that make up thrombus integrity, it is also important to identify their gross morphology. The top 
panel in figure 3-1 showed representative cases of dark red and pinkish thrombi along with their 
characteristic texture wherein, the thrombi either had a jelly-like elastic texture or a dry rigid 
texture (Fig. 3-1 top panel). Difference in the appearance of colour was potentially due to 
factors such as: amount of atmospheric exposure (oxidation), hemolysis, and erythrocyte:fibrin 
ratio. We did not perform any further analysis on thrombus texture, and we did not correlate the 
gross morphology of the thrombus to its histological composition. The gross morphology and 
texture of thrombi were briefly mentioned as a mean to show the different types of thrombi 
retrieved. 
All histological stains and immunohistochemistry for 24 samples were performed on adjacent 
sections for comparative analysis. Hematoxylin and Eosin was the routine principle stain 
performed on the samples to identify the presence of different cells (Fig. 3-1 A-D). H&E showed 
  Total area  
 
663866 
   
  
046 s1 RBC-rich 
area 
538 90046 167.372 7.328 27.47% white 
  Fibrin-rich 
area 
984 237789 241.655 19.351 72.53%   
  Total area s1 
 
327835 
   
  
046 s2 RBC-rich 
area 
466 48585 104.26 6.39 22.06% white 
  Fibrin-rich 
area 
564 171609 304.271 22.571 77.94%   
  Total area s2 
 
220194 
   
  
Average  RBC-rich 
area 
 
138631 
  
25.30% white 
thrombus 
  Fibrin-rich 
area 
 
409398 
  
74.70%   
  Total area  
 
548029 
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extensive distribution and infiltration by neutrophils (D) throughout the thrombi, thereby 
indicating acute inflammation. Qualitative assessment indicated higher neutrophil distribution in 
fibrin-rich areas than erythrocyte-rich areas. Some thrombi also showed the presence of 
eosinophils (C). Masson’s trichrome stained fibrin in blue and erythrocytes in red. Some thrombi 
had organized layers of fibrin with erythrocytes trapped in between (Fig. 3-1 F). Traditionally 
thrombi with alternating layers of fibrin and erythrocytes were characterized as “layered” while 
thrombi that appeared with patterns of fibrin:platelet bands interspersed with deposits of 
polymorphonulcear cells and erythrocytes were characterized as “serpentine”. Some thrombi had 
densely packed erythrocytes in the core, with fibrin strands densely organized in the periphery 
(Fig. 3-1 E) while some thrombi had loosely organized fibrin. CD68 stained positive for 
macrophages (Fig. 3-1 G-H), showing macrophage infiltration with no specific distribution 
patterns. However, aggregates of brown granular amorphous debris were frequently observed in 
fibrin rich areas. Factor VIII/vwF were used for immunolabelling platelets (Fig. 3-1 I, J) while 
CD31 was used as a marker for endothelial cells (Fig. 3-1 K, L). Both platelets and endothelial 
cells co-localized in fibrin-rich areas. In addition, aggregates of platelets and endothelial cells 
appeared to form patterns of sinuous bands along fibrin rich regions (Fig. 3-1 J, L). There were 
no cholesterol crystals, lipid component calcifications, intramural hemorrhage, and sheared 
intima of the vessel wall or smooth muscle cells observed in any of the thrombus samples.  
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Figure 3-1: Histological examination of thrombi. The above panel represents a macroscopic 
view of the gross appearance and texture (1-4). 5μm thick, 10% formalin fixed paraffin 
embedded sections stained with Hematoxylin and Eosin (A-D) show organized fibrin layers 
indicated in black arrow (B), eosinophils (C), and neutrophils indicated in black arrowheads (D), 
Masson’s trichrome show fibrin (stained blue) and RBCs (stained red) organized in layers (E-F), 
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anti-CD68 show macrophages (G-H) with a high magnification insert showing amorphous 
granular debris, Factor VIII/von Willebrand factor (vWF) show platelets (I-J), and anti-CD31 
show endothelial cells (K-L) distributed and forming sinuous bands in fibrinous areas (green 
arrows). Images were acquired using the Nikon microscope. Scale bars: 100 μm (A), 80 μm (C-
L). 
3.3 Correlations between clinical variables and thrombus composition 
3.3.1 Assessing the effects of stroke etiology on thrombus composition  
To validate whether biological composition was altered in thrombi originating from the proximal 
arteries (artery-to-artery embolism) as opposed to the heart (cardioembolism), we correlated 
source of origin with the proportions of erythrocytes and fibrin, derived from ImageJ analysis. 
Since, the classification of an entire thrombus as red or white was not reliable based on just 
section analysis, we chose to represent the data using the mean percentage of erythrocytes and 
fibrin instead of correlating the etiology with the number of red/white thrombi. The data was 
normally distributed (Shapiro–Wilk test - % RBC: p = 0.56 versus % Fibrin: p = 0.13). 
Comparing proportion of erythrocytes and fibrin within each etiologic group independently, our 
results showed that thrombi in patients with cardioembolism had a significantly higher 
proportion of erythrocytes and a lower proportion of fibrin (59.03% ± SEM 4.59 versus 40.97% 
± SEM 4.59; p = 0.009). Similarly, thrombi in patients with artery-to-artery embolism showed a 
higher proportion of erythrocytes and lower proportion of fibrin (53.02% ± SEM 5.68 versus 
46.80% ± SEM 4.68; p = 0.436), however, the differences were not statistically significant in this 
group. In addition, cross-comparing proportions of erythrocytes and fibrin across the two 
etiologic groups, our findings showed higher proportion of erythrocytes in cardioemboli than 
artery-to-artery emboli (59.03% versus 53.20%), and higher proportion of fibrin in artery-to-
artery emboli than cardioemboli (46.80% versus 40.97%), however, these differences were not 
statistically significant (p = 0.437) (Fig. 3-2).  
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Figure 3-2: Correlation between stroke etiology and thrombus composition. Bar graph 
compares proportion of erythrocytes and fibrin present in thrombi arising from cardioembolism 
(heart) and artery-to-artery embolism (large artery). Pie graphs are included as an alternative 
representation to indicate that the proportions of erythrocytes and fibrin are complimentary 
percentages. RBC = red blood cells (erythrocytes). (*) p = 0.009 
3.3.2 Accessing the effects of thrombus composition and occlusion location on stroke severity  
Stroke severity was assessed using the NIHSS scores. Of the 28 patients who were scored on a 
range of 0-42 prior to thrombectomy (at admission), thrombi retrieved from 6 patients were 
excluded from further analysis as pre-admission NIHSS were not scored for 3 patients (#22, #26, 
and #28), and formalin-fixed samples of 4 patients were misplaced during transportation (#18, 
#22, #33, and #42), as mentioned previously. The NIH scores of 22 patients were recorded in one 
of the two groups; NIHSS ≤ 10 or NIHSS > 10, where 10 was used as a baseline score because it 
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differentiated a minor stroke from a moderate-to-severe stroke [142]. The data showed nothing 
against normality (Shapiro–Wilk test - NIHSS ≤ 10: p = 0.754 versus NIHSS > 10: p = 0.278). 
Comparing the percentages of erythrocytes and fibrin within each NIHSS groups, independently, 
our findings suggested that patients who suffered a minor stroke (NIHSS ≤ 10) had a 
significantly higher proportion of erythrocytes and lower proportions of fibrin (65.37% versus 
34.63% ± SEM 4.53%, p = 0.0014) while patients that suffered a moderate to severe stroke 
(NIHSS > 10) had thrombi that statistically showed no difference in erythrocyte and fibrin 
percentages (53.30% versus 46.70% ± SEM 4.56%, p = 0.3). However, when we compared the 
percentages of erythrocytes and fibrin across the two NIHSS groups, patients who suffered a 
minor stroke (NIHSS ≤ 10) had higher proportions of erythrocytes (65.37% versus 53.30%) 
while patients who suffered a major stroke (NIHSS > 10) had higher proportions of fibrin 
(46.70% versus 34.63%) but the differences across the groups were insignificant (p = 0.19) (Fig. 
3-3). 
Patients with occlusions in their left MCA usually show more severe stroke symptoms than 
patients with occlusions in their right MCA due to aphasia. Our findings however, showed that 
both right MCA occlusions and left MCA occlusions resulted in volumetrically equal underlying 
infarcts (right 15.8 ± 3.3 versus left 14.5 ± 7.4, p = 0.61).  
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Figure 3-3: Correlation between stroke severity and thrombus composition. Bar graph 
compares proportion of erythrocytes and fibrin (%) in thrombi of patients that presented with 
either a minor stroke (NIHSS ≤ 10) or a severe stroke (NIHSS > 10), to determine whether 
thrombus composition affects stroke severity. The NIHSS scores were collected at admission 
prior to thrombectomy. The data does not include NIH scores for 3 patients who suffered a 
basilar stroke as the scores were not recorded at admission. NIHSS = the National Institute of 
Health Stroke Scale, RBC = red blood cells. The values represented above the error bars in graph 
are the mean percentages of thrombus composition. 
  
 
 
 
 
 
p = 0.0014 
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3.3.3 Thrombus composition does not affect the choice of thrombectomy device used for 
achieving full recanalization.  
Since, the goal of EVT is to achieve higher rates of complete recanalization and improve long-
term health outcomes, it is important to determine if recanalization success and long-term 
outcomes are dependent on factors such as; thrombus composition or the choice of EVT device.  
The data was normally distributed (Shapiro–Wilk’s test – ADAPT: p = 0.617 versus Stentriever: 
p = 0.187). Our findings suggested that thrombi retrieved by ADAPT had lower proportions of 
erythrocytes (55.81% ± SEM 6.49% versus 57.36% ± SEM 4.35%) and higher proportions of 
fibrin (44.19% versus 42.64%) than thrombi retrieved by stentrievers. However, the differences 
across the two groups were not statistically significant (p = 0.833). In the overall comparison 
between the two groups (ADAPT, Stentrievers), all samples indicated a higher percent of 
erythrocytes regardless of their retrieval device, suggesting that the choice of thrombectomy 
device used for retrieving the thrombus successfully did not correlate with the thrombus 
composition (Fig. 3-4A) and regardless whether a thrombus was composed of high erythrocytes 
or fibrin, it was equally well retrieved using either of the two techniques.  
When expressing a correlation between thrombus composition and recanalization success, the 
data was normally distributed (Shapiro–Wilk test- TICI 1-2a versus TICI 2b-3: p = 0.09). 
Patients in whom incomplete recanalization (TICI 1-2a, n = 2) was achieved, had thrombi 
composed of higher proportion of fibrin and lower proportion of erythrocytes compared to 
thrombi of patients in whom near-to-complete recanalization (TICI 2b-3, n = 26) was obtained 
(fibrin: 48.31% vs 42.69%,  erythrocytes: 51.69% vs 57.31% , p = 0.67). However, just analyzing 
thrombi from the TICI 2b-3 group, revealed that these thrombi were composed of significantly 
higher proportion of erythrocytes and lower proportion of fibrin (57.37% vs 42.69% ± SEM 3.81 
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%, p = 0.01). However, because the results were insignificant across the two TICI groups (p = 
0.657), the data suggested no correlation between thrombus composition and recanalization 
outcomes (Fig 3-4B). Additionally, it is important to keep in mind that, since TICI 1-2a had a 
small size (n = 2) the comparisons between the two groups were less powered.   
TICI scores were also compared within the two groups of thrombectomy devices to assess 
whether the choice of thrombectomy device used for opening the occluded vessel influenced 
recanalization status. In the number of thrombectomy cases where near-to-complete 
recanalization was obtained (TICI 2b-3), n = 14 were successfully treated with stentrievers while 
n = 8 were successfully treated with ADAPT. Likewise, in the number of thrombectomy cases 
where minimal to incomplete recanalization was obtained (TICI 1-2a), n =2 were successfully 
treated with stentrievers while we had no patients in this group that were treated with ADAPT. 
There was no significant correlation between EVT device and TICI scores (p = 0.536), 
suggesting that recanalization status was not dependent on the choice of thrombectomy device 
used for thrombus retrieval. These results would have to be validated using a larger sample size 
(Fig. 3-4C).  
 
 
 
 
 
 
97 
 
 
 
 
 
 
Figure 3-4: Correlation between thrombus composition, EVT device choice and 
recanalization success. Bar graphs shows comparisons between (A) thrombus composition and 
retrieval device, (B) thrombus composition and TICI scores to determine whether histological 
composition affects recanalization outcomes (C) TICI scores and retrieval device to determine 
whether the choice of devices (ADAPT or Stentrievers) affect recanalization outcomes (C). 
ADAPT = A Direct Aspiration First Pass Technique, TICI = Thrombolysis in Cerebral Infarction 
where 1-2a defines incomplete recanalization and a score of 2b-3 defines near-to-complete 
recanalization, AIS = Acute Ischemic Stroke, RBC= red blood cells. The values represented 
above the error bars in graph A and B are the mean percentages of thrombus composition. 
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3.3.4 Assessing the effects of thrombus composition, thrombectomy devices and recanalization 
status on 3-month functional outcomes  
Studies have shown that the first 3-months after suffering a stroke are crucial, where the risks of 
poor health outcomes are higher and directly related to the stroke. In that context, we used three 
variables; histological composition, primary retrieval device that successfully retrieved the 
thrombus, and recanalization status to investigate if these factors influenced the prognosis of 3-
month functional outcomes. Three-month functional outcomes were evaluated by mRS and 
NIHSS scores which were assigned by a neurologist during the “standard of care” 90-day visit.  
Data analyzing the effects of thrombus composition on 90-day mRS (n = 24), was normally 
distributed (Shapiro–Wilk test- mRS 0-2: p = 0.077 vs mRS 3-5: p = 0.875 vs mRS 6: p = 
0.247). Patients with thrombi composed of significantly higher proportions of erythrocytes and 
lower proportions of fibrin had moderate to severe disabilities (mRS 3-5: 65.75% vs 34.25% ± 
SEM 3.37%, p = 0.003); while patients who suffered minor disabilities also had thrombi with 
higher erythrocytes than fibrin, however the differences in composition were insignificant (mRS 
0-2: 56.84% vs 43.16% ± SEM 5.5%, p = 0.09). This trend was also true for patients who died 
within 90-days as their thrombi had higher erythrocytes than fibrin, but the differences were 
statistically insignificant as well (mRS=6: 51.02% vs 46.98% ± SEM 4.92%, p = 0.4). Overall, 
the findings across all three groups suggested that the thrombi composition did not affect mRS 
outcomes (p = 0.892) (Fig. 3-5A).   
In addition, data analyzing the effects of thrombus composition on 90-day NIHSS (n = 16; 4 
samples misplaced, 7 patients died within 90 days, and 1 patient was not scored), our results also 
showed that patients with severe NIH outcomes (NIHSS > 10), had thrombi composed of 
significantly higher percentage of erythrocytes and lower percentage of fibrin (68.55% vs 
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31.45% ± SEM 3.24%, p = 0.01) than thrombi of patients who suffered minor to no disabilities 
(NIHSS ≤ 10), where percentages of erythrocytes and fibrin were insignificantly different 
(57.74% vs 42.26% ± SEM 5.66%, p = 0.06). However, comparing proportions of erythrocytes 
and fibrin across the two groups, showed no significant differences (p = 0.512) (Fig 3-5B).  
Data evaluating the effects of EVT devices on 90-day mRS, showed no differences across any of 
the groups (p = 0.363), mRS 0-2 (minor disabilities): ADAPT n = 6 vs Stentrievers n = 8, mRS 
3-5 (moderate to severe disabilities): ADAPT n = 1 vs Stentrievers n = 2, and mRS=6 (dead): 
ADAPT n = 1 vs Stentrievers n = 6. Similarly, evaluating the effects of EVT device on 90-day 
NIHSS, showed no differences across both the groups (p = 0.869), NIHSS ≤ 10 (minor 
impairments): ADAPT n = 5 vs Stentrievers n = 9, and NIHSS > 10 (moderate impairments): 
ADAPT n = 1 vs Stentrievers n = 1. Thus, the results suggested that retrieval devices did not 
affect the degree of disability dependence (Fig. 3-5C, D). Moreover, we also evaluated the 
correlation between TICI and mRS scores. Majority of the patients in whom near-to-complete 
recanalization was achieved (15 of the 26 patients) suffered minor disabilities while patients in 
whom minimal or incomplete recanalization was achieved either suffered severe disability or a 
fatal outcome (table 3-3). Nevertheless, our data statistically showed that the correlation was 
insignificant, thereby suggesting that recanalization outcomes did not affect 3-month 
functionality (p = 0.193).  
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Figure 3-5: Correlation between the effects of various clinical parameters on 3-month 
functional outcomes. Graphs A and B show the effects of thrombus composition on mRS and 
NIHSS, respectively. Graphs C and D show the effects of EVT devices on mRS and NIHSS, 
respectively. mRS = Modified Rankin Scale (mRS 0-2: minor disabilities and no assistance 
required, mRS 3-5: moderate to severe disabilities with assistance required for daily activities, 
mRS 6: dead), NIHSS = National Institute of Health Stroke Scale (NIHSS ≤ 10 = minor stroke, 
NIHSS > 10 = severe stroke), AIS = Acute Ischemic Stroke, TICI = Thrombolysis in Cerebral 
Infarction. For graphs represented in the left panel, 2 pts were excluded from group (mRS 6) as 
they died of non-stroke related causes (GI bleeding and lung cancer), and for graphs represented 
in the right panel 8 pts had incomplete evaluation as they died within the 90 days with no 90-day 
NIHSS records. Significance: (A) p = 0.003, (B) p = 0.01. The values represented above the 
error bars in graph A and B are the mean percentages of thrombus composition. 
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Table 3-3: Comparison between TICI and mRS scores. Assessing the effects of recanalization 
outcomes on 3-month functionality. 
 
Recanalization Score 
Total Sample (n = 28) 
Functional Outcomes P Value 
TICI 1-2a (n = 2) 
 
 
 
mRS 0-2 – 0  
mRS 3-5 – 1 (50%) 
mRS 6 – 1 (50%) 
 
 
0.193 
 
TICI 2b-3 (n = 26) 
 
mRS 0-2 – 15 (57.7%) 
mRS 3-5 – 3 (11.5%) 
mRS 6 – 8 (30.7%) 
 
 
 
It is important to consider other factors that are likely to correlate with poor prognostic outcomes 
such as the volume and duration of ischemia in neuroanatomically eloquent tissue, length of the 
thrombectomy procedure, procedural delays in initiation, and once underway, the number of 
retrieval attempts made. Additionally any possible procedural complications that might occur 
including distal embolization, vessel perforations and occurrence of ICH will contribute to 
outcome. We did not test for every potential factor involved in poor patient outcomes, but we did 
correlate the effects of longer procedural times and the number of retrieval attempts with 3-
month functional outcomes. We found that as length of the thrombectomy procedure increased, 
the outcomes worsened. Of the 15 patients who suffered minor disabilities (mRS 0-2) after their 
EVT procedure, 66% (10/15) of those patients had their thrombus retrieved within 30 mins. On 
the other hand, of the 8 patients who died (mRS 6), 75% (6/8) of those patients had a longer 
procedural time, > 30 mins. Furthermore, 86.7% (13/15) of the patients with mRS 0-2, had their 
thrombus retrieved within ≤ 2 attempts. Despite these trends observed, statistical significance 
was not reached when correlating either of the two variables with the mRS scores (p = 0.162 and 
0.504), respectively.  
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Figure 3-6: Correlation between procedural and functional outcomes. Bar graphs show a 
correlation between (A) the length of EVT procedure and mRS scores and (B) the number of 
retrieval attempts and mRS scores. AIS = acute ischemic stroke, EVT = endovascular therapy, 
mRS = Modified Rankin Scale.  
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3.4 Correlations between elemental distribution, thrombus composition and clinical parameters  
Since the histological composition of a thrombus is not known pre-operatively, we aimed to 
identify thrombi using elemental markers, whereby we correlated elemental concentrations with 
their histological classifications to determine if elements distributed differently in erythrocyte-
rich thrombi as opposed to fibrin-rich thrombi. The analysis of 16 thrombi on beamline 10-2 
indicated statistically insignificant differences between elements found in erythrocyte-rich 
thrombi and fibrin-rich thrombi: P (p = 0.945), S (p = 0.181), Cl (p = 0.534), K (p = 0.366), Ca 
(p = 1.000), Fe (p = 1.000), Cu (p = 0.051) and Zn (p = 0.073) (Fig 3-7).  
Figure 3-7: Correlation 
between histological and 
elemental composition. Bar 
graph compares 
concentration of various 
biological elements 
including phosphorous (P), 
sulfur (S), chlorine (Cl), 
potassium (K), calcium 
(Ca), iron (Fe), copper (Cu) 
and zinc (Zn) in RBC-rich 
and fibrin-rich thrombi. 
Elements were quantified 
from XFI maps produced on 
BL 10-2 at SSRL using 
Sam’s Microprobe Analysis 
Kit (SMAK) software.  
3.4.1 XFI distribution maps 
XFI heat maps generated on beamline 10-2, characterizing the distribution of S, Cl, K, Ca, Fe, 
and Zn showed similar distribution patterns to XFI heat maps generated on beamline 14-3. Both 
maps revealed S and Cl to be abundant in the core and peripheral regions of the thrombi. 
Furthermore, K and Fe were elevated in erythrocyte-rich areas; whereas, Ca was dispersed in 
higher concentration in fibrin-rich areas of the thrombus. Cu and Zn levels were detected at trace 
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levels (Fig. 3-8A and Fig. 3-9). Moreover, high resolution images collected for thrombus 24  on 
beamline 2-3 indicated elevated levels of K and Fe and reduced levels of Cl and Ca in the 
erythrocyte-areas of the thrombus, thereby revealing the same distribution pattern as observed on 
XFI maps produced on beamline 10-2 (Fig. 3-8B).  
Sulfur maps produced for 2 thrombi on BL 14-3 showed a strong difference between the 
distribution patterns of the three sulfur species. Sulfonic acid indicative of taurine was highly 
concentrated in fibrin-rich areas compared to erythrocyte-rich areas, sulfoxide indicative of 
methionine sulfoxide was abundantly dispersed throughout the thrombi while O-linked sulfate 
esters were barely detected (Fig. 3-10).  
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Figure 3-8: XFI elemental distribution pseudo coloured maps. (A) BL 10-2 generated heat 
maps show elemental distribution patterns for sulfur–S, chlorine–Cl, potassium–K, calcium–Ca, 
iron–Fe, zinc–Zn and iodine–I, present within the samples where rainbow matrix pseudo-colours 
are added to indicate high concentrations in red and low concentrations in blue. The left panel 
contains images of the untreated sample to indicate erythrocyte-rich (E) and fibrin-rich (F) 
regions of the thrombus. (B) BL 2-3 generated high resolution heat map for thrombus #24 shows 
the distribution of S, Cl, K, Ca and Fe in thrombus 24. Scale bar = 1mm (A), 80 μm (B). 
 
A 
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Figure 3-9: BL 14-3 
XFI maps 
representing low Z 
elements. X-ray 
fluorescence imaging 
heat maps show 
elemental distribution 
patterns for 
phosphorous (P), sulfur 
(S), chlorine (Cl), 
potassium (K), calcium 
(Ca) where rainbow 
matrix pseudo-colours 
are added to indicate 
high concentrations in 
red and low 
concentrations in blue. 
Scale bar: 1mm. 
 
 
 
Figure 3-10: BL 14-3 XFI sulfur distribution pseudo coloured map. X-ray fluorescence 
imaging heat maps show different sulfur species, sulfoxide (methionine sulfoxide), sulfonic acid 
(taurine) and O-linked sulfate ester, present within the samples represented using rainbow matrix 
pseudo-colours to indicate high concentrations in red and low concentrations in blue. The left 
panel contains images of the untreated samples mounted on thermox coverslips indicating 
erythrocyte-rich (E) and fibrin-rich (F) areas. Scale bar: 2mm. 
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3.4.2 Spectroscopy: XAS and FTIR maps 
Analysis of the normalized Fe spectra generated by XAS for 4 thrombi samples, presented the Fe 
pre-edge spectral peaks at 7,112.7 eV (Fig. 3-11A). When these peaks were compared to various 
Fe standard compounds of different oxidation states, the spectral peaks derived from the 
thrombus samples were similar to the peak indicative of oxygenated hemoglobin characterized at 
7,113 eV (Fig. 3-11B) [164]. However, to validate if the Fe pre-edge spectra represents 
oxygenated hemoglobin, peak fitting would have to be performed in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11: Fe Spectroscopy. (A) Normalized Fe K-edge XAS spectra collected from 
thrombus samples on beamline 7-3 at SSRL. (B) The Fe K-edge reference spectra of oxygenated 
and deoxygenated hemoglobin redrawn from Wilson SA et al. [164]. The pre-edge spectral peak 
at ~7,113 eV in thrombus samples represents oxygenated hemoglobin (black arrow). 
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The distribution maps produced by infrared spectroscopy on Mid-IR beamline indicated a higher 
presence of amide I and amide II bands in the erythrocyte-rich regions, platelets to be co-
localized in the fibrin-rich regions whereas, fibrinogen, glutamate and cholesterol esters to be 
present throughout the thrombi with no specific distribution patterns (Fig. 3-12).  
 
Figure 3-12: FTIR distribution map. Spatiotemporal comparison of organic biomolecules 
distributed in the fibrin-rich (F) and erythrocyte-rich (E) regions of the cerebral thrombi 
represented using bgy (blue green yellow) pseudo-colours to indicate high concentrations in 
yellow and low concentrations in blue. Scale bar = 1mm. 
3.4.3 Effects of stroke etiology on elemental composition and organic molecules in thrombi 
XFI analysis of 16 samples revealed that elemental composition of thrombi was not altered by 
stroke etiology such that, the differences in areal concentration (μg/cm2) of all elements of 
interest between artery-to-artery emboli and cardioemboli were statistically insignificant: P (p = 
1.000), S (p = 0.792), Cl (p =0.958), K (p = 0.792), Ca (p = 0.428), Fe (p = 0.562), Cu (p = 
0.713), and Zn (p = 0.958) (Fig. 3-13A).  
Similarly, FTIR analysis for 15 of the 16 samples (1 sample was damaged) collected adjacent to 
XFI samples, showed that thrombi originating from either of the two sources, artery-to-artery 
embolism or cardioembolism were insignificantly different in their biochemical composition 
(measured by area under the curve, units: A.U.) of lipids (p = 0.56 ), platelets (p = 0.48), 
glutamate (p = 0.41), amide I (p = 0.09), amide II (p = 0.13), cholesterol esters (p = 0.72), and 
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fibrinogen (p = 0.64), suggesting that stroke etiology had no effect on organic molecules 
characterizing thrombus composition (Fig. 3-13B-C).  
 
Figure 3-13: Correlating the effects of 
stroke etiology on elements and organic 
molecules. Bar graph comparing composition 
of biological elements, quantified using XFI 
maps (A), and organic molecules, quantified 
using FTIR maps (B, C), in thrombi either 
originating from artery-to-artery embolism or 
cardioembolism.  
 
 
3.4.4 Effects of elemental composition and organic molecules on recanalization and 3-month 
functional outcomes 
Thrombi that resulted in either partial or incomplete recanalization (TICI 1-2a) had higher 
concentration of Cl and K than thrombi that resulted in near-to-complete recanalization (TICI 
2b-3). However, there was no statistical significance observed when elemental concentrations 
were compared across the two groups, TICI 1-2a and TICI 2b-3: P (p = 0.998), S (p = 0.999), Cl 
(p = 0.999), K (p = 0.998), Ca (p = 0.999), Fe (p = 0.998), Cu (p = 0.998), and Zn (p = 0.998) 
(Fig. 3-14A). Similarly, when mRS scores were compared with elemental composition to assess 
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if elements within the thrombi contributed to severe functional outcomes, there were no 
statistically significant differences observed within the three mRS groups for any of the elements 
of interest (Fig. 3-14B), suggesting that biological elements were not a contributory factor in 
determining long-term functionality.  
FTIR results showed no significant relationship between organic biochemical composition and 
recanalization success in either of the two groups, TICI 1-2a and TICI 2b-3: lipids (p = 0.510), 
glutamate (p = 0.475), platelets (p = 0.361), cholesterol esters (p = 0.760), fibrinogen (p =0.473) 
and amide I (p =0.426) (Fig. 3-15A-C). Similarly, there was no significant relationship between 
organic biochemical composition and mRS score in either of the three groups, mRS 0-2, mRS 3-
5, and mRS 6: lipids (p = 0.621), glutamate (p = 0.436), platelets (p =0.887), cholesterol esters 
(p = 0.881), fibrinogen (p = 0.892) and amide I (p = 0.777) (Fig. 3-15D-F). 
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Figure 3-14: Correlating elemental with clinical outcomes. Bar graphs comparing the effects 
of various biological elements, quantified using XFI maps, on recanalization success (A) and 3-
month functional outcomes (B). TICI = Thrombolysis in Cerebral Infarction (TICI 1-2a: 
partial/incomplete recanalization, TICI 2b-3: near to complete recanalization), mRS = Modified 
Rankin Scale (mRS 0-2: minor disabilities, mRS 3-5: moderate to severe disabilities, mRS 6: 
dead). 
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Figure 3-15: Correlating biochemical composition with clinical outcomes. Bar graphs 
comparing the effects of various organic molecules, quantified using FTIR maps, on 
recanalization success (A-C) and 3-month functional outcomes (D-F). TICI = Thrombolysis in 
Cerebral Infarction (TICI 1-2a: partial/incomplete recanalization, TICI 2b-3: near-to-complete 
recanalization), mRS = Modified Rankin Scale (mRS 0-2: minor disabilities, mRS 3-5: moderate 
to severe disabilities, mRS 6: dead), A.U. = Absorbance Units. 
3.5 Thrombus perviousness 
The presence of iodine was used as a biomarker to measure thrombus perviousness. Qualitative 
assessment of XFI distribution maps generated on beamline 10-2 revealed that iodine levels were 
elevated in fibrinous regions of the thrombus and did not penetrate regions containing high 
erythrocyte proportions, thereby suggesting that fibrin-rich clots were more pervious than 
erythrocyte-rich thrombi (Fig. 3-16A). 
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Additionally, to determine if stroke etiology correlated with thrombus perviousness and whether 
thrombus perviousness correlated with clinical outcomes, we measured the amount of contrast 
agent in the thrombus and correlated the total iodine concentration (μg/cm2) with stroke etiology 
and recanalization outcomes. Our data showed that thrombi originating from artery-to artery 
emboli had higher iodine concentration than cardioemboli (p = 0.958) (Fig. 3-16B). Also, 
patients in whom a score of TICI 1-2a was achieved had lower iodine concentration than patients 
in whom a score of TICI 2b-3 was achieved (p = 0.834) (Fig. 3-16C), suggesting that thrombi 
that resulted in near-to-complete recanalization were more pervious than thrombi that resulted in 
minimal-to-incomplete recanalization; however, we did not achieve statistical significance at n = 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-16: Effects of thrombus perviousness on clinical outcomes. (A)XFI distribution map 
represents iodine permeability with elevated iodine levels in fibrin rich areas and lower 
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permeability of iodine in erythrocyte rich areas, denoted by letter F and E, respectively. Graphs 
B and C correlate iodine concentration (μg/cm2) quantified from X-ray fluorescence imaging 
distribution maps with stroke etiology and recanalization outcomes, respectively. 
3.6 Summary of the results  
In summary, our findings suggest the following:  
1) The dichotomous classification of thrombi as red or white based on just histological 
constituents and stroke etiology is an oversimplified and invalid classification paradigm. 
2) Thrombus composition was not affected by stroke etiology. Even though cardioemboli were 
composed of significantly higher proportion of erythrocytes than fibrin (p = 0.009), comparing 
proportions of erythrocytes between cardioemboli and artery-to-artery emboli revealed 
insignificant differences (p = 0.437).  
3) Patients with NIHSS ≤ 10 had significantly higher erythrocytes than fibrin in their thrombi (p 
= 0.0014). However, comparing proportions of RBCs and fibrin across the two NIHSS groups 
revealed that thrombus composition had no effect on the pre-treatment NIHSS scores. Even 
though the area occupied by erythrocytes was greater in patients with NIHSS ≤ 10 (65.37% vs 
53.30%) and the area occupied by fibrin was greater in patients with NIHSS > 10 (46.70% vs 
34.63%), the differences were statistically insignificant (p = 0.19) suggesting no correlation 
between histological thrombus composition and baseline severity.  
4) The effectiveness of a thrombectomy device was not associated with histological composition. 
Patients treated with stentrievers had thrombi composed of higher proportions of erythrocytes 
than patients treated with ADAPT (57.36% vs 55.81%). Accordingly, the area occupied by fibrin 
was higher in patients treated with ADAPT than patients who were treated with stentrievers 
(44.19% vs 43.64%). However, these differences were statistically insignificant (p = 0.833).  
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5) Patients with near-to-complete recanalization (TICI 2b-3) had thrombi composed of 
significantly higher proportions of erythrocytes and lower proportions of fibrin (57.37% vs 
42.69%, p = 0.01) than patients with incomplete recanalization (TICI 1-2a) but, comparisons of 
erythrocyte or fibrin proportions across the two TICI groups revealed statistically insignificant 
differences (p = 0.657).  
6) Thrombus composition had no effect on 3-month functional outcomes assessed by 90-day 
mRS and 90-day NIHSS. In fact, regardless of the mRS group the patient belonged to, mRS 0-2, 
mRS 3-5 or mRS 6, the composition revealed higher proportions of erythrocytes than fibrin in 
each of the three groups (56.84% vs 43.16, 65.75% vs 34.25%, 53.02% vs 46.98%) with overall 
non-significant differences (p = 0.892). Similarly, for the 90-day NIHSS categories, thrombi of 
patients in either of the NIHSS categories (≤ 10, > 10) revealed higher proportions of 
erythrocytes than fibrin (57.74% vs 42.26%, 68.55% vs 34.45%) with non-significant differences 
overall (p = 0.512). 
7) The choice of thrombectomy device did not influence recanalization (p = 0.536), 90-day mRS 
(p = 0.363) or 90-day NIHSS outcomes (p = 0.869).  
8) There was no association between recanalization success and 3-month functional outcomes. 
Even though a majority of the patients in whom near-to-complete recanalization (TICI 2b-3) was 
obtained had mRS ≤ 2 than those patients in whom recanalization was not obtained, the overall 
differences were statistically insignificant (p = 0.193). 
9) XFI heat maps collected on beamline 10-2 revealed abundant presence of S and Cl in all 
samples. On the other hand, K and Fe were elevated in erythrocyte-rich regions while Ca was 
concentrated in fibrin-rich regions of the thrombus. Cu and Zn were detected at very low 
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quantities. Nevertheless, quantification of elements from XFI heat maps revealed insignificant 
differences between RBC-rich and fibrin-rich thrombi: P (p = 0.775), S (p = 0.317), Cl (p = 
0.568), K (p = 0.475), Ca (p = 0.668), Fe (p = 0.668), Cu (p = 0.199) and Zn (p = 0.063). 
Furthermore, XFI heat maps collected on beamline 14-3 revealed distribution differences in 
sulfur species wherein, sulfonic acid (taurine) was highly concentrated in fibrin-rich areas of the 
thrombi.  
10) Analysis of the X-ray absorption spectroscopy data revealed that the Fe pre-edge spectra was 
representative of oxygenated hemoglobin present in the thrombi. However, pre-edge peak fitting 
is required to validate this finding.  
11) Stroke etiology did not alter the elemental or biochemical composition of thrombi. 
Moreover, elemental and biochemical composition of thrombi did not correlate with 
recanalization or 3-month functional outcomes. 
12) Patients in whom near-to-complete recanalization was obtained, had elevated concentration 
of iodine in their thrombi, but the data was statistically insignificant (p = 0.834). Subsequently, 
XFI distribution maps illustrated high iodine permeability through fibrinous regions of the 
thrombus. There was no statistical difference between stroke etiology and thrombus perviousness 
(p = 0.958).  
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Chapter Four: Discussion 
Endovascular techniques have improved tremendously over the last two decades, from catheter-
dependent intracranial delivery of thrombolytic drugs to the development of 2nd generation stent-
retrievers [64]. Positive results from randomized controlled trials conducted worldwide 
demonstrated superior efficacy of EVT compared to IV-tPA treatment alone, and led 
endovascular therapy to be the standard of care for AIS patients [60], [62], [73], [75], [76]. 
However, studies have suggested the following: more than the specific device, rapid and safe 
recanalization might depend on other factors too, such as; pre- and post-treatment management, 
local versus general anaesthesia [59], anatomy of large vessel occlusions (LVO), mechanism of 
occlusion formation, size and location of vessel occlusion, collateral flow status, high rates of 
fragmentation and thrombus characteristics including composition, density/burden and length of 
the thrombus [165]. While all the above listed factors play a dynamic role in determining the 
clinical outcomes of stroke treatment, we were particularly interested in investigating the 
correlation between thrombus characteristics and interventional parameters as well as long-term 
clinical outcomes, as thrombi are the proximate cause of ischemic strokes and the primary target 
of current stroke treatments [81]. Hence, we aimed to investigate the histological, elemental and 
biochemical composition within retrieved thrombi to determine the clinical impact of 
composition on endovascular efficacy, interventional parameters and clinical outcomes in 
patients with acute ischemic stroke (AIS). To answer the research questions proposed in this 
study, we used a multitude of techniques including conventional histology and 
immunohistochemistry, X-ray fluorescence imaging and Fourier-transform infrared 
spectroscopy. 
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4.1 Validity of classifying thrombi as red and white based on histopathology and etiology 
Analysis of the histological composition revealed that all thrombi were composed of similar 
structural components including; erythrocytes, platelets (vWF/Factor VIII), endothelial cells 
(CD31), fibrin, neutrophils, and eosinophils which were constituted into unique histological 
entities and proportions with each demonstrating a distinct pattern. For instance, in some 
thrombi, erythrocytes were present abundantly within the core, while fibrin/platelets and 
endothelial cells were distributed in the periphery. On the other hand, in some thrombi, 
erythrocytes were distributed in the periphery while the core was interspersed with fibrin and 
polymorphonulcear cells. In addition to the predominant components, all thrombi had abundant 
macrophage infiltration and presence of granular debris which we speculate were either 
byproducts or metabolites produced by macrophages. The first histopathological evaluation of 
cerebral thrombo-emboli was conducted in 1964 by Torvik and Jörgensen [84]. They conducted 
analysis on <1.5 months old vascular obstruction in post-mortem cases and reported the 
histopathological components of thrombi within the occluded vessel emphasizing on the process 
of thrombus organization. For instance, red blood cells packed closely together were attributed to 
vascular stasis, while organizing fibrin-platelet materials were attributed to the age of the 
cerebral infarct [166]. They were also the earliest to experimentally study histological 
differences in arterial and venous thrombi of varying age [167]. However, Marder et al. 
performed the first systematic histological analysis in freshly retrieved thrombi to identify fibrin, 
platelets and nucleated cells [85]. Almekhlafi et al. were the first to identify the presence of 
calcium and endothelial cells in freshly retrieved thrombi [86]. Despite many previous works that 
have reported the presence of common histological components of fibrin, platelets, erythrocytes 
and white blood cells, every thrombus is comprised of a different histological pattern as well as 
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ratios of these components [168], and it remains controversial whether either of these 
components predominantly affects clinical parameters [163].  
In this study, thrombi that had a predominance of red blood cells were classified as erythrocyte-
rich while thrombi that had a predominance of fibrin were classified as fibrin-rich. However, the 
terminology used for distinguishing thrombi based on their predominant histological component 
is quite contradictory within literature. For instance, some previous studies have termed 
erythrocyte-rich thrombi as red while fibrin-rich thrombi as white [85], [87]. On the other hand, 
some studies have defined red thrombi as being rich in erythrocytes and fibrin while white 
thrombi being rich in platelets and fibrin [169], [170]. However, since we found that platelets 
and endothelial cells only co-localized in fibrin-rich areas [171], we defined the two dominant 
components of thrombi as erythrocytes and fibrin rather than erythrocytes and platelets.  
Sheer number of studies have focused on histological characterization of thrombus. Yet, the 
studies are limited by a lack of uniformity in histologically characterizing thrombi [172]. In fact, 
discrepancies observed in the classification of thrombi may be attributed to non-standardized 
assessment tools leading to biases induced by specimen fixation, processing, staining, 
interpreting results and measuring levels of each component using different methods [163]. In 
fact, some studies have quantified thrombi as red or erythrocyte-rich if RBCs outnumbered 
fibrin/collagen by > 15% [87], [173] while some others have used a Positive Pixel Count 
Algorithm or other semi-qualitative analysis tools and applied a semi-automated colour 
segmentation [163], [91], [95]. Furthermore, even though most semi-quantitative or semi-
qualitative methods have utilized PhotoShop and ImageJ to measure erythrocytes, leukocytes, 
and fibrin/platelet composition within thrombi, researchers have not adhered to standardized 
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colour and intensity parameters during analysis. Lastly, some papers do not mention the 
parameters used in their study [95], [174]. 
Histological characterization of thrombi using conventional stains and immunohistochemical 
tools has been retrospective in nature. Thus, some studies have suggested an approach in 
delineating thrombotic occlusions by using non-invasive imaging techniques. In fact, for over 30 
years, studies have utilized non-invasive modalities for identifying early vessel signs indicative 
of occlusive thrombus such as Hyperdense Middle Cerebral Artery Signs (HMCAS) [175]. 
However, some of these older studies have not corroborated the histopathology of the underlying 
thrombus [81]. Liebeskind et al. was the first study to correlate HMCAS and Blooming Artifact 
(BA) using non-contrast computed tomography (NCCT) and echo-gradient MRI with thrombus 
histopathology to determine its effects on clinical outcomes in patients who underwent 
thrombectomy. They found that HMCAS and BA were indicative of thrombi composed of higher 
proportions of erythrocytes than fibrin [162]. This finding was later supported by another study 
in which they associated increased thrombus attenuation (> HU) with the presence of high 
amounts of erythrocytes in the thrombus [173]. Thrombus attenuation (i.e. Hounsfield Units, 
HU) has shown to have a linear correlation with hemoglobin and weak negative correlation with 
platelets in the thrombi [173], [176]. Thus, platelet-rich thrombi have been identified as isodense 
on NCCT [177].  
Historically, thrombi were also classified as red/erythrocyte-rich or white/fibrin and platelet-rich 
based on their source of origin or etiology. While it is true that thrombi vary in architecture, 
rigidity, and morphology based on their predominant cellular component (erythrocyte or fibrin), 
it is not necessarily true that these features are also affected by their source of origin. This study 
showed that there was no correlation between thrombus composition and stroke etiology [85]. In 
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fact, regardless of where the thrombi were dislodged from, heart or the proximal arteries, the 
percent of erythrocytes in all thrombi were higher than the percent of fibrin. Many studies in the 
past have revealed that thrombi originating from a cardiac source led to the development of 
fibrin-rich thrombi while thrombi originating from proximal arteries led to the development of 
erythrocyte-rich thrombi [178], [171], [95], [179]. On the contrary, authors of some studies have 
also credited the distinctive proportions in composition to the chaotic forces of blood flow, shear 
and turbulence at sights of thrombus initiation and growth suggesting that, thrombi originating 
from a cardiac source with low blood flow led to the development of red or erythrocyte-rich 
thrombi while thrombi originating from an arterial source with high blood flow led to the 
development of in situ arterial thrombosis mediated by platelet-aggregated white or fibrin-rich 
thrombi [87], [169], [173]. With such discrepancies in the previous studies as well as the present 
study revealing a nonsignificant correlation between thrombus composition and stroke etiology, 
it is clear that the histological composition of thrombus is not altered by its source of origin. 
Observing such heterogeneity of thrombus composition, the conventional classification of red 
versus white thrombi seems truly inapplicable [168]. 
Moreover, as shown in table 3-1, the predominant component defining the histological category 
of the thrombus changes from section-to-section, wherein for instance, if one section collected 
from the proximal end shows higher proportions of erythrocytes, the next section collected from 
the distal end shows higher proportions of fibrin, thereby challenging the classification of a 
thrombus based on its dominant composition. To avoid such biases in section-analysis, studies 
have suggested total thrombus analysis (i.e. bulk analysis) [163]. However, there are two 
drawbacks to this method including: 1) limiting the use of alternative staining tools required for 
characterizing other cellular entities and 2) thrombus fragmentation that occurs during the 
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procedure whereby some smaller fragments are lost or eliminated from bulk analysis. A previous 
study reported that in > 90% of the cases, primary occlusions occur due to a single thrombus 
[180] and any occlusions distal from the primary occlusion site are considered to occur due to 
periprocedural thrombus fragmentation [181]. That being said, why some thrombi are more 
prone to fragmentation – remains unclear. Some studies have attributed higher proportions of red 
blood cells in causing thrombus mobilization and fragmentation [92] while some have suggested 
the role of neutrophil invasion [181], even though white blood cells only make up 3.9% of the 
histological composition [177]. Qualitative assessment of neutrophil distribution in this study 
indicated a higher presence of neutrophils in fibrin-rich areas than erythrocyte-rich areas. This 
finding was expected, as neutrophils are known to exhibit fibrinolytic activity that potentially 
weaken thrombus stability and promote fragmentation [181]. But since we did not perform a 
quantitative analysis of neutrophil infiltration, we could not determine the role of neutrophils in 
promoting fragmentation. 
4.2 Data trends and literature overview 
Our study showed no correlation between thrombus composition and pre-treatment NIHSS 
scores. To date, very few studies have investigated the effects of thrombus composition on pre-
treatment NIHSS. Similar to this study, Kim et al. reported no correlation between histologic 
composition and initial stroke severity [174]; however, the authors of the study did not provide 
data for this correlation. Boeckh-Behrens et al. revealed that post-treatment NIHSS was 
influenced by percentage of leukocytes but not erythrocytes or fibrin where higher percentage of 
white blood cells were associated with less favourable post-treatment NIHSS scores [182]. Choi 
et al. reported a significant increase in baseline NIHSS scores as the RBC fractions increased (p 
= 0.043) [91] which contradicted our data showing significantly higher RBCs in patients with 
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decreasing NIHSS scores (NIHSS ≤ 10). Prochazka et al. indirectly investigated the correlation 
between thrombus composition and patient outcomes by assessing biomarkers such as vWF and 
ADAMTS13 (vWF-cleaving protease) in 131 retrieved thrombi. They found patients with 
increasing NIHSS scores (NIHSS ≥ 15) had significantly higher levels of vWF [183]. Similarly, 
Schuhmann et al. also reported a positive correlation between high pre-treatment NIHSS scores 
and the presence of increased vWF [87].  
When engaging a thrombus with a thrombectomy device, optimal interventional outcomes are 
likely best achieved when the entire thrombus is engaged with the device and retrieved in one 
pass, preventing distal fragmentation [172]. When this does not happen, it is possible that the 
mechanical properties (texture, stiffness, and adherence) of the thrombus play a role in the choice 
of device as well as the success of achieving favourable outcomes. However, it is still debatable 
whether choice of therapies ought to take into consideration thrombus composition and its role in 
predicting interventional and clinical outcomes [168]. Our data showed no correlation between 
thrombus composition and the thrombectomy device that resulted in successful retrieval. 
Likewise, another study supported similar findings and revealed no association between 
thrombus composition and retrieval device [177]. On the other hand, our data contradicted 
previous work by Shin et al. in which retrospective analysis revealed that thrombi retrieved by 
ADAPT had higher percentage of red blood cells while thrombi retrieved via stentrievers were 
composed with higher proportions of fibrin [163]. Another study showed that thrombi rich in 
erythrocytes were retrieved more successfully via stentrievers alone and required reduced 
number of maneuvers [95]. This was likely due to the fact that fibrin-rich thrombi had a higher 
coefficient of friction and thereby adhered strongly to the vessel wall [184]. Another study 
reported that fibrin-rich thrombi required higher number of attempts during EVT as well as 
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contributed to higher rates of incomplete reperfusion than RBC-rich thrombi. Authors attributed 
these outcomes to fibrin structure suggesting the influence of fibrinous rigidity on thrombus 
engagement and its tendency to disengage at the tip of the guiding catheter [92]. 
Moreover, this study also revealed no correlation between thrombus composition and 
recanalization outcomes when comparing erythrocyte and fibrin proportions among the two TICI 
groups. However, comparing erythrocyte and fibrin proportions only for patients in whom TICI 
2b-3 was achieved, the data revealed that the thrombi in this group had significantly higher 
erythrocytes than fibrin. Some studies have reported similarly where patients with thrombi 
composed of higher proportions of erythrocytes had higher success rate for complete 
recanalization [163], [185] while some have contradicted this finding and suggested RBC-rich 
thrombi to result in low recanalization success due to the ability of RBC-rich thrombi to induce 
distal migration [186] or increase the risk of thrombosis by increasing blood viscosity [187]. 
Some studies utilizing non-enhanced computed tomography (NECT) and NCCT revealed a 
strong significant correlation between increased thrombus density, i.e. hyperdense thrombus, and 
increased recanalization success [172], [176], [188], while other studies suggested otherwise, 
revealing no correlation between thrombus density or thrombus burden with recanalization 
outcomes [189], [190]. Furthermore, our data showed no correlation between thrombus 
composition and 3-month functional outcomes which were assessed by 90-day mRS and 90-day 
NIHSS scores. Similarly, a previous study supported our findings showing no correlation 
between histological composition of thrombus and functional outcomes [95] as well as no 
correlation between thrombus density measured on NCCT and functional outcomes [189].  
Even though the effectiveness of EVT has been proven beyond reasonable doubt, the key 
challenge is to implement it safely when maneuvering through tortuous or ectatic vessels with 
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unfolded aortic arch or redundant cervical loops [64]. Thus, we hypothesized that longer 
procedural time and increased case complexity, may result in poorer clinical status and higher 
complication rates. However, our data rejected that hypothesis, revealing no association between 
choice of thrombectomy device and recanalization success or 90-day functional outcomes 
measured by mRS and NIHSS. On the contrary, Prochazka et al. showed that patients treated 
with ADAPT had significantly better recanalization outcomes while patients treated primarily 
with stent-retriever had significantly better 3-month mRS scores [72]. One study proposed that 
the use of multiple device types during solitary thrombectomy resulted in significantly low rate 
of recanalization success [181] while another, retrospective study suggested a strong correlation 
between increased number of maneuver counts (> 2 maneuvers) and decreased recanalization 
success [191]. Studies have also suggested other factors besides thrombus composition and 
choice of thrombectomy device to play a role in failed recanalization attempts including 
challenging anatomical access, resistant occlusion and procedural complications [192].  
While a majority of the patients in whom near-to-complete recanalization (TICI 2b-3) was 
obtained had mRS scores between 0-2 and NIHSS ≤ 10 (i.e. 15 of the 28 patients) compared to 
those patients in whom recanalization was not obtained, the differences were statistically 
insignificant. In a meta-analysis performed by Rha et al. which combined findings from 33 
studies, it was revealed that patients in whom complete recanalization was achieved had 4- to 5- 
fold improvement in functionality and low fatality outcomes than patients in whom no 
recanalization was achieved [193]. Although our study showed that 3-month functional outcomes 
did not significantly depend on thrombus composition, choice of thrombectomy device, or 
recanalization success, we assume that there are several other factors that could explain why 
some patients in whom good interventional outcomes were achieved, still had poor functionality. 
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For instance, in the 4 patients who suffered moderate-to-severe disabilities (mRS > 3 and 90-day 
NIHSS > 10), successful recanalization (TICI 2c-3) was achieved in 3 of those 4 patients. 
Likewise, in the 9 patients who died (mRS 6), successful recanalization was achieved in 8 of 
those 9 patients. This phenomenon where successful recanalization fails to achieve favourable 
prognostic outcomes, has been defined as futile recanalization [194]. Interestingly, our data 
suggested that, 8 of the 11 patients who suffered severe disabilities or died despite successful 
recanalization, had thrombi composed of significantly higher proportions of erythrocytes than 
fibrin. This finding thereby associated the presence of high proportions of erythrocytes with poor 
prognostic outcomes despite the fact that high proportions of erythrocytes were also significantly 
correlated with good recanalization outcomes. Nevertheless, along with histopathological 
composition of thrombi, there could be several other potential factors contributing to futile 
recanalization such as:  
1) Delayed reperfusion. Several different target times for mechanical thrombectomy have been 
reported to date, including onset-to-treatment, where a study indicated that the odds of good 
outcomes reduced by 6% for every hour of delay from onset-to-treatment [195], onset-to-
reperfusion, where achieving long-term good outcomes after reperfusion were significantly time-
dependent [196] whereby, the odds of good outcomes decreased by 12-21% for every 30 min 
delay from onset-to-reperfusion [197]. Similarly, delayed time between door-to-puncture [198] 
and imaging-to-puncture [199] also significantly reduced the probabilities for good outcomes;  
2) Occlusion location (i.e. left versus right hemisphere tissue damage). A previous study 
described the mechanistic differences in functionality, severity, mortality and frequency of left- 
and right-hemisphere strokes. They found that patients with left occlusions had significantly 
higher pre-admission NIHSS, worse Glasgow coma scale, higher mortality rates and increased 
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occurrence of mechanical thrombectomy [200]. The severity associated with left hemisphere 
strokes could be due to that fact that left vessel occlusions affect more modalities, including right 
hemiplegia (stroke affecting motor cortices), Broca’s aphasia (stroke affecting speech 
production) or Wernicke’s aphasia (stroke affecting speech comprehension), facial droop, and 
memory problems, as opposed to right vessel occlusions where patients are affected mostly by 
spatial disorientation [201], [202];  
3) Blood pressure. A small study with a cohort of 378 patients showed that high mean systolic 
blood pressure post-EVT were associated with poorer mRS scores [203]. This trend was also true 
for patients that received IVT treatment alone [204];  
4) Age and sex differences. A study by Hedna et al. suggested that patients ≥ 75 years had higher 
occurrence of mortality than patients < 75 years of age [200]. Likewise, another study revealed 
patients < 70 years of age to have better mRS scores [205]. As for sex differences, a study by 
Madsen et al. revealed that females were less likely to be independent at 90 days than males 
[206];  
5) Peri- and post-procedural complication. Studies have suggested that re-occlusion of the 
vessel by distal embolization after achieving recanalization of the primary occlusion site 
contribute to neurologic deterioration [181], [194]. Along with distal embolism, the occurrence 
of ICH remains one of the prominent complications after successful EVT [62]. A study by 
Nawabi et al. identified lower ASPECTS, low collateral score and high CT-based quantitative 
net water uptake as statistically significant independent predictors of ICH after successful 
thrombectomy [207];  
6) Efficacy of combined treatment. Some researchers believe that rtPA contribute neurotoxic 
effects by damaging the blood brain barrier and vessels, consequently downregulating cerebral 
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autoregulation and inducing distal embolization [181], [194]. While some studies have reported 
that patients administered with IV-tPA prior to thrombectomy required less EVT attempts, had 
better mRS, higher recanalization success, and lower mortality rates [208]. Thus, with such 
contradictory findings, the effects of combined treatment on futile recanalization remain 
controversial. And lastly,  
7) Previously prescribed drugs (anticoagulants and thrombolytics). A study by Myint et al. 
found that patients who were on prescribed anti-thrombotics prior to their stroke onset, had better 
long-term outcomes [209]. Likewise, in an observational study of 94,474 patients, they found 
that patients who were on anticoagulants, warfarin or non-vitamin K dependent antagonists, prior 
to their stroke onset, had significantly less severe strokes and decreased mortality rates [210].  
4.3 Innovative contribution of this study 
The novel contribution of this study was the use of synchrotron-based imaging technique and 
FTIR which were utilized for identifying elemental and biochemical composition of thrombi. To 
the best of our knowledge, we are the only study to report such findings. Although the elemental 
and biochemical composition of blood components in normal blood samples have been under 
investigation for over a century, the exact concentration and distribution of bioelements and 
organic biomolecules present in blood under pathological conditions such as thrombosis are not 
well-known.  
Previous studies have reported the presence of sodium, potassium, magnesium, zinc, calcium, 
and copper in normal human red blood cells [211] as well as platelets [212], [213]. However, 
these studies have utilized basic laboratory-based techniques, including emission 
spectrophotometry [211], absorption spectroscopy [213] and neutron activation analysis [212], 
respectively, to report the concentration of these elements. On the contrary, in our study we were 
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able to not only measure elemental quantities, but also visually illustrate how elements 
distributed within the tissue sections. The elemental distribution observed in the tissues are a true 
representation of the elements present in the samples as we ensure tissue thickness consistency, 
use exact same beamline settings during each beamtime, normalize quantified data by correcting 
for I0 flux, normalize fluorescence peak differences and use the same scale to threshold 
intensities.  
For years, researchers have reported distinctive histological patterns formed by fibrin, 
erythrocytes, platelets and polymorphonuclear cells. However, we are the first to report how 
elements are distributed and co-localized in fibrin and erythrocyte-rich regions of the thrombus. 
The XFI distribution maps showed an abundant presence of chlorine, potassium and sulfur 
within the core as well as the peripheral regions of the thrombi, whereas iron as predicted, was 
only dispersed in the erythrocyte-rich areas. Calcium on the other hand, had elevated distribution 
in the fibrinous regions. Calcium is an integral element in the coagulation cascade because it acts 
as a tissue factor (factor IV) and also plays several important roles including activating other 
downstream tissue factors, stabilizing factor VIII and linking tenase/prothrombinase complexes 
[42]. Other elements including copper and zinc also play an important role in the coagulation 
cascade. Zn is released by platelets to modulate thrombus strength and stability, and potentiate 
thrombus formation [214]. In cerebral ischemia, generation of significant amounts of free oxygen 
radicals and their derivatives contribute to oxidative stress and induce brain damage. Therefore, 
to control oxidative damage, antioxidant enzymes alternatively metabolize oxidative toxic 
substrates in the presence of cofactors that enhance catalysis. For instance, superoxide dismutase 
catalyzes the dismutation of superoxide radicals in the presence of Cu and Zn cofactors [215]. 
Despite the important roles of Cu and Zn, these two elements were only detected at trace levels. 
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Furthermore, under ischemic conditions, several proteins undergo reversible methionine 
oxidation to perceive oxidative stress whereby methionine residues are post-transitionally 
oxidized to methionine sulfoxide [216]. Some of the possible targets of protein methionine 
oxidation in the coagulation cascade include vWF, factor VII, antithrombin, α2-antiplasmin and 
fibrinogen [216]. Distribution maps generated to characterize the presence of different sulfur 
species revealed copiously dispersion of methionine sulfoxide throughout the thrombi. 
Additionally, the distribution maps also demonstrated a high presence of sulfonic acid (i.e. 
taurine). Taurine, unlike other amino acids is not utilized in protein synthesis [217] and is found 
in most of the biological tissues to regulate osmoregulation, anti-inflammation, calcium 
homeostasis etc. [218]. In fact, supplementation of taurine with tPA has shown to improve long-
term clinical outcomes, reduce tPA-induced ICH and improve vascular patency [218]. Moreover, 
studies have shown taurine to stabilize against platelets [219] such that it exerts inhibitory effects 
on platelet aggregation [217]. This explains why we observed such high taurine distribution in 
the fibrin-rich areas.  
Previous literature has also reported the presence of Mg2+ and Na+ in blood constituents. In an in 
vitro study, Sekiya et al. showed that, in the presence of Mg2+, lower amounts of factor VIII 
were required to activate factor X than those needed with Ca2+ alone. They revealed that Mg2+ 
stabilized factor IX and accelerated all factor IX-dependent activities in the cascade [214]. On 
the other hand, Na+ is crucial for maintaining a hemodynamic balance. Along with being an 
important electrolyte, Na+ has shown to allosterically modulate the activity of thrombin by 
increasing its proteolytic activity for cleaving prothrombotic substrates [41]. Even though Mg2+ 
and Na+ are important elements in the coagulation cascade, it is difficult to detect them using 
hard-X-ray beamlines because they attenuate before the detector can pick up any photons. Thus, 
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Mg and Na are imaged on a soft X-ray beamline (BL 6-2) that uses a low incident energy (below 
5 keV). Additionally, in order for soft X-ray beamlines to operate ideally and offer high spatial 
resolution, high energy resolution and high spectral brightness, imaging is performed in a helium 
or vacuum environment that prevents high attenuation of photons [127]. In this study we also 
quantified elements and organic biomolecules of interest and retrospectively correlated the 
concentrations (μg/cm2) with TICI and mRS scores. Our study revealed that the elemental and 
biochemical composition of thrombi did not correlate with the recanalization or 3-month 
functional outcomes. However, these findings need to be validated further using bulk-analysis 
and a larger sample size.  
Several studies have used thrombus perviousness as a biomarker to predict recanalization and 
functional outcomes. These studies have revealed that increased thrombus perviousness 
(measured via contrast agent penetration on CTA and thrombus attenuation on NCCT) resulted 
in better recanalization rates and improved functional outcomes [220], [221], [222]. We were 
able to show that the contrast agent (iodine) only penetrated the fibrin-rich areas using the XFI 
distribution maps. The contrast agent, Isovue-300, is a hydrophilic non-ionic contrast agent that 
contains 3 iodine atoms and has a molecular weight of 0.777 kDa. Our finding supported the 
results of a previous study that found thrombi permeable to the contrast agent had low fractions 
of red blood cells [223]. To date, we are the first to visually illustrate and quantify contrast 
agent-based thrombus perviousness by combining XFI and thrombus histology, directly using the 
thrombi samples as opposed to measuring thrombus density. Correlating iodine concentration 
with stroke etiology, we found no significant correlation between thrombus perviousness and 
stroke etiology. It is important to note that, the permeability measured and described in this study 
refers to the amount of contrast agent used during the thrombectomy procedure unlike other 
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studies that have predicted the outcomes based on the amount of contrast agent used during MRI 
or CTA imaging prior to thrombectomy. Additionally, we have yet to statistically prove if 
thrombus perviousness affects clinical and interventional outcomes. To validate correlations 
between thrombus perviousness and clinical outcomes in future studies, future studies would 
need to take into account how much and for how long was the contrast agent administered during 
imaging prior to EVT as well as during the thrombectomy procedure.  
Considerable research involving thrombus perviousness, describes the impacts of thrombus 
permeability on the efficacy of IV-tPA. For instance, one of the studies showed that erythrocyte-
rich thrombi allowed tPA penetration through the fibrin networks, consequently resulting in 
effective thrombolysis compared to that in fibrin-rich thrombi [91]. On the contrary, another 
study revealed that the presence of erythrocytes provided fibrin with lytic resistance to tPA by 
downregulating tPA-induced plasminogen activation of the fibrinolytic pathway [224]. A 
majority of the research has targeted fibrin as a key player for poor clinical outcomes where 
higher percentage of fibrin has been associated with lower recanalization rates [92], increased 
EVT failures [94], and increased resistance to plasmin drugs [89, 90]. Retrospective analysis in 
our study revealed that, the 4 patients who underwent EVT after unsuccessful IV-tPA 
thrombolysis, had erythrocyte-rich thrombi. Moreover, even though Isovue-300 is a relatively 
smaller molecule than tPA (0.777 kDA vs 70 kDA), our data demonstrated lack of Isovue-300 
permeability through the RBC areas of the thrombus, suggesting that erythrocyte-rich thrombi 
were less permeable than fibrin-rich thrombi. That said, it is important to keep in mind that the 
iodine concentration in the thrombus is also dependent on other factors. For instance, longer 
procedural times would naturally result in increased iodine accumulation. Furthermore, during 
thrombectomy any amount of contrast agent administered intra-arterially would potentially 
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accumulate more in the thrombus due to blood stagnation. Moreover, since the half-life of 
iosvue-300 is approximately 2 hours, the amount of contrast agent administered during pre-
procedural imaging as well as during the EVT procedure would cumulatively increase the iodine, 
thereby affecting the iodine distribution in the clotted thrombus.  
4.4 Limitations of this study 
There were several limitations in this study. For instance, even though all thrombi were 
histopathologically classified using the same threshold values in ImageJ-based trainable WEKA 
segmentation plugin, there were certain discrepancies observed from sample to sample stained 
with Masson’s Trichrome, wherein some sections were stained darker than the others. 
Consequently, this made it difficult for us to identify and highlight lighter stained pixels using 
consistent intensity parameters. Furthermore, we also had limitations beyond the common ones 
of a retrospective study design. Sometimes in retrospective studies, challenges of inherent 
selection bias or misclassification bias can be eliminated with a larger sample size. However, the 
sample size in this study was relatively small (n = 25) which potentially introduced false 
positives as well as decreased the validity and statistical power for correlations where a trend 
was observed but statistical significance was not reached.  
Another limitation of this study was the lack of histopathological analysis on frozen sections. We 
were eager to correlate XFI distribution patterns with cellular morphology on serially collected 
frozen sections. However, we could not achieve good histological results on frozen sections and 
therefore, elemental and histological correlations were derived from frozen and paraffin sections, 
respectively even though the sections belonged to different fragments of the same thrombus. 
Moreover, patterns and ratios of histological components changed from distal to the proximal 
end of the thrombus. This weakened the categorization of thrombi due to the lack of total 
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thrombus analysis in this study. Overcoming this issue in the future would require inclusion of 
inductively coupled plasma mass spectrometry (ICPMS)-based bulk spectroscopy.  
Conclusions and Future Direction 
In conclusion, we were able to show that thrombus composition was not affected by etiology. 
Additionally, thrombus composition did not affect stroke severity, choice of thrombectomy 
device, recanalization outcomes or three-month functional outcomes. Importantly, our results 
refuted the traditional paradigm of classifying a thrombus as red and white. To further our 
insights into thrombus composition, we used advanced imaging techniques, XFI and FTIR, to 
evaluate distribution patterns for biological elements and biomolecules. However, even these 
powerful techniques revealed no significant findings in elemental and biochemical composition 
of thrombi and their effects on interventional and clinical parameters. An interesting finding 
worth exploring in the future is the correlation between thrombus perviousness, etiology and 
thrombus composition which suggested that erythrocyte-rich thrombi are less pervious than 
fibrin rich thrombi. To date, a majority of the research has targeted fibrin as a key player in poor 
prognostic outcomes, however, our combined histology and XFI data reveals erythrocytes to be 
the new potential target for poor prognostic outcomes and ineffectiveness of tPA. 
Future direction could elaborate certain aspects of this study and include a larger cohort. 
Correlation of puncture-to-reperfusion time with thrombus composition to determine whether a 
specific type of thrombus increases procedural time and worsen outcomes may be worthwhile. In 
the second phase of this study, we would like to combine X-ray mass attenuation coefficients of 
each biological element with thrombus density measured on CTA and certain parameters from 
patients’ blood work to further our insights on classifying thrombi on CTA using elemental 
information instead of histological biomarkers. And lastly, to avoid selection biases in FTIR 
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analysis, we would include K-mean clustering to quantify the presence of biomolecules in the 
entire tissue section rather than using concentration values from selected ROIs. 
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